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Abstract 
Immuno-epidemiology of uro-genital schistosomiasis: focusing on 
atopy and pre-school age children 
 
Urogenital schistosomiasis, due to Schistosoma haematobium, is one of the helminth 
infections of public health importance in sub-Saharan Africa where children carry the 
heaviest burden of infection. Treatment with the drug praziquantel is the only widely 
available tool for control. Current schistosome control programs are essentially 
school-based and exclude younger pre-school children. However, increasing reports 
of significant infection levels in this age group call for the inclusion of these young 
children in control programs.  
 
The hygiene hypothesis suggests that helminth infections, including schistosome 
infection, may protect against atopy, implying that helminth eradication may carry a 
detrimental burden of immune disorders. However, this conjecture is controversial. 
This study was designed to investigate the relationship between schistosome infection 
and atopy. In a comparative epidemiological approach between two schistosome 
endemic areas with differing infection levels, it is shown that atopy is inversely 
associated with current schistosome infection intensity but not with cumulative 
history of infection. This inverse relationship was subsequently shown to be 
associated with the levels of soluble CD23, the low affinity IgE receptor, but not with 
the polyclonal IgE stimulation.  
 
However, while praziquantel treatment was associated with an increase in 
schistosome-specific responses, a decline in atopic responses was observed in these 
communities, suggesting that treatment differentially affect anti-schistosome and 
atopic responses. In addition, the study has shown that praziquantel treatment of pre-
school age children increases, quantitatively and qualitatively, their schistosome-
specific antibody responses purportedly associated with resistance to schistosome 
infection/reinfection.  
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1. 1. Helminths and immune disorders 
 
Helminth infections and immune disorders are both public health burdens which, in 
general, do not geographically overlap. The former are highly prevalent in developing 
tropical countries, afflicting the poorest people (Bethony et al. 2011), while the latter 
are purportedly more prevalent in industrialised countries and urban areas of 
developing countries (Ait-Khaled et al. 2009; Ring 2012).  
 
Helminths: The major human helminth parasites belong to two phyla. The nematodes 
(or roundworms) which include intestinal soil transmitted helminths (STH) and 
filarial worms (which cause lymphatic filariasis and onchocerciasis), and the 
platyhelminths (or flatworms) which include the flukes (or trematodes, including 
schistosomes) and the tapeworms (or cestodes). Although common in most parts of 
the world sixty years ago (Stoll 1947), these parasites are currently mainly prevalent 
in sub-Saharan Africa, Asia and South America (Hotez et al. 2004; Hotez et al. 2008; 
GaHI 2012), where they are responsible for considerable disabilities including 
blindness and elephantiasis (filarial worms). Furthermore, helminth infections are 
responsible for morbidities that include anaemia, stunted growth, poor cognitive 
development and malnutrition (King et al. 2005; Bethony et al. 2006; King and 
Dangerfield-Cha 2008), hence exerting a negative socio- economic impact in already 
poor communities. 
 
The World Health Organization identifies helminth infections among neglected 
tropical diseases (NTDs), in contrast to better known conditions such as HIV-AIDS, 
malaria and tuberculosis (Yamey and Torreele 2002). One of the characteristics of 
NTDs is that they do not often result in death and therefore have been ignored and 
neglected by public health officials. However, with the use of disability adjusted life 
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years (DALYs), i.e. expected-life lost due to premature ill-health or death, to estimate 
disease burden (Murray 1994; Murray et al. 1994), it has been shown that NTDs 
account for almost the same burden as malaria and half of the global burden of HIV-
AIDS (DALYs= 38 million; 39.8 million and 84 million respectively for NTDs, 
malaria and HIV-AIDS; averaged from (W.H.O. 2004; Hotez et al. 2006a; Hotez et 
al. 2006b)). 
 
In addition to reduced productivity of disabled affected people, helminth infections 
are also responsible for economic loss in animal husbandry (see (Perry et al. 2002)). 
For instance, the cestode Taenia solium affect pigs, while the gastrointestinal 
nematode Teladorsagia circumcincta constrains survival and productivity of sheep 
and goats (Craig et al. 2006). Helminth parasites continue to affect animals in 
developed and developing countries where efforts and resources are put into research 
and development projects for sustainable control programs (see (Gray et al. 2011)). 
Furthermore, a number of helminth parasites such as Fasciola sp are important 
zoonoses, i.e. transmissible between animals and humans (Mas-Coma et al. 2005; 
Robinson and Dalton 2009), which may be re-emerging and/or expanding (Mas-
Coma 2005). Schistosoma spp also represent a livestock burden (e.g. S. japonicum  
(Riley et al. 2008)), and may be a threat to endangered mammals such as non-human 
primates (Standley et al. 2012).  
 
 
Immune disorders: Immune-mediated diseases include auto-immune diseases (such 
as type 1 diabetes, inflammatory bowel diseases and rheumatoid arthritis) and allergic 
diseases (such as asthma, allergic rhinitis and atopic eczema). These are purportedly 
more prevalent in developed countries and in urban areas of developing countries 
(Williams 1999; Ait-Khaled et al. 2009). The public health aspect of immune 
disorders has emerged following their rise in western countries since the end of 
World War II, possibly as a consequence of industrialisation (Emanuel 1988). They 
have been responsible for increased mortality and morbidity worldwide (Davis et al. 
1985; Jackson 1985; Beasley et al. 1998) and they negatively impact on economic 
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growth for the elevated cost of their treatment (Gupta et al. 2004; Brown et al. 2007). 
In addition, possibly because of their shared aetiology, developing a given immune-
mediated disease increases the risk of developing another, leading to co-morbidities 
(Makredes et al. 2009). Recent studies by Hemminki and colleagues have shown that 
autoimmune disorders increase the risk of cancer (Hemminki et al. 2011b; Hemminki 
et al. 2011a) as well as the mortality rate among cancer patients (Hemminki et al. 
2012). There is also increasing evidence that allergic disorders, especially allergic 
rhinitis, are associated with attention deficit disorder and hyperactivity in children 






Box 1: Index 
 
Acute schistosome infection: infection, usually at an early stage, which translates into 
clinical symptoms. These include fever, cough and fatigue. This stage is also 
characterised by inflammatory reaction around deposited schistosome eggs  
 
Asymptomatic infection: Infection which does not translate into clinical disease 
 
Atopy: the genetic predisposition to become extremely sensitised to environmental 
allergen(s) and produce high levels of IgE antibodies. This is usually diagnosed by skin 




Chronic schistosome infection: infection accumulated over several years. This is 
common in schistosome endemic areas and are often characterised by extensive tissue 
damage in affected individuals 
 
Heavy schistosome infection: schistosome worm burden is determined by the egg 
excretion in urine or stool. For S. haematobium, heavy infection is defined as excretion of 
more than 100 eggs in 10mls of urine 
 
Light infection: for S. haematobium, light infection is defined as excretion of less than 50 
eggs per 10mls of urine 
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1. 2. Unifying theme between allergy and helminth infection: The 
hygiene hypothesis 
 
Paradoxically, while efforts and resources are put together to control and ultimately 
eliminate helminth infections in developing countries (Hotez et al. 2008), it is 
hypothesised that the decline in childhood infections, including helminth infections, 
in developed countries is responsible for, or at least associated with, the rise in allergy 
and auto-immune disorders  (Strachan 1989; Wills-Karp et al. 2001).  
 
Increasing rates of childhood allergies have long been a puzzle to epidemiologists 
(Taylor et al. 1984; Emanuel 1988). Thus, Taylor et al (1984), observed increasing 
rates of eczema when cohorts of children born in 1946, 1958 and 1970 were 
compared, with a higher increase in breastfed children, and suggested that a ‘new 
environmental agent’, contained in breast milk and possibly infants’ food was 
responsible for the increase in eczema. Emmanuel, reviewing medical literature 
published from 1820 to 1900, concluded that the hay fever ‘epidemic’ was associated 
with the rapid industrial growth of the 19
th
 century since this disorder was rarely 
described prior that period (Emanuel 1988). It was Strachan (1989) who, observing 
that the rate of hay fever and eczema was consistently negatively associated with 
family size and birth position in households hypothesized that reduced exposure to 
childhood infections due to increased hygiene was responsible for the allergy 
epidemics. This hypothesis, currently referred to as the ‘hygiene hypothesis’, was 
subsequently supported by epidemiological studies. For example, it was shown that 
early non-wheezing lower respiratory tract illnesses were associated with suppression 
of atopy (Martinez et al. 1995) while a history of measles infection was associated 
with reduced risk of skin prick test positivity (Shaheen et al. 1996). However, this 
hypothesis was challenged by studies showing for example that early mycobacterial 
infections or Bacillus Calmette Guerin (BCG) vaccination had no effect on 
subsequent development of atopy (Alm et al. 1997; Strannegard et al. 1998). In a 
retrospective case control study on Italian military cadets, Matricardi and colleagues 
were able to show that cumulative exposures to foodborne and orofecal infections (T. 
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gondii, H. pylori, hepatitis A virus), but not infections transmitted via other routes 
(mumps, measles, rubella, chickenpox, cytomegalovirus and herpes simplex virus 
type 1), were associated with a reduced risk of being atopic (Matricardi et al. 2000). 
These authors suggested that the mode of transmission of the pathogen was a 
determining factor in subsequent protection (or no protection) against atopy and 
asthma, hence explaining inconsistencies in previous studies.  
 
Immunologically, the ‘protective’ effect of childhood infections on atopy has been 
explained by the crossregulation between the T helper type 1 (Th1) and Th2-like 
immunity (Lucey et al. 1996). Thus, infections capable of immune ‘polarisation’ 
towards the Th1 immune response were considered protective by regulating the Th2 
atopic response (Strannegard et al. 1998; Matricardi et al. 2000). However, the high 
incidence of helminth infections (which are Th2 mediated diseases) in less developed 
countries and their negative association with allergic reactivity (Godfrey 1975; Lynch 
et al. 1984; Masters and Barrett-Connor 1985; Lynch et al. 1987; Hagel et al. 1993c) 
could not be explained by the simple Th1/Th2 paradigm.  
 
 
1. 2. 1. Polyclonal and/or cross-reactive IgE stimulation 
 
Documentation on a link between helminth infections and allergies dates back in the 
1970s. For example, in an editorial letter to the Lancet, Turton reported that self- 
infection with Necator americanus (roundworm) larvae protected him against hay 
fever (Turton 1976). It was then shown that although a direct association was 
controversial, the incidence of asthma was negatively associated with the incidence of 
helminth infections (reviewed by (Masters and Barrett-Connor 1985)).  
 
The earliest protective mechanism of helminth infection suggested was ‘mast cell 
saturation’(Bazaral et al. 1973). These authors observed that individuals with high 
serum IgE, mainly resulting from helminth (Ascaris) infestation, did not show skin 
hypersensitivity and suggested that mast cell sites (Fc receptors) may be saturated by 
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non-sensitizing IgE. Further supportive evidence for the Fc saturation hypothesis 
came from a study showing that histamine release of human mast cells from lung 
fragments could be blocked by pre-exposure of these fragments to high total IgE 
(Godfrey and Gradidge 1976). It was then known that helminth infections induced 
high levels of IgE and the protective effect of helminth infection via non-specific 
(polyclonal) IgE production was reported by several authors (Godfrey 1975; Lynch et 
al. 1987; Hagel et al. 1993c). However, more recent studies on basophils have shown 
that high levels of polyclonal IgE and polyclonal/specific IgE ratios from filarial and 
hookworm infected patients do not prevent antigen-induced histamine release (Mitre 
et al. 2005; Pritchard et al. 2007). Nevertheless, Mitre and colleagues were able to 
show that extremely high ratios of polyclonal/specific IgE, enhanced with polyclonal 
myeloma IgE in vitro, could prevent histamine release (Mitre et al. 2005). Although 
basophils and mast cells may be differentially regulated (Galli 2000), these 
experiments suggested that the FcεRI receptor saturation may not be the primary 
mechanism by which helminths ‘protect’ against allergy.  
 
Another hypothesis suggested in regard to IgE was that helminth parasites induce a 
‘clinically irrelevant’ allergen-specific IgE response, which would be cross-reactive 
between helminths and allergens (Yazdanbakhsh et al. 2002). Cross-reactive anti-
tropomyosin IgE antibodies between helminth and allergen have recently been 
demonstrated, where monkeys infected with Loa loa (filarial parasites) mounted an 
IgE cross-reacting between filarial tropomyosin and Derp 10 allergen but not with 
timothy grass (Santiago et al. 2011). However, field studies report mixed results on 
the effects of helminth infections on allergen-specific IgE in endemic areas (Lynch et 
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1. 2. 2. Immunomodulation 
 
Advances in the immuno-biology of helminth infections have shaped current views of 
their relationship with allergic reactivity. Helminth infections are generally 
characterised by a Th2 polarised immune response (Maizels and Yazdanbakhsh 2003; 
Everts et al. 2009; Oliphant et al. 2011), which are often associated with host 
resistance. However, this Th2 response is also associated with pathology (Morais et 
al. 2008), consistent with the role for Th2 in allergic diseases (Jutel and Akdis 2011). 
Nevertheless, helminth parasites are capable of modulating this response to prolong 
their survival and minimize severe pathology in their host (Pearce and MacDonald 
2002; Maizels and Yazdanbakhsh 2003; Maizels 2009). This immunomodulation is 
thought to affect unrelated antigens such as allergens, hence dampening the clinical 
manifestation of allergy. Indeed, experimental mouse models have demonstrated 
helminth-induced suppression of allergic responses via multiple pathways, some of 
which have been investigated in humans (Figure 1.1).  
 
Thus, schistosome-induced IL-10 producing B cells (regulatory B cells) could protect 
infected mice from anaphylaxis (Mangan et al. 2004). Regulatory B cells (Bregs) 
have also been shown to prevent and suppress allergic airway inflammation by 
recruiting regulatory T cells, independent of TGFβ (Amu et al. 2010). The role of IL-
10 in suppressing atopic asthma was shown in a Heligosomoides polygyrus mouse 
model (Kitagaki et al. 2006). However, S. mansoni infection could also modulate 
experimental asthma in Treg dependent IL-10-independent manner (Pacifico et al. 
2009). Consistent with these findings, H. polygyrus infection has been shown to 
suppress airway allergy via Tregs and TGFβ expression, independent of IL-10 
(Wilson et al. 2005). More recently, these investigators showed that this suppression 
was dependent on CD23
 










Figure 1.1 Possible regulatory mechanisms in helminth infections 
Primary response (a) to parasite antigens involves Th2 polarization, IgE production and 
eosinophil, mast cell and basophil activation (I.), mechanisms similar to those observed in 
allergic sensitisation (c). This Th2-response may be induced by parasite secreted antigens 
such as the Omega-1 secreted by S. mansoni eggs (Everts et al. 2009). However, with 
increasing parasite load or chronic infection (b), regulatory B cells are activated which 
suppress Th2 responses (II.) via IL-10 secretion or CD23 expression (Wilson et al. 2010), 
and/or contribute to the recruitment of Tregs (Amu et al. 2010). Tregs (III), which may also 
be induced and expanded by parasite antigens (McSorley et al. 2008; Grainger et al. 2010), 
either induce anergic Th2 cells (expressing GITR and CTLA4) unable to progress through to 
effector cells, or modify downstream effector functions such as B cell switch to IgG4 and/or 
alternative activation of macrophages, resulting in immunological tolerance (reviewed by 
(Allen and Maizels 2011)). This immuno-suppression is induced in the context of helminth 
infection but may also expand to allergen-induced inflammation (gray line), hence 
suppressing allergy. DC: dendritic cell; B: B cell, Eos: eosinophil; Bas: basophil; MC: mast 
cell; GITR: glucocorticoid-induced TNFα-related protein; CTLA4: cytotoxic T lymphocyte 
antigen 4; AAM: alternatively activated macrophage; Breg: regulatory B cell; Treg: 
regulatory T cell. The question mark (?) denotes lack of strong evidence. Figure adapted from 






Chapter 1                                                                                       General Introduction                                                                                                           
  
 9 
Human studies investigating the regulatory mechanisms underlying the protective 
effect of helminth infections on atopy have primarily focused on IL-10. Thus, 
parasite-induced IL-10 production and skin prick reactivity were negatively 
associated in Ascaris lumbricoides (Flohr et al. 2010) and Schistosoma haematobium 
(van den Biggelaar et al. 2000) infected populations. Furthermore, allergen-induced 
IL-10 was associated with reduced Th2 responses (IL-4 and IL-5) in asthmatic 
schistosome infected patients (Araujo et al. 2004). More recently, it has been shown 
that the frequency of PBMCs expressing cytotoxic-T-lymphocyte antigen 4 (CTLA-
4) and monocytes expressing IL-10 from asthmatic patients infected with S. mansoni 
was significantly higher compared to their asthmatic uninfected counterparts 
(Oliveira et al. 2009). However, a study on an Ecuadorian population showed no 
association between skin prick reactivity with either IL-10 or IL-10-producing T cells 
induced by Ascaris lumbricoides (Cooper et al. 2008a). The potential role for the 
CD23 expression, often associated with acquired immunity to helminth infection 
(Hagel et al. 2006; Mwinzi et al. 2009; Black et al. 2010a) remains unexplored in 
regard to atopy.  
 
 
1. 3. Controversy behind the hygiene hypothesis  
 
The potential protective effect of helminth infection on atopic disorders has provided 
an alternative explanation to the hygiene hypothesis (i.e via immuno-modulatory 
mechanisms); however, conflicting results have been reported in human studies (See 
table 1.1). Although the high polymorphism in immune complexes associated with 
regulatory antibodies may explain these discrepancies (Mekhaiel et al. 2011), meta-
analyses of human studies suggest several other hypotheses: 
 
1. Helminth species:  There is increasing evidence for the importance of the parasite 
species in the relationship between helminths and allergies. Thus, infection with 
hookworm may reduce the risk of asthma while Ascaris infection may exacerbate this 
risk (Leonardi-Bee et al. 2006; Flohr et al. 2009). These analyses also show a 
Chapter 1                                                                                       General Introduction                                                                                                           
  
 10 
negative association between skin sensitisation and schistosome, Trichuris and 
hookworm infections but the effect of schistosomiasis on asthma is not clear. One 
study showed no effect of chronic schistosomiasis mansoni on the prevalence of 
asthma and rhinitis (Catapani et al. 1997) but was contradicted by another which 
associated S. mansoni infection with a reduced course of asthma (Medeiros et al. 
2003). Nevertheless, S. mansoni infection has been associated with impaired Th2 
responses (i.e. reduced IL-4 and IL-5 production and increased IL-10 and CTLA-4 
expression) in asthmatic patients (Araujo et al. 2004; Oliveira et al. 2009). 
 
2. Timing: it has been suggested that the age of first infection and the duration 
(chronic vs. acute infections) may determine whether or not helminth infection 
protects against atopy (Cooper et al. 2006a). Consistent with this hypothesis, 
Rodrigues and colleagues have shown that early (below 5 years of age) heavy 
infection with Trichuris prevents allergen skin test reactivity in later childhood even 
after elimination of the infection (Rodrigues et al. 2008). Furthermore, antihelminthic 
treatment of S. mansoni infected pregnant women increases the chances of atopic 
eczema in their children, suggesting that helminth ‘protection’ may begin already in 
utero (Mpairwe et al. 2011). However, whether this protection persists during 
adulthood and/or whether this is applicable to all helminth species remain to be 
determined.  
 
3. Infection intensity: it is suggested that heavy parasite burden may confer protection 
via active immune suppression while mild infections may exacerbate allergic disease 
(Cooper et al. 2006a). The role of heavy parasite burden and chronic infection has 
been shown in S. mansoni/mouse model (Smits et al. 2007) but is yet to be 
demonstrated in human populations.  
 
4. The host genetics and socio-economic status are also important factors likely to 
determine the relationship between atopy and helminth infections. Thus, individuals 
genetically predisposed to atopic diseases are likely to develop allergic responses to 
helminth infections and may be more resistant (Lynch et al. 1998). The socio-
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economic status of individuals may also be directly or indirectly associated with the 
levels of exposure and reaction to allergens and/or parasites (Hagel et al. 1993b; 
Hagel et al. 1993d). 
 
Thus, meta-analyses suggest that host genetics and socio-economic status, helminth 
infection intensity, time and duration of infection as well as parasite species are likely 
to influence the ‘protective’ effect of helminth infection on atopy. However, the 
relative contributions of each of these factors remain elusive in human populations, 
possibly due to the complex host-parasite relationships in helminth endemic areas. 
For instance, since the host immune system is ‘sensitized’ already in utero (Weil et 
al. 1983; King et al. 1998), the age of first infection is usually immunologically 
biased. Understanding the relationship between atopy and helminth infections is 
imperative not only in terms of the management of immune disorders but also to 
predict the short and long term consequences of the currently expanding helminth 
control programs. This may also be relevant for the management of allergy in 
helminth exposed populations. 
 
 




Parasite sp., Authors Atopy outcome Association Population age 
Ascaris lumbrocoides    
(Dagoye et al. 2003)
1
 Wheeze, SPT Negative 1-4 years 
(Lynch et al. 1993a)
2
 IgE, PK Negative 5-15 years 
(Palmer et al. 2002)
1
 SPT, airway 
responsiveness 
Positive 8-18 years 
(Cooper et al. 2008a)
2
 Allergen-induced Th2 
cytokines 
None 7-13 years 
(Cooper et al. 2006b)
2
 SPT, wheeze None 9 years mean age 
(Flohr et al. 2010)
2
 SPT 




Trichuris trichiura    
(Lynch et al. 1993a)
2
 IgE, PK Negative 5-15 years 
(Dagoye et al. 2003)
1
 Wheeze, SPT None 1-4 years 
(Rodrigues et al. 2008)
#
 SPT Negative 2-8 years 
    
Hookworm    
(Dagoye et al. 2003)
1
 Wheeze, SPT None  1-4 years 
(Flohr et al. 2010)
2
 SPT 




Schistosoma mansoni    
(Araujo et al. 2000)
1
 SPT, IgE Negative 18±9.7 years 
(Medeiros et al. 2003)
#
 SPT, asthma symptoms Negative 15 years mean age 
Schistosoma haematobium    
(van den Biggelaar et al. 2000)
1
 SPT Negative 5-14 years 
 




) and treatment-follow up (
2
) studies are reported here. 
#
Longitudinal approach but treatment intervention was not the primary objective of 
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1. 4. Schistosomiasis and allergy/atopy 
 
To address the controversy behind the hygiene hypothesis discussed above, the 
current project focuses on uro-genital schistosomiasis, one of the most important 
helminth infections which is highly prevalent in Zimbabwe (Midzi et al. 2008b), and 
atopy, an important risk factor for developing allergic diseases (Johansson et al. 
2004).   
  
 
1. 4. 1. The global burden of schistosomiasis  
 
Schistosomiasis accounts for 3 to 70 million DALYs annually (King and Dangerfield-
Cha 2008), with an estimated 15,000 deaths (Hotez et al. 2008), and children carry 
the heaviest burden of infection (Hotez and Fenwick 2009). With these figures, 
schistosomiasis is classified second only to malaria in terms of human morbidity and 
mortality (Fenwick et al. 2009) and yet, the morbidity due to infection acquired at a 
very young age (i.e below 5 years) may be underestimated (Stothard et al. 2011b). 
 
Schistosomiasis is due to digenetic blood-dwelling trematodes of the genus 
Schistosoma, of which S. haematobium, S. mansoni and S. japonicum are the main 
cause of human schistosomiasis (Gryseels et al. 2006), although S. mekongi and S. 
intercalatum also affect humans (Peters and Pasvol 2007). The global distribution of 
these parasite species as well as the incidence of schistosomiasis is illustrated on 
figure 1. 2 (A-C). It should be noted that the levels of endemicity are highly variable 
within the African continent.   
 
S. haematobium is the causative agent of uro-genital schistosomiasis and is the most 
widely spread in Sub-Saharan Africa. The disease is characterised by both urinary 
and genital lesions (hence the name uro-genital). The urinary aspect of the disease is 
characterised by haematuria (blood in urine), and dysuria (painful urination) and, in 
severe cases, congestive alteration of the kidneys and bladder cancer may occur 
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(Ferguson 1911; Rosin et al. 1994; Gouda et al. 2007). Morbidity associated with 
genital schistosomiasis in women include ovarian cysts, fibroid mass in uterus, 
cervical calcification and subsequent spontaneous abortion (Leutscher et al. 1998) or 
infertility (Bullough 1976; Kjetland et al. 2010). Furthermore, S. haematobium 
infections of the genital mucosa presenting with genital lesions (characteristic of the 
egg granuloma) may be a cofactor for the transmission of HIV (Feldmeier et al. 1995; 
Kjetland et al. 2006). In males, prostatitis, haemospermia (blood in the semen) and 
dyspareunia (painful sexual intercourse) may result from chronic inflammation of 





































Figure 1.2 The global distribution and burden of schistosomiasis 
(A) Distribution of S. haematobium, S. japonicum and S. mekongi; (B) Distribution of S. 
mansoni and S. intercalatum; (C) The prevalence of schistosomiasis (any species). Images are 
from (Peters and Pasvol 2007) and the Schistosomiasis research group at Cambridge 
University (http://www.path.cam.ac.uk/~schisto/, accessed 11
th
 August 2012). 
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Schistosomiasis is typically prevalent in rural areas where natural streams, ponds, 
rivers and lakes harbouring contaminated snails are the main sources of water for 
domestic or occupational purposes such as washing and fishing. School-children 
usually become actively infected by swimming or collecting water while younger 
children and infants become infected when accompanying adults (washing clothes or 
collecting water) or by being bathed in these water sources (Stothard and Gabrielli 
2007).   
 
In Zimbabwe, where the current project was carried out, schistosomiasis has been 
documented for many years. The Atlas of the global distribution of schistosomiasis, 
published in 1987 (WHO), indicates that schistosomiasis was common at least since 
1909, although extensive national surveys were only conducted since 1980 by the 
Blair Research Laboratory of the Ministry of Health (the current National Institute for 
Health Research, NIHR). There is also evidence that molluscicide treatment for the 
control of snail intermediate hosts to reduce transmission has long been applied in 
various regions of the country (Shiff and Clarke Vde 1967; Shiff et al. 1979). S. 
haematobium is the most prevalent and widespread schistosome species in 
Zimbabwe, although S. mansoni also occur in some foci (Taylor and Makura 1985; 
Midzi et al. 2008b). 
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1. 4. 2. The global burden of allergy  
 
Rising rates of allergic diseases have been reported in developed countries since the 
end of World War II (Taylor et al. 1984) and currently constitute a major public 
health issue (Ring 2012). Demographic data in the US have shown an average 
increase in childhood asthma prevalence of 4.3% per year from 1980 to 1996, with 
associated deaths and hospitalisation increasing by 3.4% and 1.4% respectively 
(Akinbami and Schoendorf 2002). In the United Kingdom, according to the British 
Allergy Foundation, 1 in 3 people suffer from allergy at some time in their lives. This 
report indicates that 58% of allergic sensitisations are triggered by house dust mites 
(HDM), a known risk factor for developing asthma and allergic rhinitis (Smith et al. 
1969; Miranda et al. 2011). Consistently, increasing prevalence of asthma in adults 
over a period of 10 years and doubling in school-children over 20 years have been 
reported in Australia (Hopper et al. 1995). A recent study involving 12 European 
countries and 19 centres reported incidences of asthma alone between 5 and 17% 
(average 8%) while allergic rhinitis varies between 23 and 44%, with an average of 
30% (Jarvis et al. 2011). 
 
In less affluent countries, comparable rates of allergic diseases are generally reported 
in urban and suburban areas. Thus, a prevalence of asthma of 9% was reported in 
urban areas of Rwanda (Musafiri et al. 2011) while the International Study of Asthma 
and Allergies in childhood (ISAAC) reported an overall prevalence of 10.9% across 
22 centres in Africa (Lai et al. 2009). Reported incidences of allergic rhinitis range 
from 14% to 54% in urban and suburban areas across African countries (reviewed by 
(Katelaris et al. 2011)). Importantly, according to the ISAAC phase three, although 
the prevalence was generally lower, there were more severe symptoms of 
rhinoconjoctivitis reported in urban centres of developing countries compared to 
those reported in developed countries (Ait-Khaled et al. 2009).  
 
In Zimbabwe, the national prevalence of allergic diseases is unknown; however, 
Sibanda reported that up to 14000 people (1 to 62 years old) were referred to the 
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unique private allergy clinic in Harare, the capital city, for severe disease between 
1997 and 2002 (Sibanda 2003). The study indicated that this allergic population was 
only representative of the very few people who could afford services from the private 
clinic rather than a national prevalence of allergic diseases. The authors also showed 
that the majority (53%) of these individuals were sensitised to the HDM, followed by 
Bermuda grass extracts (35%), findings confirmed by other studies in this country 
(Kambarami et al. 1999; Westritschnig et al. 2003). Interestingly, an atopic 
phenotype was closely related to the overall rainfall during patient’s year of birth 
(Sibanda 2003).  
 
In terms of public health cost, the management of allergy in the UK alone has been 
estimated at £1 billion per year (Gupta et al. 2004). In addition to the cost of 
management, allergic disorders affect the quality of life and personal productivity. 
For example, childhood asthma and allergic rhinitis have been associated with 
attention-deficit disorder, depression, fatigue, learning disabilities as well as the risk 
of drug abuse (Blackman and Gurka 2007; Meltzer et al. 2009; Suwan et al. 2011). 
Furthermore, allergic reactions may result in life threatening conditions such as 
airway obstruction and/or anaphylaxis in susceptible patients (Langran and Laird 
2004; Warner 2007). 
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1. 4. 3. Schistosome life cycle and relevance for atopy  
 
Schistosomes are dioecious (separate males and females) and adult worms live in the 
host’s uro-genital (S. haematobium) or mesenteric (S. mansoni and S. japonicum) 
venous plexus, feeding on blood and globulins through anaerobic glycolysis (Tielens 
1994). The females produce hundreds (S. mansoni, S. haematobium) to thousands (S. 
japonicum) of eggs per day, which are released in the urine (S. haematobium) or 
faeces (S. mansoni, S. japonicum) and excreted to the environment where they can 
remain viable for several days. The life cycle of schistosomes is illustrated on Figure 
1.3. The major stages are shared between the different Schistosoma species, the main 
differences being their snail intermediate hosts (S. haematobium is transmitted by 
Bulinus spp, S. mansoni by Biomphalaria spp and S. japonicum by Oncomelania spp) 
and their localisation in host tissues. These species also differ in their rate of 
penetration into the skin, S. japonicum being faster than S. mansoni and S. 
haematobium (He et al. 2002). 
 





                                         
 
Figure 1.3 Schistosoma life cycle.  
In contact with fresh water, excreted eggs hatch and release the miracidium that 
actively seek out and infect the snail intermediate host in which an asexual 
reproduction cycle is initiated. Four to six weeks after snails have become infected, 
cercariae emerge and search for a suitable definitive host. When the definitive host is 
found, the cercariae penetrate the skin using proteolytic enzymes (McKerrow and 
Salter 2002; Curwen et al. 2006). Within the skin, cercariae transform into 
schistosomula in a process that involves important structural changes to the surface. 
These include shedding of the cercariae glycocalyx and elaboration of a second 
plasma membrane above the single membrane of the cercariae (Hockley and 
McLaren 1973). Schistosomula migrate via the blood to the lungs and then to the 
liver within 7 days post-infection. During this migration, schistosomula acquire host 
proteins and become increasingly resistant to immune attack (Clegg et al. 1971; 
Modha et al. 1996). Schistosomula mature in the portal vein, where adult worms mate 
before migrating via the blood to their uro-genital destination and the female starts 
laying eggs. Image source: www.googleimage.com (Accessed 25th August 2012). 
 
 
Thus, the human immune system is exposed to the parasite larvae (cercariae and 
schistosomula), adult worm and egg antigens. It is important to note that there is a 
non-linear relationship between the number of cercariae infecting, the number of 
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adult worm pairs and the amount of eggs in contact with the host immune system. 
Indeed, there is a large variation in terms of parasite survival and fecundity within the 
host that may determine heterogeneities observed in immune responses within the 
same population. In addition, there is a considerable variation in snail-parasite 
compatibility even within small geographic areas (Rollinson et al. 2001), and a 
relatively small number of snails are generally infected (Akinwale et al. 2011). 
 
Nevertheless, animal studies as well as in vitro studies have demonstrated 
immunological changes and regulatory mechanisms associated with the different life 
cycle stages of Schistosoma spp. Thus, the surface of cercariae (enriched in 
carbohydrates (Samuelson and Caulfield 1985)) and newly transformed 
schistosomula activates the complement (Culbertson 1936; Dias Da Silva and 
Kazatchkine 1980) and elicit pro-inflammatory responses (Jenkins et al. 2005; 
Paveley et al. 2011). Excessive immunological reaction to skin stage cercarial 
antigens results in cercarial dermatitis or swimmer’s itch (Lambertucci 2010), an 
allergic condition also occurring in contact with non-human schistosomes that is 
prevalent in developed countries (Brant and Loker 2009; Fraser et al. 2009; Soleng 
and Mehl 2011). This inflammatory reaction is rarely reported in populations in 
which schistosomiasis is endemic, possibly due to regulatory responses resulting from 
multiple exposures as has been demonstrated in mice (Cook et al. 2011). Such 
regulatory responses may be induced by skin stage schistosomula derived molecules 
such as prostaglandin E2 (PGE2) which up-regulates IL-10 production during skin 
penetration by the parasite (Ramaswamy et al. 2000). These authors also showed that 
human or mouse keratinocyte cultures produce elevated levels of PGE2 upon 
exposure to cercariae. The PGE2 is also secreted by the lung stage schistosomula 
during migration through the capillary beds of the lungs, and this is thought to 
diminish eosinophil infiltrates around the parasites (and thus inflammation (Angeli et 
al. 2001)). In addition, these parasites are capable of inhibiting the expression of 
endothelial adhesion molecules such as E-selectin and vascular cell adhesion 
molecule (VCAM-1), limiting leucocytes recruitment in the lungs (Trottein et al. 
1999). These anti-inflammatory mechanisms in the lungs may explain the reduced 
Chapter 1                                                                                       General Introduction                                                                                                           
  
 22 
severity of asthma symptoms in schistosome infected asthmatic patients (Medeiros et 
al. 2003).  
 
Schistosome eggs are major Th2 triggers as demonstrated in murine studies (Pearce 
and MacDonald 2002; Pearce et al. 2004) and they induce formation of fibrotic 
lesions or granulomata (Henri et al. 2002; Dessein et al. 2004; Coutinho et al. 2007). 
Indeed, an S. mansoni egg-secreted glycoprotein, omega-1, has recently been 
identified that conditions dendritic cells for a Th2 polarisation (Everts et al. 2009). 
However, egg secretions are capable of inhibiting the specific binding of chemokines 
such as CXCL8 (IL-8) and CCL3 (MIP-1α), therefore blocking chemokine-elicited 
migration of neutrophils and macrophages respectively during granuloma formation 
(Smith et al. 2005). These authors identified chemokine binding proteins in S. 
mansoni egg secretions (smCKBPs) and showed that their secretion by live, but not 
dead, eggs alters cellularity (reduced neutrophils and macrophages) and size of the 
granuloma.   
 
Schistosome adult worm antigens also induce Th2 responses and IgE in mice (de 
Oliveira Fraga et al. 2010), baboons (Nyindo et al. 1999) and humans (Hagan et al. 
1991). However, this parasite life stage elicits high levels of modulatory responses 
capable of inhibiting anti-parasite (Maizels and Yazdanbakhsh 2003) as well as 
allergic reactions (Mangan et al. 2004). The latter authors demonstrated that worm 
infection induces IL-10 producing B cells that could protect mice against anaphylaxis 
(measured by a drop in core body temperature and death). They later on demonstrated 
that egg-laying worms exacerbate while single sex worms (precluding egg 
production) inhibit airway hyperresponsiveness (Mangan et al. 2006).  
 
Together, these studies show that the different parasite life cycle stages are associated 
with different mechanisms of regulation and inflammation. Although concurrent 
exposure to all or most antigens is likely in endemic areas, and that the different 
parasite life cycle stages may induce cross-reactive immune responses (Curwen et al. 
2004), different parasite life stages may differentially affect atopic responses.  
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1. 4. 4. Epidemiology  
 
The epidemiological patterns of schistosomiasis differ from those of atopy, mainly 
because of their aetiology. Indeed, while schistosome infection is acquired as a result 
of exposure to parasites, atopy is a genetic predisposition (although the clinical 
manifestations are influenced by environmental factors). 
 
 
1. 4. 4. 1. The epidemiology of schistosomiasis 
 
In schistosome endemic areas, infection levels follow a convex shape with host age, 
where infection intensity rises to peak (highest levels) in childhood-adolescence and 
decline in adulthood (Fisher 1934).  
 
An age-related peak of infection has been recognized in various infectious diseases in 
endemic areas although the age of peak is variable across pathogens: for example, 
severe malaria incidence peaks in early infancy (Snow et al. 1998); higher 
proportions of visceral leishmaniasis are observed in childhood (Davies and 
Mazloumi Gavgani 1999), while Trichuris worm burden peaks in childhood-
adolescence (Bundy 1986).  
 
In schistosomiasis, this peak has been interpreted as reflecting water contact levels 
(Warren 1973). However, longitudinal studies showed that with the same exposure 
rate, ‘resistant’ individuals (i.e those who did not become re-infected at follow up 
despite continuous exposure after treatment) were older than ‘susceptible’ individuals 
(Butterworth et al. 1985; Dunne et al. 1987; Butterworth et al. 1988b), suggesting an 
age-dependent acquired resistance to re-infection. In addition, in communities of 
different parasite transmission, infection intensity peaks at a younger age in areas of 
high transmission compared to low transmission areas (Fisher 1934; Anderson and 
May 1985; Woolhouse et al. 1991a; Fulford et al. 1992), a phenomenon referred to as 
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a ‘peak shift’. This phenomenon, initially demonstrated in malaria infections, reflects 
a positive association between the levels of parasite transmission and the rate of 
development of acquired immunity (Marsh and Snow 1997; Woolhouse 1998).  
 
These observations suggested that rather than host age alone, the age-infection 
patterns of schistosomiasis mirror protective immunity gradually acquired following 
cumulative exposure to parasite antigens (Woolhouse 1998). Consistent with this 
hypothesis, age-related changes in immune responses, with the peak of protective 
antibody and cytokine levels coinciding with the decline in infection levels have been 
reported in S. haematobium endemic areas (Hagan et al. 1991; Mutapi et al. 1997; 
Mutapi et al. 2007). Furthermore, it has been shown that isotype-specific antibody 
responses also follow the peak shift in S. haematobium infection (Mutapi et al. 1997).  
 
More recently, Black and colleagues observed that the rate of acquisition of anti-
schistosome protective responses by schistosome exposed adults, following treatment, 
is dependent on their history of exposure to S. mansoni parasites, being faster in those 
with a longer history of exposure (Black et al. 2010b). These studies, consistent with 
earlier studies on adults occupationally exposed to S. mansoni (Satti et al. 1996b; 
Karanja et al. 2002), were able to demonstrate that resistance to schistosome 
infection/reinfection is acquired independent of the physiological changes and age-
dependent immunological effects (Fulford et al. 1998). However, studies in 
populations recently exposed to S. mansoni have shown that schistosome immune 
responses of children are intrinsically different from those of adults, the latter having 
a propensity to mount more protective responses (Gryseels et al. 1994; Scott et al. 
2004). Fulford et al (1998), explaining these observations, pointed out that age-
related hormones such as adrenal androgens may affect the host’s immune system and 
determine schistosome re-infection rate. Furthermore, they suggested that 
physiological and anatomical changes with age (such as skin thickness) may increase 
host innate resistance. 
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Together, these observations suggest that host age and exposure history are both 
important parameters affecting acquired protective immunity to schistosomiasis, 
although both parameters are closely related. Therefore, in endemic settings, young 
children with a short history of exposure are considered more susceptible to 
infection/re-infection than adults, and this is reflected in the increased intensity (and 
morbidity) among school age children. In addition, recent studies indicate that the 
burden of schistosomiasis may be heavier than previously thought at a younger age 
(i.e in pre-school age children (Odogwu et al. 2006; Garba et al. 2010b; Mutapi et al. 
2011b; Stothard et al. 2011b)).  
 
However, these observations do not preclude the possibility that some individuals 
may be genetically predisposed to heavy infections (Quinnell 2003; Gatlin et al. 
2009). In addition, the patterns of exposure may also influence the host’s 
development of acquired immunity. For example, successive light infections (trickle 
infections) may provide more protective immunity compared to a single mass 
infection as demonstrated in the baboon host (Farah et al. 1997). Furthermore, 
contamination via the oral route may be associated with less egg excretion and more 
tissue-trapped eggs as shown on S. bovis in goats  (Boulanger et al. 1999) and/or 
stimulate levels of anti-schistosome immune responses associated with lower 
intensities of infection (Noureldin 1999) compared to contamination via the 
percutaneous route.  
 
Dumont and colleagues demonstrated in mice that trickle infections with 1 parasite 
genotype provides more protection than trickle infections with 5 parasite genotypes, 
suggesting that the genetic diversity of schistosome parasites in a given area also 
plays a significant role in the development of acquired immunity (Dumont et al. 
2007). These authors also showed that trickle infections with male but not female 
parasites induced subsequent resistance to challenge, a phenomenon thought to be 
associated with antigenic differences between male and female schistosomes 
(Boissier et al. 2003).  
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Collectivelly, these studies indicate that the development of acquired protective 
immunity to schistosomes is highly heterogeneous and that, within a small geographic 
area, some individuals may be more resistant than others despite the fact that their 
source of contamination is the same (rivers, ponds,…). This is translated into large 
variations in terms of individual worm burden but also in terms of regional 
endemicity levels (see Figure 1.2).   
 
 
1. 4. 4. 2. The epidemiology of atopic diseases 
 
Atopy is the genetic predisposition to become excessively sensitised to environmental 
antigens and produce high levels of IgE (Johansson et al. 2004). Atopic diseases 
result from the genetic predisposition in combination with environmental stimuli such 
as allergens, smoke, diet and/or infectious agents (Herr et al. 2011; Prescott 2011). 
The epidemiology of atopic diseases is complex as some diseases may become more 
prominent with age while others diminish or disappear (Spergel and Paller 2003). The 
earliest phases of atopic diseases usually manifest during the first five years of life 
and the severity (and prevalence) of clinical symptoms seem to increase in late 
childhood/adolescence and plateau throughout adulthood (Sporik et al. 1991; 
Bhattacharyya et al. 2011; Martinson et al. 2011) or decline for some conditions 
(Weinberg 2005; Hwang et al. 2010).  
 
It has been suggested that a natural history of allergic manifestations in atopic 
individuals involves progression from atopic eczema (below one year of age) to 
asthma or allergic rhinitis (late childhood/adolescence), a phenomenon referred to as 
the ‘atopic/allergic march’(Weinberg 2005). However, this is not always consistent as 
some children may develop atopic dermatitis long after the onset of asthma (Barberio 
et al. 2008), while some atopic individuals may only develop one of these conditions 
throughout life.   
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Longitudinal studies indicate that atopy in infancy predicts the occurrence and 
severity of asthma (Klinnert et al. 2001) and bronchial hyperresponsiveness (Van 
Asperen et al. 1990) in later life. Total and allergen-specific IgE levels also seem to 
increase throughout childhood in allergic individuals (Matricardi et al. 2009). 
However, a number of events occurring in the first few years of life and in utero are 
likely to influence the onset and persistence of disease. Thus, Klinnert and colleagues 
have shown that respiratory infections during the first year of life and parenting 
difficulties (e.g. post-natal maternal depression) were independent predictors of the 
onset of asthma during early (3 years) and late (6-8 years) childhood in genetically 
pre-disposed children (i. e. those from asthmatic parents (Mrazek et al. 1999; Klinnert 
et al. 2001)).  
 
Microbial exposures and diet of pregnant mothers may also alter early gene 
expression in neonates, influencing the onset of allergy in childhood (see (Holt and 
Strickland 2009; Prescott 2011)). Consistent with this hypothesis is the finding that 
maternal exposure to farm milk and farm animals during pregnancy was associated 
with demethylation within the FOXP3 (Treg transcription factor) locus in cord blood 
and subsequent elevated levels of Tregs in offsprings (Schaub et al. 2009). These 
authors also showed that Tregs of children from farm exposed mothers had 
significantly higher suppressive activity (measured by reduced division and 
proliferation of effector cells) than those from their non-exposed counterparts.  
 
Murine studies have also shown that, when exposed to a methyl rich diet during 
pregnancy (as may be the case for folate supplementation in humans), foetal DNA 
may endergo changes in methylation that results into decreased gene transcription 
activity, leading to subsequent enhanced development and severity of allergic 
diseases (Hollingsworth et al. 2008). These authors also showed that this diet-
associated allergic phenotype was transgenerationally inheritable (persistence of high 
levels of IgE and eosinophilia into the F2 generation). Interestingly, a recent study 
has generated genome-scale DNA methylation maps in mouse gametes and zygote up 
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to post-implantation, which show that this ‘epigenetic’ modification is most dynamic 
and regulated during embryogenesis (Smith et al 2012). 
 
 
1. 4. 5. Effector responses 
  
IgE 
Identified in the 1960s as a ‘carrier of reaginic activity’ (Ishizaka and Ishizaka 1966; 
Ishizaka and Ishizaka 1967), IgE is well known to be a central player in atopic 
diseases and anaphylactic reactions. Investigations in the biology of IgE function 
have revealed that this antibody is part of a protein network involving its 3 receptors, 
namely the FcεRI, the CD23 (or FcεRII) and galectin-3 (Gould and Sutton 2008), all 
of which can be found in soluble forms (Dehlink et al. 2011; Platzer et al. 2011). The 
FcεRI (also termed high affinity receptor) is mainly expressed on mast cells and 
basophils but also on epidermal Langerhans cells (Bieber et al. 1992) and eosinophils 
(Gounni et al. 1994a; Gounni et al. 1994b). Cross-linking of these high affinity 
receptors by IgE induce activation of mast cells and basophils and their 
degranulation. The galectin-3 receptor is expressed on neutrophils and on trophoblast 
cells in placentas (Jeschke et al. 2007), where it is thought to facilitate IgE transport 
(Rindsjo et al. 2010). The CD23 receptor is thought to facilitate the transport of IgE-
antigen complexes but is also involved in the regulation of IgE synthesis (Gould and 
Sutton 2008).  
 
Highly conserved in mammalian lineages (Vernersson et al. 2004), IgE is thought to 
have evolved as a first line of defence against helminth parasites. However, the role 
for IgE in defence against parasites may differ across species depending on the 
distribution of receptors. For example, in contrast to rat and human eosinophils, 
mouse eosinophils do not express the FcεRI or the CD23 (de Andres et al. 1997). 
Therefore, the role for IgE in parasite killing, which has been shown to be enhanced 
by eosinophils in vitro (Butterworth et al. 1977), may differ between these species.     
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IgE antibodies are naturally strongly regulated (possibly because of their 
‘detrimental’ effect) and have the lowest concentrations of all antibodies in serum of 
healthy non-atopic individuals (Gould and Sutton 2008). Mechanisms of regulation of 
IgE include its short half life in serum (Vieira and Rajewsky 1988), the 
poor/inefficient processing of mRNA for the membrane ε heavy chain (Karnowski et 
al. 2006), and the negative feedback regulation by the CD23 (Yu et al. 1994). The 
latter has been a subject of investigations in terms of therapeutic application in atopic 
diseases (as discussed later) but also in autoimmune diseases (Plater-Zyberk and 




The CD23, referred to as the low affinity receptor for IgE, differs dramatically from 
the high affinity FcεRI receptor in terms of structure and function. Thus, while cross-
linking of the latter results in degranulation of mast cells and release of mediators, 
engagement of membrane-bound CD23 suppresses the production of IgE by B 
lymphocytes (Acharya et al. 2010). Indeed, the CD23 has long been proposed as a 
natural regulator for IgE synthesis (Yu et al. 1994) although elevated levels of CD23+ 
B cells have been reported in atopic patients (Aberle et al. 1997). In reality, as 
initially suggested by Aubry and colleagues (Aubry et al. 1992), the CD23 not only 
binds IgE but also CD21, a cell-surface protein expressed on T-cell, B-cell and 
follicular dendritic cells, classically identified as a receptor for complement proteins 
(Weis et al. 1984) or Epstein-Barr virus (Aubry et al. 1992). The interaction between 
CD23, IgE and CD21 may lead to either negative or positive regulation of IgE 










Figure 1.4 Interaction between CD23 and its ligands, IgE and CD21 
Binding of IgE stabilises membrane-bound CD23 (mCD23) and inhibit IgE synthesis 
(I) from activated B cells while in the absence of IgE binding the CD23 is cleaved by 
ADAM10 (a disintegrin and metalloprotease protein 10) and this destabilisation 
enhances IgE synthesis (II.). However, soluble CD23 (sCD23) fragments resulting 
from the cleavage have the ability to bind IgE with different affinities depending on 
their oligomerization state: trimers (III) bind IgE with high affinity while monomers 
(IV) bind with low affinity. Trimers enhance IgE synthesis by their ability to also 
bind CD21 receptor (III) while monomers fail to bind CD21 and inhibit IgE synthesis 
(IV) (adapted from (Hibbert et al. 2005; Conrad et al. 2007; Gould and Sutton 2008; 
Acharya et al. 2010; Bowles et al. 2011)). 




Serum IgG4 antibodies, the least abundant among human IgG subclasses, have long 
been associated with IgE-mediated diseases (Desvaux et al. 1989; Aalberse et al. 
1993; Aalberse et al. 2009). However, rather than the cause of disease, these 
antibodies seemed to be involved in the regulation of IgE-induced anaphylactic 
reactions (Hussain et al. 1992). Indeed, IgG4 may interfere with antigen recognition 
by IgE due to their similar antigenic specificity (Rihet et al. 1992), although different 
epitope-binding (Mutapi et al. 2011a). In a process that involves exchange of fab 
molecules (figure 1.5), IgG4 are structurally hetero-bivalent and often function as 
monovalent (Aalberse and Schuurman 2002; Aalberse et al. 2009), hence their anti-
inflammatory properties (van der Neut Kolfschoten et al. 2007). The interaction 
between IgG4 and a given antigen results in small and non-pathological immune 
complexes (since these antibodies cannot cross-link antigens) (Aalberse and 
Schuurman 2002). Furthermore, in contrast to other IgG subclasses (albeit with 
different affinities: IgG3>IgG1>IgG2), IgG4 cannot fix the complement and in fact 
inhibit complement activation by IgG1 (van der Zee et al. 1986). IgG4 antibodies, in 
allergy or helminth infection, are secreted in response to high antigen loads (Maizels 
et al. 1995; Aalberse et al. 2009; Adjobimey and Hoerauf 2010). The fact that IgG4 
and IgE may not only originate from the same ancestor (Warr et al. 1995), but are 
also differentially regulated by the same cytokines (Punnonen et al. 1993), suggest an 










Figure 1.5 Fab-arm exchange in IgG4 molecules 
The heavy and attached light chain (blue or red) is exchanged between two molecules 
of IgG4 in a continuous process. Although the resulting molecule has two different 
antigen-binding sites, it usually binds a single antigen (monovalent). Figure adapted 




1. 4. 5. 1. Th2 responses in Atopy 
  
The human immune system must distinguish between a dangerous pathogen and 
ubiquitous environmental allergens and has evolved to mount appropriate defensive 
responses to the first while tolerating (or ignoring) the latter. However, a certain 
proportion of individuals fail to tolerate environmental allergens and develop allergic 
diseases such as asthma, atopic dermatitis and allergic rhinitis, which result from 
excessive sensitisation to ordinary exposures to allergens (Johansson et al. 2004). IgE 
antibodies are critical effector molecules in the pathogenesis of these diseases 
(Nguyen and Casale 2011). Mast cells and basophils are coated with specific IgE 
antibodies and this results in immediate hypersensitivity (release of mediators) and/or 
late phase inflammatory reaction (cytokine secretion and recruitment of leucocytes). 
 
In atopic individuals, allergen products (e.g. cysteine proteases) activate epithelial 
cells, which produce thymic stromal lymphopoietin (TSLP), IL-25 and IL-33 which 
in turn initiate Th2 polarisation with increased production of IL-4, IL-5 and IL-13 
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cytokines (Kay 1991; Jutel and Akdis 2011). Th2 cytokines are involved in the class-
switching to IgE as well as the development and recruitment of basophils, mast cells 
and eosinophils (see figure 1.1, c). IgE binds to the high affinity FcεRI receptor on 
mast cells, basophils and eosinophils which (upon exposure to allergens) results in 
their activation and degranulation (via cross-linking of allergens), with the release of 
pre-formed mediators such as histamine, cysteinyl leukotrienes, and prostaglandin D2 
(Dimeloe et al. 2010; Paul and Zhu 2010).  
 
However, a complex interplay between innate and adaptive immune responses 
underlies the heterogenous characteristics of atopic diseases. Thus, recruitment of 
eosinophils into the lungs of asthmatics may be promoted not just by Th2 (IL-5) alone 
but in conjunction with natural killer T cells (NKT) as well as CD8+ T cells (see 
(Lloyd and Hessel 2010)). In addition, IL-17 producing T cells (Th17 (Harrington et 
al. 2005)) may be involved in the severity of asthma (DeKruyff et al. 2009). These 
promote the recruitment and activation of neutrophils and lead to corticosteroids-
resistant (severe) asthma (DeKruyff et al. 2009). IL-9 producing T cell subset (Th9), 
which probably derive from Th2 cells under the influence of TGFβ1 (Veldhoen et al. 
2008), may also be involved in the production of IgE and mast cell recruitment in the 
lungs (Lloyd and Hessel 2010). In allergic rhinitis, mast cells accumulate in the 
epithelium of the nasal mucosa where they secrete inflammatory cytokines (IL-6, IL-
8 and TNFα) in addition to Th2 cytokines (Pawankar et al. 2011).   
 
 
1. 4. 5. 2. Th2 responses in schistosome infection 
 
Acquired immunity to schistosome infection was recognised by Fisher in the 1930s 
when analysing data from animal studies as well as those from hospital-diagnosed S. 
haematobium infected people. Two types of immunity, α and β, arose from Fisher’s 
analysis, the first being directed against schistosomulae for subsequent invasions 
while the latter was directed against the adult worm following hyper-infestation 
(Fisher 1934). The α immunity was based on observations that the decline in infection 
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intensity in endemic communities became nil at an age corresponding to the 
maximum life span of schistosomes, suggesting that incoming larvae do not reach 
maturity once first infections are established. The β immunity was based on his 
observation that infection intensity declined more rapidly in a community where 
exposure to infection was more intense when compared to a community where 
exposure was lighter (Fisher 1934). 
 
The susceptibility of schistosome larvae to immune attack was demonstrated by in 
vitro studies showing that sera from S. mansoni infected individuals could damage 
schistosomula in the presence of normal human peripheral blood leucocytes 
(Butterworth et al. 1974). This antibody-dependent (serum) killing was subsequently 
shown to be eosinophil mediated (Butterworth et al. 1974; Hagan et al. 1985) and 
studies on monoclonal antibodies led to the identification of IgE antibodies with the 
highest cytotoxicity for the schistosomula (Capron et al. 1975; Verwaerde et al. 1979; 
Capron and Dessaint 1981). Field studies were conducted to identify antibody 
responses predictive of resistance to re-infection following chemotherapy. Hagan et 
al (Hagan et al. 1991) demonstrated in a multivariate logistic regression that 
reinfection with S. haematobium  was less likely in individuals producing high IgE 
levels against the worm antigens and more likely in those producing high levels of 
IgG4 against the worm or egg antigens. The role of IgE in resistance was also 
demonstrated by (Rihet et al. 1991), who identified specific antigens (120-165KDa 
and 85KDa) to which IgE reacted (on immunoblots) and showed that these 
antibodies, in contrast to IgM and IgG, were significantly higher in the sera of the 
most resistant individuals. These authors showed that some of the immunogenic 
antigens were readily accessible to IgE on living S. mansoni larvae as they were 
located on the outer membrane. However, Dunne and colleagues, working on S. 
mansoni as well, showed that IgE (produced following treatment) against adult worm 
antigens, particularly a 22kDa tegumental antigen (Sm22), but not against any other 
life-cycle stages were associated with resistance to reinfection following treatment 
(Dunne et al. 1992). Both anti-adult worm and anti-schistosomula tegument IgE 
antibodies were associated with resistance to S. mansoni re-infection in another study 
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in Brazil (Caldas et al. 2000) while anti-egg IgE antibodies also could confer 
protection against S. japonicum re-infection (Zhang et al. 1997).  
 
Collectively, although controversial in terms of the specific target antigen, these 
studies and several others (Satti et al. 1996a; Naus et al. 1998; Jiz et al. 2009; Pinot 
de Moira et al. 2010) have suggested that resistance to schistosome 
infection/reinfection is dependent on IgE antibodies, consistent with findings in the 
baboon host (Nyindo et al. 1999). However, data on other antibody isotypes have 
been reported which correlated with resistance to infection/reinfection. For example, 
IgG3 against the recombinant antigen Sh13 has been associated with resistance to S. 
haematobium infection (Mutapi et al. 2006) while anti worm and cercariae IgM were 
significantly higher in individuals more resistant to reinfection with S. mansoni 
(Caldas et al. 2000). Furthermore, a decline in IgA together with an increase in IgG1 
were associated with resistance acquired with host age as well as following treatment 
in S. haematobium endemic area (Mutapi et al. 1998a).  
 
More recently, anti-worm IgE antibodies, as well as eosinophilia and the low affinity 
receptor for IgE (the CD23) have been shown to correlate with resistance in 
individuals undergoing multiple rounds of treatment (Mwinzi et al. 2009; Black et al. 
2010b), again suggesting that IgE may be directly involved in parasite killing via 
antibody-dependent cellular cytotoxicity (ADCC) in vivo. However, since 
schistosomula are more susceptible to ADCC, it is possible that adult worm specific 
antibody responses may rather target the incoming larvae, a process termed 
‘concomitant immunity’(as predicted by Fisher in 1934) and well demonstrated in 
rhesus monkeys (Smithers and Terry 1967). The latter authors conducted a series of 
experiments showing that rhesus monkeys infected with attenuated S. mansoni 
cercariae were not resistant to subsequent challenge while those to whom adult worm 
pairs were transferred were resistant to challenge (i.e very few incoming larvae made 
it through to maturation) while transferred worms could reproduce, and when 
transferred worms were sectioned and unable to produce eggs, monkeys were even 
more resistant (Smithers and Terry 1967). 




As initially demonstrated by in vitro studies (Veith et al. 1984; Sanderson et al. 1985; 
Sanderson et al. 1986), ADCC is dependent on Th2 cytokines and these have been 
involved in resistance to schistosome infection. Thus, higher ratios of IL-4/ IFN-γ and 
IL-5/ IFN-γ were produced by specific T-cell clones from S. mansoni resistant than 
susceptible individuals (Couissinier-Paris and Dessein 1995) and IL-5 correlated with 
lower levels of S. haematobium infection (Mutapi et al. 2007) and S. mansoni 
reinfection after treatment (Roberts et al. 1993). Furthermore, IL-4, IL-5 and IL-10 
levels were associated with resistance post-treatment while IFN-γ was associated with 
susceptibility (Mduluza et al. 2003). However, significantly higher levels of IFN-γ 
against adult worm and cercariae antigens by PBMCs from resistant individuals 
compared to those from susceptible individuals (Viana et al. 1994), suggesting that 
acquired resistance to human schistosomiasis cannot be exclusively classified into 




Cellular immune responses, although involved in resistance, mediate most of 
schistosome-related pathology (Caldas et al. 2008; Morais et al. 2008). These have 
been classically defined as Th1 characterised by high levels of IFNγ and IL-2, and 
Th2 characterised by high levels of IL-4, IL-5 and IL-13. Human schistosomiasis can 
be divided into acute and chronic diseases based on disease progression.  
 
Acute schistosomiasis is a debilitating febrile disease which often occurs in 
individuals with no experience of infection. It is characterized by high percentage of 
eosinophilia, which may be reversed by chemotherapy (Gazzinelli et al. 1985), 
nausea, urticaria, dry cough and fever (Bastos and Brito 2011; Clerinx et al. 2011). 
Anatomically, this stage is accompanied by a dissemination of large and destructive 
granulomata around the eggs (Cheever et al. 2000; Lambertucci 2010). Higher in 
vitro responsiveness to egg antigens (SEA) compared to adult worm antigens has 
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been shown during acute but not chronic S. mansoni (Caldas et al. 2008) and S. 
haematobium (El Ridi et al. 1997) infections.  
 
Chronic schistosomiasis is often referred to as a Th2 disease and accounts for most 
human immunopathologies in endemic areas (Ikemoto et al. 1990; Cheever et al. 
2000; Coutinho et al. 2007; Wilson et al. 2007; Morais et al. 2008). As infection 
becomes chronic, schistosome eggs lodge in the liver, gut (S. mansoni) or bladder (S. 
haematobium), and the granulomatous response (see Figure 1. 6) translates into 
extensive tissue damage and excessive extracellular matrix protein (ECMP) 
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A    B  
C  D  
Figure 1.6 Schistosomiasis associated pathology:  
A) Granuloma surrounding egg of S. mansoni in liver; B) Periportal fibrosis of the 
liver; C) Squamous-cell carcinoma of the bladder due to S. haematobium; D) 
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Cytokines play an important role in the formation (and regulation) of granulomatous 
responses and pathology (Wilson et al. 2007; Caldas et al. 2008). Thus, in S. mansoni 
infection, cells (whole blood culture supernatants) from patients with acute infection 
responded to egg (SEA) and adult worm (SWAP) antigens with significantly higher 
IFN-γ than those of their chronically infected counterparts presenting with fibrosis 
(Montenegro et al. 1999). Anti-IL-4 antibodies also decreased proliferative responses 
of peripheral blood mononuclear cells (PBMCs) to SWAP in chronically infected but 
not acutely infected patients (Malaquias et al. 1997). More recently, it has been 
shown that peripheral blood eosinophils from patients with periportal fibrosis from S. 
mansoni infection produced significantly more IL-4 and IL-5 to SEA and SWAP than 
those from non-infected and those infected but asymptomatic (Silveira-Lemos et al. 
2008). In S. haematobium infection, IL-5 (to SWAP) production following treatment 
has been associated with microhaematuria 12 months after treatment (van den 
Biggelaar et al. 2002). 
 
Malaquias et al (1997) showed that blockage of IL-10 was associated with increased 
proliferation of PBMCs from patients with S. mansoni intestinal (asymptomatic) 
chronic infection but not of those with hepatosplenic disease, suggesting a role for 
anti-inflammatory response (IL-10) in regulating progression to severe disease. 
Furthermore, in S. haematobium infection, PBMCs from children presenting with 
bladder wall pathology produced significantly lower IL-10 and higher TNFα (pro-
inflammatory cytokine) to egg antigens than those from children equally infected but 
without pathology (Wamachi et al. 2004). TNFα has been associated with 
hepatosplenic and periportal fibrosis in several other studies of S. mansoni infection 
(Zwingenberger et al. 1990; Mwatha et al. 1998; Henri et al. 2002). De Jesus et al 
also reported high levels of IL-1 and IL-6 in peripheral blood, as well as TNFα in 
plasma and peripheral blood, of patients with acute disease (de Jesus et al. 2002). 
These authors also showed that production of IFNγ was higher in PBMCs from 
patients with acute than chronic infections. However, Morais and colleagues reported 
higher levels of IFN-γ in chronically infected patients with hepatosplenic symptoms 
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than in acute patients, and showed that IL-13 could inhibit these responses (Morais et 
al. 2008). 
 
Collectively, these studies have shown that anti-schistosome immune responses are 
associated with pathology, consistent with the role for IgE and Th2 responses in 
allergic disorders. However, during chronic infection, these responses are 
accompanied by regulatory responses that may explain the scarcity of pathology as 
well as allergic symptoms in individuals chronically parasitized in endemic areas (van 
den Biggelaar et al. 2000; Oliveira et al. 2009; Nausch et al. 2011). 
 
 
1. 4. 5. 3. Control of Th2 responses  
 
In addition to the crossregulation between Th1 and Th2 identified initially (Mosmann 
et al. 1986), there is growing evidence that Th2 cells interact with a complex network 
of other T cell subsets as well as B cells and antibodies, naturally or during disease 
(atopic or infectious). Thus, it has emerged that Tregs play an important role in the 
tolerance of ubiquitous antigens and that alterations in the Tregs function (Lee et al. 
2007; Dimeloe et al. 2010) and/or the fine balance between Tregs and Th2 cells 
(Taylor et al. 2004; Akdis 2009) determine the clinical manifestation of atopy. 
Indeed, in healthy (non-atopic) individuals T cell polarization occurs in contact with 
environmental allergens but higher levels of Tregs dampen the effect of Th2 cells, 
leading to peripheral tolerance (Taylor et al. 2004). Tregs modulate the activity of 
Th2 (and Th1) cells via several mechanisms including the secretion of anti-
inflammatory cytokines such as IL-10 and TGF-β (Akdis 2009; McLoughlin et al. 
2011). 
 
IL-10 producing B cells (Bregs) are also involved in the recruitment of Tregs, hence 
contributing to the regulation of Th2 responses as demonstrated in murine models of 
helminth infection (see (Hussaarts et al. 2011)). IL-10 can inhibit effector functions 
of mast cells and eosinophils, and regulate the growth of several cells including B 
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cells, NK cells, mast cells and dendritic cells. Furthermore, IL-10 modulates 
IgE:IgG4 ratios (Dimeloe et al. 2010) possibly by indirectly inducing the antibody 
switch to IgG4 in the B-cell progeny while preventing IgE production (Jeannin et al. 
1998).  
 
IgG4 may control IgE-mediated histamine release as has been demonstrated in 
helminth (filariasis) infection (Hussain et al. 1992). Furthermore, it has recently been 
shown that the binding patterns of IgG4 antibodies correspond to natural recovery 
from childhood IgE-mediated milk allergy (Savilahti et al. 2010), suggesting their 
potential protective role in atopic diseases, although this is still controversial 
(Aalberse et al. 2009). In addition, early observations that IgG4 antibodies were 
highly elevated in sera of patients receiving allergen immunotherapy (Devey et al. 
1976) have prompted the use of IgE:IgG4 ratio as a marker for successful 
immunotherapy (Aalberse et al. 1993; Bullock et al. 2005; Gallego et al. 2010). In 
helminth infections, high IgG4:IgE ratio has been associated with reduced pathology 
while favoring a heavy worm load (Kurniawan et al. 1993; Hoerauf et al. 2005; 
Adjobimey and Hoerauf 2010). Interestingly, IgG4 may be one of the regulatory 
antibodies resulting from IgG syalilation involved in the control of immune disorders 
(Kaneko et al. 2006; Mekhaiel et al. 2011).  
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1. 4. 6. Treatment strategies  
 




The current therapy for atopic reactions is primarily aimed at antagonizing the effects 
of mediators of hypersensitivity (antihistamines), reducing inflammation 
(corticosteroids) or restore broncho-dilation (β-agonists). However, the inhibition of 
IgE synthesis remains the ultimate goal for an effective disease control (Conrad et al. 
2010). The closest approach to this objective is the allergen specific immunotherapy 
(SIT) or ‘desensitisation’. This involves repeated administration of increasing doses 
of allergen to induce regulatory responses or tolerance in atopic patients (Bousquet et 
al. 1998; Canonica et al. 2009; Gallego et al. 2010). This is the only treatment which 
can affect the symptoms as well as the cause since the course of disease is altered on 
the long term (La Rosa et al. 2011). However, well characterised allergens are 
normally required (Gallego et al. 2010) and this therapy is not applicable in case of 
patients with multiple allergies.  
 
The interaction between IgE and its Fc receptors (FcεRI and FcεRII) has been an area 
of intense investigation in terms of IgE control. Initial observations that anaphylactic 
reaction was associated with cell bound IgE and could be reversed in vitro 
(Lichtenstein et al. 1970), led to the development of anti-IgE or anti-epsilon (ε) 
treatment (Lehrer et al. 1983). Although this technique was successful in animals, it is 
with the advent of molecular engineering that ‘humanized’ anti-IgE monoclonal 
antibodies could be produced, one of which (Omalizumab, (Shields et al. 1995)) is 
currently approved for treatment of severe asthma and perennial rhinitis. Omalizumab 
is a monoclonal antibody that binds free IgE and prevent the IgE-FcεRI attachment on 
effector cells, hence blocking allergic reactivity (Vichyanond 2011).  
 
The anti-IgE therapy presents an effective add-on treatment for moderate to severe 
asthma where corticosteroids are not sufficient (Vichyanond 2011). However, in 
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addition to the risk of anaphylaxis (Cox et al. 2007; Cox et al. 2011) and the high cost 
(Brown et al. 2007), this treatment may require lifelong administration (every three 
weeks (Conrad et al. 2010)) since it does not target IgE synthesis. This has stimulated 
interest in the second receptor for IgE, the CD23, which is involved in IgE synthesis. 
Lumiliximab is an anti-CD23 monoclonal antibody thought to mimic IgE binding and 
stabilize CD23, thus preventing its cleavage, and has shown significant reduction of 
Th2 responses (Poole et al. 2005). Furthermore, the principal metalloprotease 
responsible for the cleavage of CD23, the so called ADAM10 (Weskamp et al. 2006; 
Lemieux et al. 2007), has been recently shown, in a mouse asthma model, to be 
directly involved in hypersensitivity reactions (Mathews et al. 2011). The authors 
found that ADAM10-deficient mice, or those treated with ADAM10 inhibitors, 
exhibited significantly lower levels of eosinophilia and airway hypersensitivity than 
normal untreated, and suggested that ADAM10 could be a potential new target for 
IgE-dependent diseases’ therapy. 
 
Helminth therapy is another area of current investigations, albeit yielding 
disappointing results. Thus, hookworm (geohelminth) therapy did not show 
significant effect on clinical signs (Feary et al. 2010). Trichuris suis therapy for 
allergic rhinitis patients did not show any significant effect on allergen-induced 
cytokine responses (Bourke et al, 2012), nor did it improve clinical symptoms (Bager 
et al. 2010). In addition, these interventions are often associated with undesirable side 
effects such as diarrhoea and intestinal discomfort.  
 
In an effort to prevent asthma in children at risk ( those with asthma or allergy in their 
family), large scale interventions of allergen avoidance in the first months of life have 
been conducted but these have also shown no added benefit (Kuiper et al. 2005; Maas 
et al. 2011; Kuikka and Korppi 2012). 
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1. 4. 6. 2. Schistosomiasis control strategies 
 
In the absence of a vaccine, chemotherapy remains the mainstay for schistosome 
control (Fenwick et al. 2009). Improved water supplies and sanitation as well as snail 
control have also been recognised as possible ways of controlling schistosomiasis, but 
these are not always achievable.  
 
Three drugs for treatment of schistosomiasis are recognized: Praziquantel, 
Oxamniquine and Metrifonate. Praziquantel is the drug of choice as it is relatively 
cheap, safe and effective against all the schistosome species affecting humans (Cioli 
and Pica-Mattoccia 2003; Hotez and Fenwick 2009). A single dose of praziquantel of 
40mg per kg of body weight can achieve cure rates of 70 to 95% (Gryseels et al. 
1987; Degu et al. 2002; Midzi et al. 2008a). Oxamniquine is safe but its bioreactivity 
is restricted to S. mansoni and it is very expensive (Axton and Garnett 1976; Caffrey 
2007) while Metrifonate is only effective against S. haematobium and requires 
multiple administrations (Danso-Appiah et al. 2008). The use of these 2 drugs in 
community-based programs is therefore difficult.  
 
Current schistosome control involves targeted mass treatment with praziquantel in 
endemic countries, which aims to reduce the intensity of infection, and thus morbidity 
(Fenwick et al. 2009). The WHO recommended treatment regimens (frequency, 
target) depend on parasite transmission levels: in high risk communities (i.e. ≥50% 
prevalence), treatment of all school-age children and adults at risk once a year is 
recommended; in moderate-risk communities (>10% but <50% prevalence) treatment 
targets all school-age children and adults considered to be at risk once every 2 years; 
in low-risk communities (≤10% prevalence) it is recommended to treat all school 
children once on entry into primary school and once on exit (WHO 2006). Thus, 
current control policy has focused on school-age children, mainly because of the 
higher incidence of schistosomiasis in this age group compared to the rest of the 
community (Hotez et al. 2004). However, recent reports indicate previously 
overlooked high levels of infection in pre-school children (Odogwu et al. 2006; 
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Mutapi et al. 2011b; Stothard et al. 2011b), highlighting the need to include these 
children in schistosome control programs (Stothard et al. 2011a). The safety and 
efficacy of praziquantel in this young age group have been demonstrated (Sousa-
Figueiredo et al. 2010; Mutapi et al. 2011b). However, the immunological 
consequences of treatment remain to be determined.    
 
 
Praziquantel mode of action 
The anti-helminthic action of praziquantel has been documented since 1975 and it has 
been used to treat cestode and trematode infections in animals and humans (Day et al. 
1992) but the molecular target of this drug is still elusive. The largest clinical 
application of praziquantel is the treatment of schistosomiasis (Day et al. 1992; 
Caffrey 2007; Fenwick et al. 2009), therefore efforts to understand the mechanism of 
action of this drug often use schistosomes as model (Greenberg 2005a; Gnanasekar et 
al. 2009).  
 
Praziquantel primarily targets adult worms (Day et al. 1992) but its effect on mature 
eggs and, to a lesser extent schistosomula, has been documented (Webbe et al. 1981). 
More recently, Gnanasekar and colleagues have demonstrated that praziquantel binds 
to the parasite’s myosin light chain which is expressed on adults, schistosomula and 
cercariae (albeit less abundant in the latter (Gnanasekar et al. 2009)).  
 
Upon exposure to praziquantel, schistosome tegument is disrupted and the worms 
undergo paralytic muscle disruption within seconds (Day et al. 1992). Subsequently, 
the parasite antigenicity is changed, with previously ‘hidden’ parasite antigens 
exposed on the worm surface (Sabah et al. 1985). An alteration in schistosome 
metabolism (glucose uptake and lactate excretion) has also been documented (Harder 
et al. 1987a; Harder et al. 1987b). A massive influx of calcium precedes praziquantel 
induced changes in schistosomes (Day et al. 1992), and Ca
2+
 channels have been put 
forward as possible targets of praziquantel (Greenberg 2005b; Greenberg 2005a; Nogi 
et al. 2009).   




Praziquantel and the host immune responses 
Despite direct damage to the parasite tegument, the efficacy of praziquantel also 
appears to be influenced by the host’s immune response as demonstrated in animal 
studies (Sabah et al. 1985; Modha et al. 1990; Fallon et al. 1992). Indeed, by 
exposing schistosome antigens, praziquantel works synergistically with the host 
antibodies for parasite killing, possibly via antibody-dependent cellular cytotoxicity 
reactions (Brindley and Sher 1987b; Brindley and Sher 1987a). More recent studies 
indicate that in vitro praziquantel -induced damage is reversible (Xiao et al. 2009), 
consistent with the early hypothesis that the host specific antibody binding occurs 
before the worm is able to repair the damages in vivo (Redman et al. 1996). 
Furthermore, the effect of praziquantel in immuno-compromised individuals has been 
shown to be limited to affecting fecundity of adult schistosomes (reduced egg 
excretion) while leaving them metabolically active (persistence of circulating antigen 
(Kallestrup et al. 2006)). 
 
On the other hand, praziquantel treatment boosts host antibody responses against the 
parasite (Mutapi et al. 1998a) and cellular responsiveness (Colley et al. 1986; Joseph 
et al. 2004), often resulting in subsequent resistance to re-infection (Black, Muok et 
al. 2010). This may be due to the fact that praziquantel avails previously concealed 
parasite antigens which qualitatively and quantitatively alter the host immune 
responses (Mutapi et al. 2005a) but also by removal of regulatory mechanisms 
(Watanabe et al. 2007). The latter may occur indirectly by the killing of parasites 
which otherwise elicit regulatory responses (Maizels and Yazdanbakhsh 2003), or 
directly by inhibiting the expression of TGFβ signalling and Treg function as has 
been demonstrated in murine studies using praziquantel as an ‘adjuvant’ to DNA 
vaccination against Hepatitis B (Zou et al. 2010).  
 
Naturally acquired immunity against schistosomes –and against helminth parasites in 
general- is known to be slow, partly due to the need for the host immune system to be 
exposed to a certain amount of antigens and partly to the parasite’s ability to evade 
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and modulate the host immune mechanisms (Woolhouse and Hagan 1999; Maizels 
and Yazdanbakhsh 2003). Therefore, praziquantel-induced exposure of parasite 
immunogenic proteins, as well as inhibition of immuno-modulatory responses, would 
accelerate the host protective immunity which normally takes many years to develop 
in response to the parasite’s natural death. However, anti-schistosome responses are 
affected differentially in adults versus children following praziquantel treatment 
(Grogan et al. 1996b; Mutapi et al. 2002; Mutapi et al. 2003), and it appears that 
treatment- associated immunity is related to host cumulative experience of parasite 
antigens (Mutapi et al. 2003; Black et al. 2010b). Collectively, these observations 
suggest that praziquantel- associated protective immunity may be different in young 
pre-school children than in older individuals with a longer history of exposure to 
parasite antigens. 
 
Anti-helminthic treatment has been associated with increased atopy (Lynch et al. 
1993a; van den Biggelaar et al. 2004). More recently, a longitudinal survey on anti-
helmintic treatment during pregnancy has demonstrated that both praziquantel and 
albendazole are associated with increased risk of eczema in offsprings (Mpairwe et 
al. 2011). This raises concerns that helminth control programs may carry the 
detrimental burden of allergy and immune disorders, consistent with the currently 
emerging or expanding allergies in developing countries (Ait-Khaled et al. 2009).  
However, there is little evidence in the literature to support this hypothesis as some 
longitudinal studies have shown that anti-helminthic treatment has no effect on atopy 
(Cooper et al. 2006b) or clinical allergy (Flohr et al. 2010) in helminth endemic 
areas. Nevertheless, it is important to investigate this in different settings as different 
parasites and different population genetic background, age and socio-economic status 










Acquired immunity following praziquantel treatment is generally short-lived and 
treated individuals in endemic areas become rapidly re-infected (Mutapi et al. 1999) 
and there is need for repeated rounds of treatment to achieve significant levels of 
resistance (Black et al. 2010a; Black et al. 2010b). Therefore, although praziquantel 
is effective at reducing infection intensity, vaccination provides a more sustainable 
solution for schistosomiasis control. Furthermore, mathematical models predict that 
vaccination, even with partial protection, would shift and reduce the peak of 
infection, unlike chemotherapy alone (Chan et al. 1997). However, anti-schistosome 
vaccine development has been particularly challenging, largely due to the complexity 
associated with characterizing protective immunity against schistosomes. 
 
Nevertheless, the radiation attenuated cercariae model has provided proof of principle 
for vaccination against schistosomiasis (Minard et al. 1978a; Minard et al. 1978b; 
Mountford et al. 1996). Furthermore, treatment-reinfection longitudinal studies of 
individuals living in endemic areas have shown consistent immune correlates of 
protection (Colley et al. 1986; Hagan et al. 1991; Dunne et al. 1992; Webster et al. 
1996), the knowledge of which has guided vaccine development efforts.  
 
Several schistosome antigens, most of which are shared between the larvae and adult 
worm, have been put forward by the Schistosome Vaccine Development Program 
(SVDP) as vaccine candidates over ten years ago (Bergquist 1998). Of these, the 
28kDa S. haematobium GST, Bilhvax (Capron et al. 2001; Wilson and Coulson 
2006), has successfully completed phase I and II clinical trials and is currently under 
phase III trial. The S. mansoni 14kDa Sm14, with cross-reactivity with Fasciola 
hepatica (Tendler and Simpson 2008), is also targeted for phase I safety trials. Most 
of the other antigens have been abandoned or are lagging behind, partly because they 
showed relatively disappointing results in S. mansoni/mouse experimental settings 
(Bergquist 1998), or because of the lack of industrial scaling up of antigens 
(Bergquist et al. 2005).  
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Nevertheless, none of the schistosome vaccine candidates has been able to confer 
more than partial protection in mice and it is likely that vaccination will be a 
complement to chemotherapy so as to reduce morbidity as well as transmission on the 
long term (Bergquist et al. 2005). Indeed, proteomic approaches have shown that 
praziquantel treatment enhances serological recognition of schistosome antigens, 
including vaccine candidates (Mutapi et al. 2005a). Furthemore, the Bilhvax vaccine 
candidate is currently being evaluated in clinical trial III in association with 
praziquantel treatment (clinical trial no NCT00870649). However, although it is 
predicted that vaccination programs would target young pre-school age children 
(Chan et al. 1997; Siddiqui et al. 2011), the effect of praziquantel on antigen 
recognition at this young age has not yet been investigated. 
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1. 4. 7. Young children in the control of atopy and schistosomiasis: why 
focus on them?  
 
The current project has focused on pre-school children for two main and 
complementary reasons: 
 
1) Previously neglected, evidence is now accumulating that the burden of schistosome 
infection in these young children is significant, highlighting the need to include them 
in mass drug administrations. Praziquantel releases large quantities of parasite 
antigens and works synergistically with the host immune system in the killing of 
schistosome parasites (Modha et al. 1990; Day et al. 1992; Fallon et al. 1992). In 
addition, praziquantel treatment accelerates expression of protective immunity in 
school children and adults living in schistosome endemic areas (Mutapi et al. 1998a; 
Black et al. 2010a), possibly as a result of increased serological recognition of 
parasite antigens (Mutapi et al. 2005a). The effects of praziquantel treatment on 
protective immunity in younger pre-school children, who may be the target for a 
vaccine-treatment intervention (Chan et al. 1997; Siddiqui et al. 2011), are yet to be 
characterised. On the other hand, it has been shown that schistosome infection may be 
associated with reduced levels of antibody responses to malaria vaccine candidates 
(Courtin et al. 2011), suggesting that praziquantel treatment at a young age may 
interfere with routine vaccination. 
 
 
2) Previous studies suggest that helminth infections, especially those acquired at an 
early age (Rodrigues et al. 2008) may ‘shape’ the host immune system and protect 
them from developing immune disorders, suggesting that antihelminthic treatment 
may lead to increased allergic disorders (van den Biggelaar et al. 2004). Others 
suggest that this young age presents a window of opportunity in terms of prevention 
of atopic disorders (Prescott and Nowak-Wegrzyn 2011). There is no established 
control measures for atopic disorders in Zimbabwe and in several other developing 
countries where helminth infections are endemic (and where helminth control 
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programs are expanding), and the burden of these immune disorders is usually not 
documented. Given the burden of allergy in these young children in areas where these 
disorders are prevalent, and the cost of management, it is imperative to assess the 
consequences of antihelminthic treatment in this regard.  
 
 
Humoral immunity in young children 
Early studies have pointed out that young children mount ‘ineffectual’ responses 
which may interfere with (or ‘block’) protective responses (Khalife et al. 1986; 
Dunne et al. 1987; Hagan et al. 1991), suggesting that they may be more susceptible 
to infection/re-infection than adults in endemic areas. The concept of blocking 
antibodies arose from early observations that the eosinophil-mediated cytotoxic 
activity for schistosomulae in vitro could be inhibited by some antigen-antibody 
complexes (Butterworth et al. 1977; Capron et al. 1979). Khalife and colleagues were 
then able to show that IgM antibodies were unable to mediate schistosomula killing in 
vitro and yet these antibodies could specifically inhibit IgG (which showed high 
levels of cytotoxicity)- binding to schistosomula antigen (Khalife et al. 1986). Since 
anti-schistosomula IgM antibodies were higher in susceptible than resistant children, 
these authors suggested that acquired immunity resulted from loosing a blocking IgM 
response (Khalife et al. 1986). Dunne and colleagues reported that the slow 
development of protective immunity in young children following treatment was 
attributable to ‘blocking’ IgG2 and IgM against carbohydrate epitopes expressed on 
egg and young schistosomula (Dunne et al. 1987; Butterworth et al. 1988a). 
However, comparison of different IgG isotype responses against schistosome 
unfractionated egg revealed that IgG4, but not IgG2 or total IgG, reflected the age-
infection profile since these antibodies were highly correlated with infection intensity 
(Dunne et al. 1988), suggesting a role for this isotype in susceptibility to infection. 
Subsequently, Hagan and colleagues in the Gambia, showed that the levels of IgG4 
antibodies were elevated in susceptible young children and decline with age, while 
IgE responses rose with age, and suggested that the slow build up of protective 
immunity could be due to the early development of IgG4 (Hagan et al. 1991). These 
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results were confirmed by Ndlovu and colleagues, who were able to show that IgG4 
and IgM to egg and adult S. haematobium antigens were positively correlated with 
infection intensity and negatively with host age (Ndhlovu et al. 1996). 
 
Nevertheless, although highly regulated, young children do mount protective 
responses against schistosome infection/re-infection. For example, it was shown that 
children as young as 6 years mount an anti- S. haematobium egg-specific IgA and 
IgG1 response pre- and post-treatment respectively (Mutapi et al. 1998a). Anti-
schistosome IgA has been associated with reduced S. mansoni fecundity when 
directed against the Sm28GST antigen (Grzych et al. 1993); while IgG1 was involved 
in eosinophil-mediated schistosomula killing in vitro (Khalife et al. 1989). 
Furthermore, IgG2 antibodies also showed some levels of schistosomula killing in the 
presence of activated eosinophils (Khalife et al. 1989). Although studies on protective 
immunity in children below the age of 6 are scarce, it may be argued that these 
children’s immune system is capable of mounting such responses since they mount 
protective responses to childhood vaccines for example, or malaria (Snow et al. 
1998). However, in evolutionary terms, protective responses may be a trade-off 
between anti-parasite and anti-pathology to increase host survivor in endemic areas, 
which may explain the slow development of resistance to infection/re-infection.  
 
 
1. 5. Aims of the project 
 
The project described in this thesis had two main objectives, both of public health 
significance. The first part of the project was undertaken to characterise the 
relationship between atopy and Schistosoma haematobium infection. This study 
aimed to elucidate the controversy behind the hygiene hypothesis, in keeping with 
efforts to understand the consequences of helminth control programs. Some of the 
hypotheses to explain the discrepancies in the studies investigating the relationship 
between helminth and atopy include that the ‘protective’ effect of helminth infection 
is dependent on the intensity and/or history of helminth infection as well as the 
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helminth species (Cooper et al. 2006a; Flohr et al. 2009). The relative contributions 
of current infection intensity and history of helminth infection on atopy remain 
relatively unexplored in human populations possibly because both parameters are 
inextricable in endemic areas. Comparisons between urban and rural populations in 
endemic areas have attempted to overcome this problem but are confounded by 
differences in environmental exposure and socio-economic status, factors which have 
been independently associated with atopy (Hagel et al. 1993b; Prescott 2011). In this 
project, the study investigating the relationship between schistosome infection and 
atopy was designed to separate, in the same socio-economic and environmental 
conditions, and the same ethnic group, the effects of infection history from those of 
current infection intensity so that the contribution of each parameter could be studied. 
Furthermore, the study investigated whether the soluble CD23, which is involved in 
the regulation of IgE, is associated with atopy and/or current schistosome infection. 
 
The second part of the project was undertaken to investigate the immunological 
consequences of the drug praziquantel in pre-school age (≤5 years) children as part of 
safety and efficacy studies advocated by the World Health Organization. The current 
control strategy for schistosomiasis in endemic areas involves targeted mass drug 
administration, focusing on school children and adults with ‘high risk’ occupations 
(e.g. fishing). Treatment with praziquantel not only clears or reduces schistosome 
infection intensity and associated morbidity (WHO 1993), but also boosts the host 
protective acquired immunity (Mutapi et al. 1998a; Black et al. 2010a). To-date, 
immunological studies of the effect of praziquantel in human populations have been 
conducted mainly on school children and adults, possibly because younger pre-school 
children were excluded from control programs. However, these epidemiological 
studies have shown that praziquantel-induced protective immunity is related to host 
age and history of infection (Grogan et al. 1996b; Mutapi et al. 1998a; Mutapi et al. 
2002; Mutapi et al. 2003; Black et al. 2010b). Therefore, it remains to be established 
whether praziquantel enhances expression of protective immunity in pre-school 
children, who have a shorter history of exposure to parasite antigens. Furthermore, 
with the current call to include pre-school age children in schistosome control 
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programs on one hand, and the influence of schistosome infection on bystander 
antigens (van den Biggelaar et al. 2000; Courtin et al. 2011) on the other hand, it is 
imperative to determine the effects of treatment on co-infection, vaccine development 
efforts as well as atopy. This study was designed to test the hypothesis that 
praziquantel treatment of pre-school age (5 years and below) children exposed to 
schistosome infection alters their natural development of protective immunity to 





1- What are the factors determining the relationship between atopy and schistosome 
infection? 
2- What are the immunological consequences of praziquantel treatment in pre-school 





The specific objectives of this project were: 
 
1. To relate atopy to S. haematobium infection in two Zimbabwean populations living 
in villages with differing infection intensities and dynamics of transmission; 
 
2. To determine the effect of praziquantel treatment on atopic responses as well as 
schistosome specific ‘allergy type’ responses; 
 
3. To determine the relationship of polyclonal IgE and the low affinity receptor CD23 
with atopy and S. haematobium infection;  
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4. To determine the effect of praziquantel treatment on schistosome-specific antibody 
levels, atopic responses and responses to Plasmodium crude and vaccine candidate 
antigens in pre-school children; 
 
5. To identify schistosome antigens serologically recognised by these young children 
and any changes associated with treatment. 
 
Specific hypotheses are detailed in each data chapter. 
 





Chapter 2 contains an introduction to immuno-epidemiological methods and concepts 
and describes the parasitological and immunological methods used in this project. It 
also describes the study design and the study populations for the subsequent chapters.  
 
Chapter 3 is a cross-sectional comparative study relating infection intensity to atopic 
responses in two areas of different infection levels. The relative contributions of 
current infection intensity and history of infection on atopic responses is discussed. 
 
Chapter 4 is a follow up study assessing the effect of praziquantel treatment on atopic 
responses and schistosome specific responses in the two areas. The effects of 
praziquantel treatment on atopic versus anti-schistosome responses are discussed.  
 
Chapter 5 presents the relationships between total IgE and its low affinity CD23 with 
infection intensity and atopy. The controversial role for the total IgE in the protective 
effect of schistosome infection on atopy and a possible role for the CD23 are 
discussed.  
 
Chapter 6 is a sub-cohort study assessing the effect of praziquantel treatment in pre-
school children. The effect of treatment on schistosome specific responses, on anti-
allergen and anti-malaria responses are reported and discussed. 
 
Chapter 7 is a general discussion of the findings from this project and their relevance 
in terms of schistosome control initiatives and the management of atopy.  




Materials and Methods 
2. 1. Immuno-epidemiological concepts  
Comparative approach 
Meta-analyses of human studies investigating the relationship between helminth 
infection and atopy suggest that the outcome of this relationship (negative or positive 
association) is dependent on the intensity and history of infection as well as the host 
genetic background (Cooper et al. 2006a; Flohr et al. 2009; Feary et al. 2011). In this 
project, the effect of schistosome infection intensity and history of infection on atopy 
was investigated using a comparative epidemiological approach. Two neighbouring 
populations, with the same ethnicity and socio-economic status, but with different 
levels of exposure to schistosome infection were selected and their atopic responses 
were related to their current infection intensity. This comparative approach has 
proven successful in several epidemiological studies (Woolhouse et al. 1991b; 
Fulford et al. 1992; Mutapi et al. 1997; Mutapi et al. 1999; Blackwell et al. 2011) for 
studying disease and immunological patterns where the history of exposure to the 
pathogen cannot be separated from age in lifelong permanent residents of endemic 
areas. This means that host age can be used as a proxy for the cumulative history of 
exposure to infection. 
 
In schistosome endemic areas with different transmission levels, the age of the 
population at which the highest infection intensity and prevalence occur is lower 
where transmission levels are higher (Fisher 1934). In other words, there is a negative 
correlation between the peak (highest level) of infection and the age of peak when 
areas of different infection levels are considered (Woolhouse et al. 1991a; Fulford et 
al. 1992). Thus, individuals in high infection areas accumulate infection more rapidly, 
acquiring higher infection intensities at a younger age than their counterparts in low 
infection areas (Woolhouse 1998). As a result, and because immunity is gradually 
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acquired as a function of cumulative exposures to parasite antigens (Fisher 1934; 
Woolhouse and Hagan 1999), individuals in high infection areas should acquire 
protective immunity more rapidly (Mutapi et al. 1997; Woolhouse 1998).  
 
 
Quantifying infection  
The gold standard methods used to diagnose schistosome infection in the field 
involve egg count in 10ml urine after filtration (S. haematobium) or in stool after 
sieving (S. mansoni, S. japonicum) as originally introduced by Mott and Katz (Katz et 
al. 1972; Mott 1983) respectively. Infection intensity is then expressed as eggs per 
10ml of urine or eggs per gram (EPG) of faeces. However, since egg excretion varies 
between days and within a day (Warren et al. 1978; De Vlas et al. 1992), several 
examinations are performed to increase the sensitivity of these techniques. 
 
The disadvantage of the egg count technique is that it does not always detect low 
levels of infections, in addition to its inability to detect pre-patent and single sex 
infections. Immunological based diagnostics present an alternative and these are 
currently recommended when estimating worm burdens in infants and pre-school 
children who are likely to carry early stages of infection (Stothard et al. 2011b). One 
of the immunological methods largely used is the detection and quantitation of 
circulating antibodies, which also gives an indication on the development of acquired 
immunity of an individual both before and after treatment. 
 
Detection, measurement and characterisation of antibodies 
In the current project, total and specific antibodies were detected in serum using 
Enzyme linked immuno-sorbent assay (ELISA), a technique widely used for the 
detection and quantitation of antibodies (O'Beirne and Cooper 1979; Peters et al. 
1979). Gel electrophoresis and Western blotting technique (Burnette 1981) were also 
used to identify immunogenic proteins (i.e proteins eliciting an antibody response) 
from crude homogenate parasite antigens. This is particularly relevant when 
characterising protective immunity because not all parasite proteins elicit a detectable 
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(and effective) antibody response. Gel electrophoresis allows separation of proteins 
according to their molecular weight and/or electrical charge. The resulting proteins 
are transferred (western blotting) onto a membrane (usually a nitrocellulose) and 
reactive proteins are identified by chemiluminescence or fluorescence.  
 
 
2. 2. Study design 
 
This project was part of investigations run in collaboration between researchers from 
the University of Edinburgh, the University of Zimbabwe and the National Institute 
of Health Research (NIHR), Harare, aiming to ‘understand bilharzia’ and ‘assess the 
safety and efficacy of praziquantel treatment in pre-school age children’. These 
investigations involve cross-sectional and longitudinal surveys on various aspects of 
immune responses, morbidity and exposure patterns of communities exposed to 
different levels of S. haematobium infection in Zimbabwe. The project described in 
this thesis had two aspects, both focusing on humoral immune responses before and 
six weeks following treatment. The first was a comparative study involving two 
communities living in high (Magaya) and low (Chitate) infection areas, aiming to 
investigate the relationship between infection and atopy. The second aspect of this 
project aimed to extend previous safety and efficacy studies on praziquantel treatment 
of pre-school age children at an immunological level.  
 
 
2. 2. 1. Relating atopy to schistosome infection  
 
The purpose of this study (chapter 3 to 5) was to test hypotheses raised by meta-
analyses of human studies as well as murine models investigating the relationship 
between helminth infection and atopy: 1) schistosome infection intensity and/or 
history of infection are related to atopy; 2) The effect of anthelmintic treatment on 
allergen-specific antibody responses and/or ‘allergic-type’ antibody responses to 
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schistosome antigens is dependent on infection levels at the time of treatment and/or 
the history of infection; 3) The soluble CD23 and/or total IgE are involved in the 
relationship between atopy and schistosome infection. 
 
A pre-treatment cross-sectional survey, involving recruitment of school children and 
community members was conducted concurrently with a questionnaire-based 
demographic survey. The questionnaire (Appendix II), administered in Shona (the 
local language), allowed investigations on age, gender, residency history, treatment 
history, water contact behaviours and sanitation. School registers were also used to 
ensure accuracy of age and gender data (for school children).  
 
Skin prick tests (for allergic reactivity) were performed (Figure 2.2A) and stool, urine 
and blood samples (Figure 2.2 B-D) were collected from all compliant participants. 
After collection of all samples, all compliant participants were treated with the 
recommended dose of praziquantel (40mg/kg body weight) and albendazole (400mg) 
to comply with the WHO guidelines for helminth control (Montresor et al. 1998; 
WHO 2006). Both anti-helminthics were administered regardless of infection status 
in agreement with ethical permissions. Post-treatment samples (urine, stool and 
blood) were collected six weeks after the first survey.  
 
Because placebo or staggered treatments were not ethically acceptable in these 
communities, only participants who refused treatment for religious reasons (or were 
absent on treatment days) but wished to remain in the study formed the untreated 
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2. 2. 2. Investigating the effect of praziquantel treatment in pre-school 
children 
 
This project (chapter 6 & Appendix I) follows on a previous study showing that 
praziquantel treatment was well tolerated and significantly reduced infection in this 
age group (Mutapi et al. 2011b). The study aimed to investigate the effect of 
treatment at the immunological level in light of studies in older individuals indicating 
that 1) anti-helminthic treatment alters immune responses to bystander allergen (van 
den Biggelaar et al. 2004); 2) schistosome infection impairs immune responses to 
malaria vaccine candidates (Courtin et al. 2011) and 3) praziquantel works 
synergistically with the host immune system and alters anti-schistosome immune 
responses (Modha et al. 1990; Mutapi et al. 2003; Black et al. 2010a) and humoral 
antigen recognition (Mutapi et al. 2005a).  
 
Participants in this study were recruited from grade zeros (4-5 years) but also from 
the local communities when brought by parents/guardians (mainly younger children). 
A questionnaire (Appendix III) was answered by the parents/guardians of the children 
(1-5 years old) recording age, gender, treatment history, general socio-economic 
indicators, access to health care, general health conditions, water contact behaviours 
and general knowledge on schistosome infection (Mutapi et al. 2011b). It was crucial 
to assess the current health status of these children since the primary objective of this 
study was to investigate the safety of praziquantel treatment. Therefore, in addition to 
questionnaire responses on health conditions, all children underwent a clinical 
assessment by the nursing stuff before treatment. Anti-helminthics were crushed and 
administered with orange juice with the help of the parents/guardians. 
 
Stool, urine and blood samples were also collected from these children as for older 
individuals before and six weeks following treatment. However, it was not always 
possible to obtain stool/urine samples on the spot for some children and where 
necessary (and possible) an overnight sample was collected by the parent/guardian. 
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2. 3. Ethical considerations 
 
Permission to conduct the study in the region was obtained from the Provincial 
Medical Director. Institutional and ethical approval was received from the University 
of Zimbabwe and the Medical Research Council of Zimbabwe respectively. In 
addition, the study on pre-school children received ethical approval from the World 
Health Organization’s Research Ethics Review Committee. At the beginning of the 
study, all participants and parents/guardians of participating children had the aims and 
procedures of the project explained fully in the local language, Shona. Written 
consents were obtained from participants and parents/guardians of participating 
children before enrolment into the study. After collection of all samples, all compliant 
participants were offered anti-helminthic treatment with the
 
recommended dose of 
praziquantel (40 mg/kg of body
 
weight) and albendazole (400mg). Only compliant 
participants were included in the study and all recruited participants were free to 
withdraw at any time. Each participant was allocated a unique case number and all 
pre and post-treatment samples and data collected from an individual was identified 
by case number.  
 
Collection of blood samples and administration of anti-helminthics were carried out 
by nursing staff from Murehwa District Hospital and local clinics. Diagnosis of S. 
haematobium infection and co-infections (HIV, malaria, soil-transmitted helminths 
and S. mansoni) was conducted anonymously in agreement with ethical permissions. 
 
 
2. 4. Study area  
 
The studies were conducted in three villages, Magaya, Chipinda and Chitate (see 
Figure 2.1), in the Mashonaland East Province of Zimbabwe where S. haematobium 
is endemic. Based on WHO criteria, these villages are classified into high (prevalence 
≥50%), medium (≥10% but <50%) and low (<10%) risk communities respectively 
(WHO 2006). The study villages are in close proximity within a 10km range of each 
other and within the same district (Murehwa), and villagers are of similar ethnicity 
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(Shona) and socioeconomic background (subsistent farmers). Safe water and 
sanitation coverage are equally poor in the villages (as indicted by questionnaire 
studies) and human contact with water potentially harbouring cercariae is frequent.  
 
It was not practically feasible to conduct a direct observational water contact survey 
for the purpose of the current studies. However, a subset of water contact sites (rivers, 
ponds, wells) and participant’s homesteads were mapped using global positioning 
systems (GPS) to give an indication on exposure rates. In addition, S. haematobium 
intermediate host snails, Bulinus spp, were identified from water contact sites 
determined by GPS mapping (Mitchell and Appleby, unpublished data).  
 
The samples were collected from primary and secondary schools (within the 3 
villages) that were selected based on data from a pre-survey in the area showing 
presence of S. haematobium and very low prevalence of S. mansoni and geohelminth 
infections. During the pre-survey, community meetings were held where all enrolled 
school children as well as members of the local community were informed about the 
study and invited to participate.   
 
Participants for the studies described in chapters 3 to 5 (relating atopy to schistosome 
infection) were from Magaya and Chitate which had significant differences in 
infection levels. The fundamental difference in the two villages is the seasonality of 
the rivers which provide habitats for schistosome intermediate host snails. Magaya 
village is characterized by perennial rivers which lead to high transmission rates of 
schistosome parasites compared to Chitate village which is characterized by seasonal 
streams. In addition, households in Magaya are built along rivers whereas in Chitate 
they are more dispersed and built further from the rivers (as indicated by GPS 
mapping studies).  
 
Participants for the studies described in chapter 6 (effect of treatment in pre-school 
children) came from Chipinda in addition to the two villages described above 
(Magaya and Chitate). Including children from all three villages allowed the study to 
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investigate the effect of praziquantel on early immune responses regardless of overall 
transmission levels. 
 
In this study area, malaria transmission is seasonal as indicted by previous mapping 
studies in Zimbabwe (Mabaso et al. 2005; Mabaso et al. 2006) and the prevalence is 
generally low due to the high altitude of the area (Taylor and Mutambu 1986).  
 
The incidence of geohelminth and S. mansoni infections is relatively low in the study 
area, a characteristic which has been reported in other rural areas of Zimbabwe 













Figure 2.1 Map of Magaya, Chitate and Chipinda and water contact sites.  
The map was generated from GPS coordinate data collected in the field and 
coordinates were overlaid onto a GoogleEarth’s satellite image of the area. Green 
markers represent schools where samples were collected from in the 3 villages, white 
circles represent participants’ homesteads, blue lines represent rivers, black lines are 
roads and red crosses represent local hospitals. Map coordinates are 17°39’40.18’’ 




2. 5. Methods 
2. 5. 1. Parasitology 
 
All the parasitological tests described here were performed by trained laboratory 
technicians from the NIHR. Stool samples, for the diagnosis of S. mansoni and geo-
helminths, and urine specimens, for the diagnosis of S. haematobium infection, were 
collected on 3 consecutive days (at least 2 specimen were collected from each 
participant) and processed using standard procedures (Katz et al. 1972; Mott 1983). 
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Briefly, for S. haematobium, 10mls of urine was filtered (using a syringe, see Figure 
2. 2) through a polyamide filter which was then examined under a light microscope 
and eggs (if present) counted. For S. mansoni and geo-helminths, stool specimen were 
sieved and Kato Katz slides prepared using standard templates (41.7mg), before being 
stained with glycerol-malachite green for visualisation under a light microscope.   
 
Malaria infection was diagnosed by microscopic examination of thick and thin smear 
blood slides prepared from freshly collected venous blood and confirmed by the 
paracheck Pf® kits (Orchid, catalogue #30302100). The latter is a rapid and sensitive 
test which detects the presence of HRP-2 (histidin rich protein: a water soluble 
protein released by parasitized erythrocytes) in whole blood.   
 
HIV status was determined using the USAID-approved DoubleCheckGold HIV 1&2 
(Orgenics Catalogue# 70633020), a rapid immunochromatography assay for HIV-1 
and HIV-2 antibodies in whole blood. Positive results were confirmed by ELISA 
conducted at the NIHR. HIV testing was done and recorded by technicians who were 
blinded to the identities of the study participants. 
 
2. 5. 2. Sera collection 
 
Five to 10mls of blood were collected from each participant into a silicon-coated tube 
without anti-coagulant for isolation of sera. The blood was transported on ice packs 
from the field to the Murehwa (local district) hospital laboratory and stored at 4°C 
overnight. After centrifugation (1800rpm) the following day, sera was extracted and 
frozen at -20°C, before being transported to Edinburgh (on dry ice) where 
immunological assays were conducted. All sera were stored at -80°C upon arrival to 
Edinburgh until use. 
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2. 5. 3. Skin prick tests 
 
Skin prick tests were conducted on a sub- population (N=332) before treatment using  
4 allergens prevalent in Zimbabwe (Kambarami et al. 1999), house dust mite  (HDM) 
(Dermatophagoides pteronyssinus), Grass mix, Alternaria tenius, and Aspergillus 
fumigatus (all from Diagenics, Ltd). A drop of each allergen was placed on the upper 
side of the lower arm before the skin beneath the drop was pricked using a lancet. The 
skin was then wiped and, 15 minutes later, the size of the weal diameter was 
measured whenever the skin reacted to a given allergen. Histamine and saline 
solutions (Diagenics, Ltd) were used as positive and negative controls respectively. 
Reactions were considered positive if the weal diameter was equal or greater than the 
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A   B  
C  D ...................  
Figure 2. 2. Immuno-epidemiological field survey  
Photographs showing (A) the skin prick test, (B) Kato Katz slide preparation, (C) 
urine filtration and (D) serum extraction from whole blood. 
 
2. 5. 4. Antigens and antibodies 
Antigens 
All S. haematobium antigens (soluble egg antigen, cercariae and adult worm antigens) 
were lyophilized crude homogenates obtained from the Schistosome Biological 
Supply Centre at the Theodor Bilharz Institute in Egypt. Freeze-dried preparations 
were reconstituted in ultra pure water and protein content determined by Bradford 
protein assay. Reconstituted proteins were aliquoted and frozen at -20°C until use.  
 
Dermatophagoides pteronyssinus allergen was the natural affinity purified Derp1 
allergen (NA-DP-1-2) obtained from Indoor Biotechnologies Ltd. The allergen is 
purified from a mite culture by multi-step chromatography. 




Crude P. falciparum schizont antigens were of the Wellcome strain. Briefly P. 
falciparum cultures were lysed by washing with 0.15% w/v saponin to produce a 
parasite rich pellet. Pellets obtained from saponin lysed parasite cultures were 
sonicated on ice twice for 30 sec at 10 Amp and centrifuged at 16000 rpm for 10 min; 
the supernatant was filtered through a 0.22uM PES syringe filter. Plasmodium 
merozoite surface proteins (MSP) were prepared as recombinant proteins in E. coli. 
Briefly, DH5α E. coli plasmids were inoculated in an LB broth/Ampicillin media and 
incubated overnight at 37°C on a shaker, washed and transferred in fresh 
LB/Ampicillin media and incubated until mid lag phase. Isopropyl β-D-1-
thiogalactopyranoside (IPTG), a lactose metabolite that triggers transcription of the 
lac operon was then added and cultures incubated at 25°C before the cells were 
harvested and lysed by sonication on ice. Proteins were eluted in 50mM Tris HCl 
10mM glutathione (pH8.0) and protein concentration was quantified by bicinchoninic 




All the antobodies used for ELISAs and Western Blotting, their catalogue numbers 

















Reagent Description Supplier Catalogue 
number 
IgG Detection Sheep anti-human, 
peroxidase conjugate 
The Binding Site AP003 
IgG4 Detection Sheep anti-human, 
peroxidase conjugate  
The Binding Site AP009 
IgM Detection Rabbit anti-human, 
peroxidase conjugate 
Dako P0215 
IgE Capture Rabbit anti-human Dako A0094 
IgE Detection Goat anti-human Sigma A9667 
IgE Standard Human serum 
immunoglobulin 
NIBSC 75/502 
CD23 Capture Mouse anti-human 
IgG1 
R&D Systems MAB1231 
CD23 Detection Goat anti-human IgG1, 
biotin 
R&D Systems BAF123 
CD23 Standard Recombinant human  
CD23 
R&D Systems 123-FE 
 
Table 2.1 Antibodies used for ELISA and Western blotting experiments with 
descriptions as supplied on product sheets at the time of purchase. 
 
 
2. 5. 5. Antibody assays 
ELISA protocol 
ELISA method was used to quantify antibody levels both before and after treatment 
in serum. Microtitre 96-well plates (Greiner-Bio One) were coated overnight at 4°C 
with antigen or capture antibody diluted in carbonate bicarbonate buffer (see buffers 
and gel recipes, Appendix IV). Plates were washed once in PBS/tween20 and blocked 
for 2 hours with skimmed milk or bovine serum albumin (BSA) to avoid non-specific 
binding. After three washes to remove unbound blocking agent, serum samples were 
added onto the wells and plates were incubated at 37°C for two hours. After three 
washes to remove excess serum components, the secondary antibody was added and 
plates incubated again at 37°C for 1 hour. Serum samples and secondary antibodies 
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were diluted in blocking buffer to minimize the non-specific binding effect since this 
may occur on the plate at any time during the assay. 
 
Secondary antibodies used were either horseradish peroxidase (HRP) conjugated or 
biotinylated (anti-CD23 only). In the case of peroxidase conjugated secondary 
antibody, plates were washed six times and the substrate (ABTS) added. In the case 
of biotin antibody, plates were washed 4 times and incubated with streptavidin-HRP 
(enzyme) for 2 hours before adding the substrate. The colorimetric reaction 
(expressed in optical densities) was detected and quantified by an ELISA reader 
(spectrophotometer) at a wavelength of 405nm.  
 
Optimizing ELISA protocols 
Optimum dilutions of antigens, sera, secondary antibodies and recombinant standards 
(where applicable) as well as enzyme-substrate incubation times were determined by 
several serial dilutions, based on protocols previously developed in our research 
laboratory  (Milner et al. 2010) and those recommended by manufacturers. Two 
different types of ELISA plates were tested, those from Thermo Scientific Nunc, and 
those from Greiner Bio One. No significant differences were observed between these 
microplates and the latter were selected for use in all assays as they were relatively 
cheaper.  
 
All ELISA protocols were developed in a similar way (optimum 
dilutions/concentrations and incubation times are detailed in each chapter). The 
method was developed using 6 pools of sera from: 1) European children aged 1 to 5 
years who have never been to schistosome endemic areas, 2) European adults who 
have never been to schistosome endemic areas, 3) Zimbabweans (study participants) 
aged 1 to 5 years, 4) Zimbabweans aged 6 to 15 years, 5) Zimbabweans aged 16 years 
and above and 6) Zimbabweans with the highest skin prick reactivity.  
 
ELISA plates were coated with antigen (capture antibody for total IgE) at 5ug and 
10ug per ml each (0.5ug and 1ug/ml for capture CD23 antibodies). On each plate, 
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sera were added diluted from 1:2 to 1:512 and secondary antibody at 1:250 (0.1ug or 
0.2ug/ml for CD23). This was repeated with secondary antibody diluted at 1:500, 
1:1000 and 1:2000 respectively. Optimum concentrations were deduced from 
checkerboard titrations (e.g., see figure 2.3). The same ELISA settings were 
conducted on recombinant antibody standards (for CD23 and total IgE assays) to 
determine the top standard concentration for standard curve generation. The standard 




Figure 2.3 Checker-board titration  
Titration curve of pool sera against the CD23 at 1ug/ml (pool 1: Zimbabweans aged 6 
to 15 years; pool 2: Zimbabweans aged 16 years and above; pool 3: Zimbabweans 
aged 1 to 5 years; pool 4: Zimbabweans with the highest skin prick reactivity; pool 5: 
European adults who have never been to schistosome endemic areas; pool 6: 
European children aged 1 to 5 years who have never been to schistosome endemic 
areas). The optimum serum dilution for subsequent assays was decided on 1:2 since 
this is the intermediate dilution where the linear phase of the reaction occurs for all 
sera (including sera with the largest and the smallest amount of CD23).  
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The reaction time for the enzyme-substrate reaction was determined by reading plates 
every 10 minutes for an hour and plotting the results (absorbance against time) to 
detect the linear phase.  
 
To minimize variations across plates, positive and negative controls were repeatedly 
run on each plate and plotted to detect any outliers (in which case assays were 
repeated). Outliers were statistically determined as equal or above the critical values 
for a given coefficient of variation (CV=mean/standard deviation) as described by 
(Reed et al. 2002). The positive controls were 2 pools of sera, one from individuals 
presenting with the highest infection intensities across the age range and one from 
individuals with the largest skin prick wheal sizes. The negative control was a pool of 
sera from European individuals who have never had schistosome infections. Six sera 
were assayed (and compared) at pre and post treatment time points and on all plates 
to make pre- and post-treatment assays comparable (the CVs for these were also 
determined). To account for background variation, a blank well (containing no sera) 
was included on each plate and absorbance subtracted from all plate-readings. All the 
samples and the blank were run in duplicate on each plate and reported values are the 
means of duplicates.  
 
To determine the cut-off points for IgM levels for the study on pre-school children 
(chapter 6), three sera from European children aged two to three years old who have 
never left the UK, therefore not exposed to schistosome and/or malaria infections, 
were used.  These were run on each plate and the cut-off point was determined as the 
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2. 5. 6. Statistical methods 
 
Statistical analyses were conducted using the statistical package PASW 17.0 unless 
otherwise stated. Statistical methods used to answer the different questions are 
detailed in each chapter but an overview of the statistical approach used is discussed 
here. 
 
General linear models (GLMs) were used in this project to study relationships 
between epidemiological variables. GLMs are statistical models that provide 
regression or analysis of variance (ANOVA) for models containing both categorical 
and continuous variables (Rutherford 2001). These are parametric tests and therefore 
assume fulfilment of a number of criteria (see (Mutapi and Roddam 2002)): 1) the 
normal distribution of residuals; 2) the homogeneity of variance; 3) the linearity of 
the relationship between the dependent and independent variables; 4) orthogonality 
(i.e. independent variables do not share information). The data presented in this thesis 
did not fulfil these criteria and data transformations were used to overcome these 
problems. Parametric tests were performed rather than non-parametric tests as these 
are more powerful and allow studying the relationship between epidemiological 
variables while controlling for confounding factors.  
 
Schistosome infection intensity, as is typical in most schistosome endemic areas 
(Mutapi et al. 1997; Gryseels et al. 2006), was heavy only in a small proportion of 
individuals while the majority had little or no infection, i.e. infection distribution was 
aggregated or skewed rather than normally distributed. Therefore, to fit an ANOVA 
that gave normally distributed residuals, infection intensity data were log transformed 
after adding 1 unit to all data to avoid zeros. This transformation also reduces the 
influence of large values, hence allowing the ‘homogeneity of variance’ criterion to 
be fulfilled (Mutapi and Roddam 2002). 
 
Antibody responses were also aggregated and square-root transformations were 
performed which were found to give more normally distributed residual plots. 
Pearson correlations or regression analyses were performed when relating continuous 
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variables such as antibody levels and infection intensity. For these, residuals from the 
GLM (allowing for age, gender and village of residence) were used because both 
variables are dependent on age, gender and transmission levels (Woolhouse et al. 
1991a; Woolhouse 1998). The age was categorised into either age groups in which 
the age-infection relation was linear (pre-peak, peak, post-peak) or groups of similar 
age intervals. Categorizing age is the most convenient way, rather than mathematical 
transformation (Mutapi and Roddam 2002), that allows fitting this variable in a GLM 
since the relationship between age and infection (or age and immune responses) is 
non linear. 
 
GLMs were used to test the effects of several variables on the dependent variable. 
However, some of the variables shared information (non orthogonality): for example, 
infection intensity was age-dependent and so were antibody responses. For this 
reason, the variable of interest was entered last in the model and sequential sums of 
squares rather than adjusted sums of squares were used. The sequential sum of 
squares allows the hierarchical decomposition of the sources of variation in the 
dependent variable, so that the effects of each variable on the dependent variable are 
adjusted only for the effects of preceding variable(s) (Mutapi and Roddam 2002). 
 
Prevalence data (binary: negative or positive) were analysed using Pearson Chi-
squared tests. These statistical calculations test whether two or more categories 
contain the same proportion of values by comparing expected and observed 
frequencies in each category.  
 
Non parametric tests were used in chapter 6 where transformations did not allow 
fulfilment of parametric tests’ criteria, possibly due to the small sample size. When 
performing multiple statistical comparisons, a Bonferroni correction was used to 
identify results that were significant at the ‘table-wide’ level (Rice 1989) to avoid the 
probability of making a type 1 error (rejecting the null hypothesis when one should 
not). This was particularly important since non parametric tests are not as powerful as 
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parametric tests and the chances of making type 1 error increase with the number of t-
tests performed (Rutherford 2001). 
 
2. 5. 7. Selection of study groups 
 
The numbers of recruited and followed up participants for the different studies 
(described in different chapters) are represented in figure 2.4. All compliant 
participants were recruited but to be included in the analyses a number of criteria had 
to be fulfilled:  
 
1) To be lifelong resident of the village: it was necessary to exclude individuals who 
were not lifelong residents so that host age could be used as a measure of exposure 
history. This was assessed by questionnaires (Appendix 1 & 2). Inclusion of lifelong 
permanent residents of the area also allowed separation of the effects of age alone 
from those of history of infection when comparing areas of different infection levels.  
 
2) No prior treatment: Because praziquantel treatment alters serological responses 
(Mutapi et al. 2003; Mutapi et al. 2005a), individuals who had been treated before the 
study were excluded to avoid bias in interpretation. Very few cases (6) were excluded 
on this criterion since the study area was not covered by schistosomiasis control 
program.  
 
3) Co-infections: Seven participants were S. mansoni egg positive and were excluded 
since S. mansoni and S. haematobium may differentially affect immune responses 
(Agnew et al. 1989). It is possible that some individuals carried pre-patent or single 
sex infections with S. mansoni undetected by the egg count technique but the 
detection of such cases was beyond the scope of this study. S. mansoni egg positives 
were excluded rather than accounted for in statistical analyses because of the small 
sample size (i.e. <10 cases). None of the participants were found egg positive in stool 
for geohelminth infections. Furthermore, all the blood smear slides were negative for 
P. falciparum at all time points, consistent with the low malaria endemicity reported 
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in this area (Mabaso et al. 2006). A few cases were HIV positive (42 cases, 6.25%) 
and HIV status was accounted for in all analyses. HIV status did not explain any 
significant variations and, except for chapter 5, inclusion or exclusion of HIV positive 
cases gave comparable results. Where the exclusion of HIV positive cases altered the 
results (chapter 5), these were analysed and reported separately.  
 
4) Sufficient samples: participants were excluded from a given study (chapter) if they 
did not provide enough samples (urine, stool and blood) for parasitological and 
immunological measurements. Three pre-school children were included (see chapter 
6) who did not provide urine but provided blood samples at the two time points. This 
was because the sample size was small and because infection status was also 
determined by anti-schistosome IgM levels in these children. 
 
5) Treatment efficacy: The optimal time after treatment at which PZQ efficacy is 
routinely assessed in S. haematobium endemic areas is 6 weeks (Mutapi et al. 1998b; 
Midzi et al. 2008a; Mutapi et al. 2011b), where the majority of S. haematobium eggs 
are cleared (Tchuente et al. 2004) and newly acquired infection is not yet patent 
(Loker 1983). The post-treatment study described in this thesis aimed to further 
assess the effect of treatment (when PZQ has been efficacious) at an immunological 
level. Although dead eggs may continue to be excreted in urine for much longer 
following successful treatment (McMahon and Kolstrup 1979), individuals who were 
egg positive 6 weeks post treatment were excluded from the post-treatment study to 
avoid bias due to possible treatment ‘failure’. The cure rate for the current study 
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Figure 2.4 Study populations  
(A) Diagram showing numbers of recruited and followed participants for the study 
relating atopy to schistosome infection (chapters 3&4). Of these, a sub-cohort of 332 
individuals was skin pricked. For the study described in chapter 5, all children below 
the age of 6 and a number of other participants were excluded because they did not 
provide enough serum samples for the study. (B) Participants for the study on the 
effect of treatment in pre-school children (chapter 6): only those highlighted in red 
















436 Recruited  343 Recruited  
6 S. mansoni positive 1 S. mansoni positive 
16 No urine sample 2 No urine sample 
55 No blood provided 34 No blood provided 
121 no blood at week 6  
14 Egg positive after 
treatment 




223 aged 6 years + and provided 
enough serum samples 
211 aged 6 years + and provided 
enough serum samples 
Chap 5 
104 recruited 
95 provided blood at baseline 
41 provided blood at week 6 follow up 
  31 treated                  10 untreated 
Chap 6 




Relating atopy to schistosome infection intensity and history 
of infection, a comparative approach  
 
3. 1. Introduction  
 
Atopy is the genetic predisposition to become IgE sensitized to environmental 
allergens (Johansson et al. 2004) and an important risk factor for allergic diseases 
(Wohlleben and Erb 2001). However, the clinical manifestations are influenced by 
environmental factors. The hygiene hypothesis attributes the rise in atopy to reduced 
exposure to pathogens and their products in childhood as a result of improved 
hygiene, vaccination and the use of antibiotics, which lead to disregulated immune 
responses (Strachan 1989; Matricardi and Bonini 2000; Yazdanbakhsh et al. 2002). In 
particular, helminth parasites are believed to induce regulatory immune responses that 
may dampen the clinical manifestations of atopy (van den Biggelaar et al. 2000; van 
den Biggelaar et al. 2001; Yazdanbakhsh et al. 2002; Cooper 2009; Smits et al. 2010; 
Feary et al. 2011).  
 
However, the ‘protective’ effect of helminth infection on atopy remains controversial 
since some epidemiological studies suggest the reverse to be true (de Andres et al. 
1997; Palmer et al. 2002) while others fail to demonstrate a relationship (Cooper et 
al. 2006b). It has been suggested that different helminth species and intensity, time 
and duration of infection are factors likely to influence the effects of helminth 
infection on atopy, explaining these conflicting results (Cooper et al. 2006a; Feary et 
al. 2011). However, there is paucity of studies investigating these mechanisms in 
human populations despite results from animal studies (Smits et al. 2007). The latter 
study demonstrated that OVA-induced airway inflammation was significantly 
reduced in chronically but not acutely S. mansoni infected mice and that decrease in 
lung eosinophilia lavage was dependent on infection intensity.  
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The current study investigated the effect of different infection levels on atopic 
responses in human populations naturally exposed to Schistosoma haematobium. The 
study was conducted in two villages of differing schistosome transmission dynamics, 
i.e low and high infection areas, resulting in differences in current infection intensity 
as well as cumulative history of schistosome infection (Woolhouse et al. 1991a; 
Mutapi et al. 1997), to capture the dynamics of the relationship between schistosome 
infection and atopy. Skin prick reactivity to the house dust mite (HDM) 
(Dermatophagoides pteronyssinus), Alternaria sp, Aspergillus sp, grass mix were 
assessed on a group of participants to determine the prevalence of skin sensitisation. 
Furthermore, levels of allergen-specific IgE and IgG4 antibody responses were 
measured and related to schistosome infection intensity in the two villages. 
 
The study focused on IgE and IgG4 antibody responses directed against schistosomes 
and the house dust mite because high levels of parasite specific IgE are associated 
with resistance to infection/re-infection while parasite-specific IgG4 is believed to be 
a modulator of IgE effector responses (Hagan et al. 1991; Grogan et al. 1997; Zhang 
et al. 1997; Black et al. 2010a; Pinot de Moira et al. 2010). These antibodies are also 
important in clinical atopy where high allergen specific IgE antibodies are indicative 
of an allergic phenotype (Johansson et al. 2004) while IgG4 are associated with 
improvement in allergic symptoms following immunotherapy or natural recovery 
(Bullock et al. 2005; Tseng et al. 2008; Savilahti et al. 2010). The relative 
proportions of these antibodies (or the balance between them) are therefore a key 
feature in humoral immunity against schistosomes (Hagan et al. 1991; Acosta et al. 
2004; Pinot de Moira et al. 2010) or predictors of clinical manifestations of atopy 




S. haematobium infection intensity and/or cumulative history of infection are 
negatively associated with atopy 
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3. 2. Materials and methods 
3. 2. 1. Study population 
 
The study was comparative, contrasting levels of atopic responses in high (Magaya) 
and low (Chitate) schistosome infection villages. The study focused on S. 
haematobium infection as it was the most prevalent helminth infection in the study 
area while only 2% of the population was S. mansoni positive (see Table 3.1).  
 
To be included in the study, participants had to be 1) lifelong residents of the village 
(assessed by questionnaire); 2) free from geo-helminth, S.mansoni, and Plasmodium 
infections; 3) not previously received antihelminthic treatment; 4) provided at least 2 
urine and 2 stool samples for helminth diagnosis and a blood sample for serological 
assays.  A total of 672 individuals fulfilled the inclusion criteria and formed the study 
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 High infection area 
(HIA) 
Low infection area 
(LIA) 
Total n (baseline) 436 343 
Mean age (age-range) 11.4 (3 to 86 yrs) 18.5 (1.5 to 86 yrs) 
Sex ratio (m/f) 0.825 (199/241) 0.57 (127/221) 
Ethnic group Shona Shona 
Socio-economical status Subsistence farmers Subsistence farmers 
S. haematobium prevalence 52.94% (CI95: 48-57.67) 8.6% (CI95: 5.9-12.1) 






S. mansoni cases (excluded) 6 cases (7-13 years old) 1 case (69 years old) 
Malaria prevalence 0% 0% 
STH prevalence 0% 0% 
No urine sample provided 
(excluded) 
16 cases (3-26 years 
old) 
2 cases (unknown age) 
No blood sample provided 
and/or no age record (excluded) 
55 34 
HIV positive cases (controlled 
for in analyses) 
17 25 
Total n included 359 306 
SPT sampled 26 (3 to 65 years old, 
mean infection= 
2.69eggs/10ml ranging 
0 to 22eggs/10ml) 
306 (1.5 to 86 years 
old, mean infection= 
0.758eggs/10ml 
ranging 0 to 30 
eggs/10ml) 
 
Table 3.1 Description of the study populations 
The sample sizes of recruited, selected and excluded populations are reported here. 
STH: soil transmitted helminth; m: male; f: female; HIV: human immunodeficiency 
virus; SEM: standard error of the mean; CI: confidence interval.  
 
 
3. 2. 2. Skin prick test 
Skin prick tests were conducted using  4 allergens prevalent in Zimbabwe 
(Kambarami et al. 1999), house dust mite  (HDM) (Dermatophagoides 
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pteronyssinus), Grass mix, Alternaria tenius, and Aspergillus fumigatus. The skin 
prick test (described in chapter 2) results showed that allergy to the HDM was the 
most prevalent (Figure 3.1), consistent with previous studies from Zimbabwe 
(Kambarami et al. 1999; Sibanda 2003). Therefore, serological assays focused on D. 
pteronyssinus –specifc responses.  
   

















Figure 3.1 Prevalence of atopy 
Atopy was measured by skin prick test (SPT) to 4 allergens; DP: Dermatophagoides 
pteronyssinus, AT: Alternaria tenius, AF: Aspergillus fumigatus, GM: grass mix. A 
drop of each allergen is put on the upper arm and the skin beneath pricked. The 
prevalence is the percentage (%) of individuals presenting with a skin reaction to any 
allergen (weal measured in mm) equal or larger than the reaction elicited by the 
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3. 2. 3. Serology and laboratory assays 
 
Levels of IgE and IgG4 antibodies directed against S. haematobium and D. 
pteronyssinus were measured by ELISA method (described in chapter 2). Microtitre 
plates were coated with 5µg/ml of S. haematobium crude adult worm antigen 
(SWAP), 10µg/ml of S. haematobium soluble egg antigen (SEA) or 5µg/ml of D. 
pteronyssinus affinity purified Derp1 allergen. Plates were blocked with 5% skimmed 
milk in PBS/Tween20, which was used in subsequent dilutions. The dilutions of sera 
(in skimmed milk) were as follow: 1: 10 for IgE and IgG4 against Derp1 allergen; 1: 
20 for IgE against SWAP and SEA; 1:100 for IgG4 against SWAP and 1:400 for 
IgG4 against SEA. The secondary antibodies were diluted at 1:1000 in all assays 
except for IgE and IgG4 against SWAP (1:250 and 1:500 respectively). The 
colorimetric reaction was allowed for 30 minutes at 37°C for all assays except for 
IgG4 against SWAP and SEA (15 minutes at room temperature), and stopped with 
25% HCl. 
 
3. 2. 4. Statistical analysis 
 
Schistosome infection prevalence and intensity were compared between the 2 villages 
by Pearson Chi-squared test and univariate general linear model (GLM) respectively. 
Age was categorised into 5 groups (Table 3. 2). The GLM used sequential sums of 
squares to calculate the mean squares to derive the test statistic, to allow for 
cofounding variables before testing for the effects of the variable of interest (Grafen 
and Hails 2002; Mutapi and Roddam 2002). This approach has been used to test for 
the relationship between schistosome infection and immune responses or other 
markers of immunity or pathology while allowing for the potential confounding 
effects of host sex and age (Mutapi et al. 1997; Mutapi et al. 2007).  
 
The effect of Derp1-specific antibodies on the SPT measure (continuous variable) 
was assessed by univariate GLM using sequential sum of squares to account for the 
effects of host age, sex, village, HIV status and infection intensity. A binary stepwise 
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logistic regression was used to determine which of the variables (age, sex, village of 
residence, HIV status, infection intensity or anti-Derp1 antibody levels) could predict 
the SPT status (categorical: positive or negative).  
   
Following exploratory plots showing a directional relationship, the hypothesis that 
schistosome infection is negatively associated with atopy was tested using a 1-tailed 
Pearson correlation analysis between the SPT results and infection intensity residuals 
after allowing for the effects of host age, sex and village of residence. To test whether 
this association occurs at the immunological level, the same correlation analysis was 
conducted relating antibody levels to infection intensity in each village. The effect of 
infection intensity on antibody responses was determined by multivariate analysis 
using sequential sums of squares, entering the variable ‘infection intensity’ last in the 
model. β-coefficients (for the direction of infection-antibody relationship) were 
calculated using linear regression analysis on residuals saved after accounting for the 
variations due to host age, gender and village.  































χ² and (p) 
value 
Infection 
intensity F and 
(p) value 
1-5  0-458 (49) 27.1 (13.0) 30.6% (18.3-
45.4) 




11.48 (0.001) 15.95 
(<0.001) 
6-10  0-481 (186) 22.2 (5.1) 44.1% (36.8-
51.5) 
0-27.5 (106) 0.646 (0.3) 8.5% (4-15.5) 39.9 (<0.001) 36.05 
(<0.001) 
11-15  0-692.7 (90) 43.1 (11.5) 60% (49-70) 0-20 (57) 0.96 (0.47) 12.3 (5-23.7) 32.7 (<0.001) 44.99 
(<0.001) 
16-20  0-50.7 (13) 5.8 (4.1) 30.8% (9-61) 0-25.7 (16) 2.5 (1.63) 25% (7-52) 0.12 (0.730) 0.021 (0.885) 
21&above  0-3.5 (21) 0.4 (0.2) 19 (5-42) 0-30.3 (88) 0.78 (0.41) 5.7% (2-13) 3.998 (0.046) 0.000 (0.995) 
Overall 0-692.7(359) 26.2 (4.3) 44.3% (39-49.6) 0-30.3(306) 0.758 (0.2) 8.5% (5.6-12.2) 105.4 (<0.001) 85.4 (<0.001) 
 
Table 3.2 S.haematobium infection levels by age in the selected populations  
Infection levels by age groups in the selected populations are shown for the 2 villages. Statistical results of χ² analysis and ANOVA on 
the prevalence and infection intensity respectively are presented for each age group and significant p-values are highlighted in bold. 
SEM: Standard error of the mean, CI: Confidence interval. 
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3. 3. Results 
3. 3. 1. S. haematobium infection levels differ significantly between the 
two villages 
 
Schistosome infection levels among selected participants were significantly higher in 
Magaya than Chitate with a prevalence of 44.3% vs. 8.5% (χ²=105.4, df=1, p<0.001) 
and mean infection intensity of 26.2 eggs/10ml vs. 0.758 eggs/10ml (F1, 654=85.4, 
p<0.001) in Magaya vs. Chitate.  When partitioned by age, there were significant 
differences in infection levels in the two areas in younger age groups (Figure 3.2). 
Infection peaked at a higher level and at an earlier age in Magaya, a phenomenon 
referred to as a peak shift (Woolhouse 1998) and confirmed by a significant age and 









Figure 3.2 Infection intensity and prevalence by age in the study area 
Geometric mean infection intensity (A) and prevalence (B) are plotted against age 
groups in the high infection area (red line) and the low infection area (black line). 
Bars represent standard error of the means for infection intensity and 95% confidence 
interval for the prevalence. Asterisks represent significant differences in each group 
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3. 3. 2. Antibody profiles for schistosome- and Derp1- specific 
responses 
 
Multivariate analysis (Table 3. 3) showed that anti-schistosome adult worm IgE and 
IgG4 (absorbencies) were significantly higher in the high infection area compared to 
the low infection area. Of the egg specific responses, IgG4 responses differed 
between the two villages, being also higher in the high infection area, which resulted 
in the ratio SEA-IgE/IgG4 being higher in the low infection area. SWAP- specific 
IgE: IgG4 ratio did not differ between the two areas. Amongst the Derp1-specific 
responses, IgG4 levels were higher in the high infection area, resulting in 










































Anti-  SWAP- IgG4 24.296**(M>F) 10.662** 1.428 16.264** (H>L) 42.061** (0.233) 3.535** 0.236 
schistosome SWAP -IgE/IgG4 1.893 (F>M) 2.712 1.075 1.265 (L>H) 3.854*    (-0.076) 2.819* 0.021 
Responses SEA -IgE 15.173**(M>F) 14.227** 2.735 2.305 (L>H) 10.461**  (0.112) 1.877 4.678* 
 SEA-IgG4 19.237**(M>F) 15.391** 1.088 37.127** (H>L) 172.457** (0.416) 1.813 8.532** 
SEA -IgE/IgG4 0.008 (M>F) 2.44* 1.244 22.777** (L>H) 18.743**  (-0.157) 1.268 0.219 
 

















allergen Der p 1-IgG4 6.191* (M>F) 4.352** 1.702 13.408** (H>L) 0.764  (-0.024) 1.116 0.033 
responses Der p1-IgE/IgG4 11.407*(F>M) 0.589 0.318 9.959** (L>H) 3.425 (-0.072) 1.674 0.816 
 
Table 3.3 F values from a multivariate analysis determining the effects of different variables on the levels of parasite and 
allergen-specific antibody responses and ratios  
The effects of infection intensity are determined after allowing for the effects of host’s age, sex and village of residence by sequential sums of 
squares. The β-coefficients from a linear regression are also shown for the direction of the relationship ‘infection-antibody’. SWAP: soluble worm 
antigen preparation, SEA: soluble egg antigen, H: high infection village, L: low infection village, M: male, F: female. Degrees of freedom equal 1 for 
sex, village and infection, and 4 for age; degrees of freedom for the error= 651. F-values (and β values) with significant p-values ( *=p<0.05 and 
**=p<0.01) are highlighted in bold. 




As illustrated in figure 3. 3., anti-adult worm IgE and IgG4 responses increased with 
age in both villages, being higher in the high infection area compared to the low 
infection area across the age range, while anti-Derp1 responses did no vary 
significantly with age. Anti-egg responses increased with age but declined in 
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High infection area 
Low infection area 
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Figure 3.3 Antibody levels by age 
Derp1, schistosome adult worm- (SWAP) and egg (SEA) - specific IgE (first line) 
and IgG4 (second line) responses by age in the high (red line) and low (black line) 
infection areas. Bars represent standard error of the means and asterisks represent 
significant differences in each group between the two villages at * p < 0.05 and ** p 
< 0.01, from ANOVA. 
 
 
3. 3. 3. SPT reactivity is related to allergen-specific IgE and IgG4 levels   
 
Overall the prevalence of positive SPT was 17.7% (CI95 3.96-40.1) but 67.8% (CI95 
13.4-147.2) of SPT positive individuals (i.e. 12% prevalence) were sensitised to the 
house dust mite (D. pteronyssinus). Univariate ANOVA confirmed that the severity 
of the SPT reactivity to the house dust mite was significantly associated with the 
levels of Derp1 IgE antibodies (F1, 321=37.26, p<0.001), and the interaction between 
Derp1-specific IgE and IgG4 (F1, 321= 5.1, p=0.025). Furthermore, SPT status was 
best explained by Derp1-specific IgE levels as determined by stepwise logistic 
regression analysis (Wald χ²= 11.484, df= 1, p= 0.001 and Wald χ²= 1.573, df= 1, p= 








Figure 3.4 Derp1-specific antibody levels versus SPT status 
Levels (absorbencies) of anti-Derp1 IgE and IgG4 are plotted for SPT negative and 
SPT positive people. Bars represent standard error of the means. ** Difference 
significant at p<0.01, ns: difference not significant; p-values from stepwise logistic 
regression incorporating host age, sex, HIV, village of residence, infection intensity 
and antibody levels.  
 
 
3. 3. 4. Atopic responses are negatively correlated with schistosome 
infection intensity 
 
The prevalence of sensitization to HDM (% of people positive for the SPT test) was 
higher in the low schistosome infection area (12.4%, CI95 3.48-29.1) than in the high 
infection area (7.7%, CI95 6.74-32.8) and SPT negative people had higher levels of 
schistosome infection, though these differences were not statistically significant. 
However, SPT wheal size was significantly inversely related to S. haematobium 
infection intensity after allowing for the variations due to host age, sex, HIV status 
and village of residence (Figure 3. 5).   




Figure 3.5 Correlation between skin prick test results and infection intensity 
Residuals of infection intensity after allowing for age, sex, HIV status and village of 
residence in ANOVA are plotted against the size of the weal (skin reaction to any 




An analysis to determine factors affecting levels of Derp1-specific antibodies showed 
that after allowing for host sex, age, HIV status and village of residence, schistosome 
infection intensity negatively affected levels (absorbencies for all individuals) of 
Derp1-specific IgE, but not IgG4, resulting in a significant effect on the ratio Derp1- 
IgE:IgG4 (Table 3.3). This analysis also showed that levels of these two variables 
differed between the two villages. Therefore, correlation analyses were conducted to 
determine the relationship between Derp1-responses and infection intensity in each of 
the villages (after allowing for the confounding effects of sex and age). This showed 
that the correlation between infection intensity and the levels of Derp1-specific IgE 
and the ratio Derp1-specific IgE/IgG4 was significant only in the high infection 
village but not in the low infection village (Figure 3.6-A). This contrasted with 
schistosome specific responses where although there were differences in the 
magnitude of some of the responses between the two villages (Table 3. 3), the 
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relationship between these antibodies and infection intensity was similar in the two 
villages (Figure 3. 6-B&C).   
 
These analyses suggested that the lack of a relationship between schistosome 
infection intensity and Derp1 antibodies and their ratio in the low infection area may 
be due to the overall lower levels of infection ( interaction between infection and 
village is not significant in Table 3.3; i.e. infection intensity affects antibody levels 
independent of village). Therefore, the relationship between schistosome infection 
intensity and anti-mite (Derp1) antibody responses (absorbencies for all individuals) 
was compared in people with similar levels of infection (0-30 eggs/10ml urine) in the 
high infection village, accounting for variations due to host’s age and gender. This 
showed that at these low levels of infection, there was no significant correlation 
between infection intensity and Derp1- specific antibodies (r=-0.089, p=0.062 for IgE 
and r=-0.074, p=0.095 for IgE/IgG4 ratio). 
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Figure 3.6 Correlations between schistosome/ mite - specific antibodies/ ratios 
and infection intensity 
Residuals (after controlling for age and sex in ANOVA) of IgE, IgG4 and IgE/IgG4 
against Derp-1 (A); schistosome adult worm antigens, SWAP (B) and schistosome 
egg antigens, SEA (C) are plotted against infection intensity (log-transformed) for 
Magaya (high infection area) and Chitate (low infection area). 1-tailed Pearson 
correlations performed. Correlation significant at p<0.05 are highlighted in bold 
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3. 4. Discussion and conclusions 
 
This study compared the effect of current schistosome infection and that of the 
cumulative history of infection on atopic responses in two villages of different 
schistosome transmission dynamics. Differences in schistosome transmission 
dynamics were confirmed by the differences in schistosome infection intensity and 
the existence of peak shifts (Woolhouse 1998). Moreover, the previously described 
inverse relationship between infection intensity and the ratio IgE/IgG4 against the egg 
and adult worm antigens was demonstrated in both villages. This ratio has been 
associated with the development of protective immunity against schistosome 
infection/re-infection (Hagan et al. 1991; Zhang et al. 1997; Pinot de Moira et al. 
2010) and, in this study, the relationship was significant in the high but not in the low 
infection village (p<0.001 and p=0.023 respectively). This supports previous studies 
suggesting that protective immunity develops as a function of cumulative history of 
infection and will thus develop faster in areas of high compared to areas of low 
transmission (Fisher 1934; Woolhouse 1998; Woolhouse and Hagan 1999). 
 
The majority of SPT positive participants were sensitized to the house dust mite (D. 
pteronyssinus) compared to other allergens (molds and grass) and the overall 
prevalence of the D. pteronyssinus sensitization (12%) was comparable to that 
previously reported for Zimbabwean populations (Sibanda 2003), and is consistent 
with documented levels of atopy from other African countries (Williams 1999; van 
den Biggelaar et al. 2001). The low infection area was over represented in the 
participants surveyed for the skin prick tests (SPT) for logistic reasons. However, by 
allowing for the potential confounding effects of residential village in the statistical 
analyses, it meant that the relationship between schistosome infection intensity and 
SPT status could be analyzed regardless of village of residence. Furthermore, the SPT 
participants had comparable infection range in the two villages 0-22 versus 0-30 (i.e. 
within the mild infection range as classified by the World Health Organisation), 
which meant that analyses compared people with similar infection levels for the SPT 
versus infection intensity aspect of the study.  




In this study, Derp1-specific IgE levels (absorbencies for all individuals) were 
positively correlated with the SPT reactivity to D. pteronyssinus allergens, consistent 
with published reports (Johansson et al. 2004). Mean Derp-IgG4 levels 
(absorbencies) were higher, though not significantly so (p=0.21), in SPT positive 
compared to negative people. The role of IgG4 in allergic conditions is still poorly 
understood, but the high levels of both IgE and IgG4 in the SPT positive participants 
could be related to the fact that IgE inducing allergens are also efficient IgG4 
inducers (Aalberse et al. 2009). SPT reactivity was negatively associated with S. 
haematobium infection as reported in Gabon (van den Biggelaar et al. 2000). 
Comparison of Derp1-specific antibody responses showed significant differences in 
levels of IgG4 but not IgE in the two villages together with a significant difference in 
the IgE: IgG4 ratio. Nonetheless, IgE but not IgG4 was significantly inversely 
associated with schistosome infection intensity and consequently the ratio IgE: IgG4 
was also inversely associated with schistosome infection. The IgG4 response in this 
instance seems to be modulating the pathological IgE responses, a concept which is 
important in allergy immunotherapy (Bullock et al. 2005; Gallego et al. 2010).   
 
Differences were observed in the schistosome-anti-Derp1 antibody relations with 
schistosome infection between the two villages: there was no association between 
infection intensity and Derp1-specific IgE (and the ratio IgE/IgG4) antibody 
responses (absorbencies) in the low infection area but a significant negative 
association in the high infection area.  
 
This finding  that areas of different schistosome endemicity exhibit differences in the 
relationship between anti-mite antibody responses and infection intensity may explain 
results of a recent meta-analysis which showed that the relationships between 
schistosome infection and atopy were heterogeneous (Feary et al. 2011). The fact that 
people in the low infection area mounted similar anti-schistosome IgE and IgG4 
responses (albeit at a lower level) indicates that there is no impairment in their ability 
to mount IgE and IgG4 responses. One potential reason for the lack of an association 
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between their allergen-specific antibody responses (absorbencies) and schistosome 
infection was the overall low level of schistosome infection.  
 
To investigate this, the relationship between schistosome infection intensity and anti-
mite antibody responses (absorbencies) was compared in people with similar 
infection levels in both villages. This showed that at such low levels of infection (0-
30eggs/10ml of urine), there was no significant correlation between infection 
intensity and Derp1-specific antibody responses in either village. This is consistent 
with findings from an experimental study relating S. mansoni infection and airway 
inflammation (Smits et al. 2007), which showed that only heavy and chronic 
infections were protective against airway inflammation. This result also means that 
cumulative experience of schistosome infection does not significantly affect atopic 
responses since individuals from the high infection area, with a longer history of 
exposure to parasite antigens (Mutapi et al. 1997), mounted comparable anti-Derp1 
antibody responses compared to their age and infection matched counterparts in the 
low infection area. Previous studies have shown that helminth parasites, including 
schistosomes, are capable of secreting immuno-modulatory products (Smith et al. 
2005; Grainger et al. 2010; Osada and Kanazawa 2010). Results from this current 
study suggest that these products may exert a significant effect on host atopic 
responses only during heavy infection. These findings may therefore imply that 
childhood schistosome infection does not impact on adulthood atopy. 
 
Overall, the study shows that regardless of the underlying mechanisms of 
development of schistosome protective immunity, the relationship between 
schistosome infection and HDM sensitization differs in areas of distinct schistosome 
infection levels, and this difference is dependent on current infection levels but not 
cumulative history of infection.  
 
In Zimbabwe, the majority of people showing the clinical signs of allergy i.e. allergic 
rhinitis, conjunctivitis, asthma, dermatitis and urticaria are sensitized to the house 
dust mite (measured by SPT or allergen –specific IgE) (Sibanda 2003). Nonetheless, 
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differences in the relationship between helminth infection and skin sensitization 
compared to that between helminth infection and allergic disease have been reported  
(Flohr et al. 2010), although schistosome infection may affect both (van den 
Biggelaar et al. 2000; Medeiros et al. 2003). Thus, further studies on the role of 
different parasite transmission dynamics on allergic diseases are required to inform 
therapeutic interventions and management of clinical allergy. Furthermore, 
understanding the relationship between helminth infection and atopy at different 
infection intensities as well as in areas with different transmission dynamics will help 
predict the long-term consequences of the current large scale global anti-helminthic 
treatment programmes but also may influence the management of atopic diseases in 
people with concomitant helminth infections.  
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Chapter 4 
Schistosoma haematobium infection levels influence the 
effect of praziquantel treatment on levels of anti-schistosome 
and anti-mite antibodies 
 
 
4. 1. Introduction 
 
In schistosome endemic areas, the natural development of acquired protective 
immunity to schistosome infection/re-infection is dependent on the levels of parasite 
transmission (Mutapi et al. 1997). However, praziquantel treatment (the current 
method of control for schistosome infection) alters schistosome-specific immune 
responses and may accelerate the development and expression of ‘protective’ 
immunity (Colley et al. 1986; Grogan et al. 1996a; Mutapi et al. 2003; Joseph et al. 
2004; Black et al. 2010a; Black et al. 2010b). Although praziquantel- associated 
immune responses are heterogeneous across populations, these may be influenced by 
pre-treatment infection intensity and history of infection (Mutapi et al. 2002; Mutapi 
et al. 2003; Black et al. 2010b).  
 
On the other hand, schistosome infection is inversely associated with skin 
sensitisation (Araujo et al. 2000; van den Biggelaar et al. 2000)(chapter 3), the course 
of asthma (Medeiros et al. 2003) and anti-Derp1 (allergen) atopic responses as shown 
in chapter 3. However, studies on the effects of praziquantel treatment on atopy in 
schistosome endemic populations are scarce. One study on Gabonese schoolchildren 
has reported increased skin reactivity following a concurrent administration of 
mebendazole and praziquantel but this increase was only significantly associated with 
decreased levels of Ascaris and/or Trichuris infections (van den Biggelaar et al. 
2004). 
 
Human studies on the effects of anti-helminthic (intestinal helminths) treatment on 
atopy yield variable results across populations and parasite species. Thus, the 
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treatment of Ascaris and Trichuris infected children over a period of 22 months 
increased skin sensitisation to allergen extracts in Venezuela (Lynch et al. 1993a), 
while treatment of asthmatic patients in the same country decreased the frequency of 
asthma crises and levels of allergen-specific IgE (Lynch et al. 1997). The two 
populations differed in their age, the former being younger (8.4 ± 2.4years on 
average) than the latter (18.5 ± 14.6 years), and their parasite infestation (68% vs. 40-
50% respectively). More recently, Cooper and colleagues have reported that 
albendazole treatment of Ecuadorian school children infected with various 
geohelminth parasites (Ascaris, Trichuris, Hookworm and Strongyloides) does not 
significantly increase the prevalence of skin prick reactivity or wheeze (Cooper et al. 
2006b) nor histamine release or Th2 cytokines to the house dust mite and American 
cockroach (Cooper et al. 2008b).  
 
In addition to these heterogeneities within intestinal helminth infections, there may be 
differences in immunomodulatory dynamics associated with parasite life histories and 
biologies (Bourke et al. 2011). For example, tissue -dwelling parasites may induce 
more systemic regulatory T cells and cytokines than gut dwelling parasites (Maizels 
and Yazdanbakhsh 2003), while the latter may be more efficient in downregulating 
gut inflammation (Summers et al. 2005; Bager et al. 2010). It is therefore important 
to determine the effects of praziquantel treatment of S. haematobium infections on 
atopy in endemic areas. Findings from the previous chapter show that schistosome 
infection intensity is inversely associated with anti-Derp1 atopic responses. However, 
it is currently unknown how different pre-treatment schistosome infection levels 
impact on atopic responses following praziquantel treatment.  
 
In this study, levels of IgE and IgG4 against the house dust mite Dermatophagoides 
pteronyssinus (Derp1) as well as those against schistosome adult worm and egg 
antigens were quantified before and 6 weeks after a single dose of praziquantel 
(40mg/kg) was given. The aim was to investigate the dynamics of the relationship 
between atopic responses and schistosome-specific responses when pre-existing 
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schistosome infection is cleared and newly acquired infection (if any) not yet patent 
(Loker 1983; Tchuente et al. 2004) in human populations.  
 
Hypothesis 
Praziquantel treatment alters levels of anti-allergen and anti-schistosome antibody 
responses and in a manner dependent on pre-treatment schistosome infection intensity 
and history of infection. 
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4. 2 Materials and methods 
 
4. 2. 1. Study population 
 
From the baseline cohort described in chapter 3 (665 people); 325 individuals (224 
from the high infection area and 101 from the low infection area) provided urine, 
stool and blood specimens at 6 weeks follow up. The details of the study population 
are given in Table 4.1. All these individuals were lifelong residents of the villages 
(assessed by questionnaire), free from patent malaria infection and were tested egg 
negative for geohelminth and S. mansoni infections. To be included in the analysis, 
treated people had to be S. haematobium egg negative at 6 weeks sampling. Sixty-one 
(61) individuals who refused treatment for religious reasons or were absent on 
treatment days (40 from the high infection area, 21 from the low infection area) but 
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High infection area Low infection area  
Treated Untreated Treated Untreated 
     
Total n 184 40 80 21 
 
Age groups, n  
-Age group 1 (6-10 years) 
-Age group 2 (11-15 years) 


















Sex ratio (M:F) 0.8 1.7  0.6  0.9  
 




     
Mean infection intensity 
@ baseline (range) 





Egg positive cases @ 
baseline (prevalence) 
97 (52.7%) 10 (25%) 5 (6.25%) 3 (14.3%) 
 
Table 4.1 Description of the study population 
The sample sizes are given for each of the age groups used in all analyses for the 
treated and untreated groups. F: female, M: male, n: sample size. The mean infection 
intensity is expressed as eggs/10ml urine. 
 
 
4. 2. 2. Antibody assays 
 
A standard indirect enzyme-linked immunosorbent assay (ELISA) was optimized and 
used to quantify levels of IgE and IgG4 directed against S. haematobium adult worm 
antigen (SWAP), soluble egg antigen (SEA) and Derp1 allergen. Antigen, sera and 
antibody dilutions are those described in chapter 3. ELISA assays for pre and post-
treatment samples were conducted in the same period of time (consecutively) and six 
samples were run on all plates to minimize plate to plate variations (these were 
statistically compared). Furthermore, 2 positive controls (pool of sera from 
individuals presenting with the highest infection levels and that of individuals with 
the highest skin prick reactivity across age) and a pool of negative controls (European 
individuals who had never had schistosome infection) were run on each plate. For all 
comparisons between positive responders (for each isotype), the coefficient of 
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variation (CV) was less than 20% and readings were below the critical values as 
defined by (Reed et al. 2002), therefore no correction factor was used. 
 
4. 2. 3. Statistical analysis 
 
Antibody data were square root transformed while infection intensity was log10(x+1) 
transformed. Age was categorised into 3 age groups reflecting epidemiological 
patterns of infection (pre-peak, peak, post peak) to allow the non-linear relationship 
between age and infection to be fitted in the models used (Mutapi and Roddam 2002). 
It was not possible to partition the 3
rd
 age group into two to capture the slight 
variation observed at baseline (chapter 3) because of the small sample size post-
treatment. The younger age group (i.e children below the age of 6) was analysed 
separately and reported in chapter 6. Schistosome infection prevalence and intensity 
at baseline were compared between the 2 villages by Pearson Chi-squared test and 
univariate GLM respectively. A repeated measures general linear model (GLM) was 
conducted to determine whether there were overall changes in antibody levels within 
6 weeks post-praziquantel treatment and whether these changes were due to treatment 
regardless of host age, gender, village of residence (high vs. low infection area; HIA 
vs LIA) and infection intensity at baseline. GLM repeated measures analyze groups 
of related dependent variables that represent different measurements of the same 
attribute. In this model, antibody levels (square root transformed) were the dependent 
variables while the  independent variables were age (categorized into 3 age groups: 
group1, 6-10yrs; group2, 11-15; group3, 16&above), gender (categorical, 
male/female), village (categorical, HIA/LIA), infection intensity at baseline 
(covariate, log transformed) and treatment status (categorical, treated/ untreated). The 
analysis used sequential sum of squares to determine the effect of treatment (entered 
last) on antibody changes after allowing for the effects of all other variables. This 
initial analysis showed that the changes in antibody levels between the two time 
points differed between the villages of residence and consequently the data were 
partitioned by village for subsequent analyses.  
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The effect of treatment on the magnitude of antibody changes and ratios (calculated 
as post-treatment values minus pre-treatment values) was determined by multivariate 
GLM in each village, allowing for the variations due to host age, sex and baseline 
infection intensity. In this analysis, the sequential sums of squares were used to 
calculate the test statistics, with treatment status entered last in the model. To test the 
hypothesis that baseline infection intensity affects the magnitude of change in 
antibody levels, the variable ‘infection intensity’ was entered after ‘sex’ and ‘age’ in 
this model. β coefficients were used to determine the strength and direction of this 
effect. All statistical analyses were conducted in PASW statistics 17 and p-values 
<0.05 were considered significant. 
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4. 3. Results 
 
4. 3. 1. Baseline infection levels in the follow up cohort 
 
Consistent with the larger cohort described in chapter 3, baseline infection intensity 
and prevalence were significantly higher in the high infection area compared to the 
low infection area (mean 22.6 vs. 0.51, F=40.828, p<0.001 and 47.8% vs. 7.9%, 
χ²=48.342, p<0.001 respectively for infection intensity and prevalence) in this cohort. 
When partitioned by age groups, there were significant differences in infection levels 
in the two areas in younger age groups (F=25.402, p<0.001; F=20.338, p<0.001 and 
F=1.701, p=0.2; respectively for age groups 1, 2 and 3). In addition, there was a 
significant age and village interaction in the GLM (F1,579 = 6.963, p=0.009), which is 
indicative of a peak shift (Mutapi et al. 1997).  
 
In the treatment groups, all individuals included were egg negative six weeks post-
treatment. In the untreated groups, infection levels also declined but not significantly 
(mean 5.9 to 2.6, F=3.514, p=0.069 and 0.8 to 0.03, F=0.38, p=0.55 respectively for 
the high and the low infection areas). 
 
4. 3. 1. Overall change in antibody levels between the two time points  
 
Results from the repeated measures GLM analysis between pre- and post-treatment 
antibody levels (Table 4. 2) show significant changes in anti-schistosome and anti-
Derp1 antibody responses over time (i.e time between baseline and 6 weeks post-
treatment). This analysis shows that only changes in anti-schistosome adult worm IgE 
and IgE/IgG4 ratio as well as anti-Derp1 IgE were attributed to treatment (significant 
interaction between time and treatment for these variables in Table 4. 2) while 
baseline infection intensity was associated with the changes in anti-worm and egg IgE 
and IgG4 antibodies. Host age was also significantly associated with the levels of 
anti-worm IgG4, anti-egg IgE and anti-Derp1 IgE, IgG4 and IgE/IgG4 ratio, while 
Chapter 4                                                   Atopy, Schistosome infection and PZQ  
 113 
gender was only associated with the levels of anti-Derp1 IgE. Furthermore, this 
analysis showed that the host village of residence was significantly associated with 
the variations in anti-schistosome adult worm and egg IgE, anti-egg IgE/IgG4 ratio 
and all the anti-Derp1 responses (IgE, IgG4 and ratio IgE/IgG4). The data was 
therefore spilt by village of residence for subsequent analyses.  
 
 







































Anti-  SWAP- IgG4 49.485(<0.001) 2.077(0.15) f<m 11.024(<0.001) 0.354(0.552)H>L 26.952 (<0.001) 0.209(0.648)T>U 
SWAP -IgE/IgG4 4.72(0.031) 0.558(0.455) f>m 1.778(0.171) 0.095 (0.758)H>L 1.052 (0.306) 4.342(0.038)T<U schistosome 
Responses SEA -IgE 5.00(0.026) 1.315(0.252) f<m 5.828(0.003) 50.299(<0.001)H>L 15.534 (<0.001) 3.193(0.075)T<U 
 SEA-IgG4 0.323(0.57) 0.279(0.597) f<m 0.321 (0.726) 2.638(0.105)H>L 6.086 (0.014) 2.368(0.125)T>U 
SEA -IgE/IgG4 2.070(0.151) 0.44(0.508) f>m 1.378 (0.254) 36.535(<0.001)H<L 1.586(0.209) 1.041(0.308)T<U 
 















allergen Der p 1-IgG4 42.278(<0.001) 3.548(0.061)f<m 13.72 (<0.001) 34.706(<0.001)H<L 1.783 (0.183) 0.768(0.382)T<U 
responses Der p1-IgE/IgG4 34.963(<0.001) 0.271(0.603)f>m 4.347 (0.014) 15.063(<0.001)H>L 3.786(0.053) 3.414(0.066)T<U 
 
Table 4.2 Results from a repeated measures GLM analysis 
F (and p) values from repeated measures GLM analysis of the parameters explaining the variations in antibody responses (and ratios) 
over time (time here stands for the 6 weeks between pre- and post- treatment collection day). Significant p-values <0.05 are highlighted 
in bold. SWAP: Soluble worm antigen preparation, SEA: soluble egg antigen, Derp1: D. pteronyssinus allergen 1, PZQ: praziquantel, 
f: female, m: male, H: high infection area, L: low infection area, T: treated, U: untreated 


















      
High infection area 
 
 SWAP -IgE  0.699(0.404)f>m 5.511(0.005)  21.882 (0.079) (<0.001) 1.996(0.159)T>U 
Anti-  SWAP- IgG4 0.864(0.354)f<m 9.212(<0.001)  27.121 (0.084) (<0.001) 1.087(0.298)T>U 
schistosome SWAP-gE/IgG4 0.048(0.827)f<m 1.902(0.152)  1.810 (-16.99) (0.175) 5.916 (0.016)T>U 
Responses SEA -IgE 6.509(0.011)f>m 1.229 (0.294)  19.913 (0.09) (<0.001) 0.522(0.471)T>U 
 SEA-IgG4 0.115(0.735)f>m 0.924(0.399)  6.824 (0.035) (0.01) 3.293(0.071)T>U 
SEA -IgE/IgG4 0.764(0.383)f>m 2.297(0.103)  3.981 (-22.7) (0.047) 7.717(0.006)T<U 
Derp1-IgE  4.787(0.030)f<m 2.286(0.104) 0.108 (0.006) (0.742) 5.617(0.019)T>U 




Derp1-IgE/IgG4 0.716(0.398)f<m 3.945(0.021) 2.726 (7.875) (0.100) 3.858(0.051)T>U 
 
Low infection area 
    
     
  SWAP -IgE  1.217(0.273)f<m 11.314(<0.001) 0.003(0.022)(0.96) 5.982 (0.016)T>U 
Anti-  SWAP- IgG4 1.576(0.212)f<m 4.413(0.015) 0.013(-0.017)(0.909) 0.98(0.325)T<U 
Schistosome SWAP -IgE/IgG4 0.754(0.388)f>m 1.079(0.344) 0.00(4.442)(0.988) 0.428(0.514)T>U 
Responses SEA -IgE 0.155(0.695)f<m 16.568(<0.001) 1.462(-0.109)(0.23) 3.914(0.051)T>U 
 SEA-IgG4 0.559(0.457)f>m 5.395(0.006) 1.991(-0.095)(0.161) 0.000(0.993)T=U 
 SEA -IgE/IgG4 0.756(0.387)f<m 1.053(0.353) 0.009(-1.549)(0.926) 0.438(0.51)T>U 
Derp1-IgE  2.485(0.118)f<m 5.864(0.004) 0.952(-0.048)(0.332) 0.462(0.498)T<U Anti-  
Allergen 
Derp1-IgG4 10.005(0.002)f<m 18.219(<0.001) 0.065(0.058)(0.800) 0.503(0.48)T>U 
Responses Derp1-IgE/IgG4 0.343(0.56)f<m 2.305(0.105) 0.054(-0.26)(0.817) 1.626(0.205)T<U 
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Table 4.3 Results from a multivariate GLM analysis  
F (and p-) values from multivariate GLM analysis of the effect of treatment on the 
magnitude of change in antibody responses (and ratios) in the high and low infection 
areas after allowing for the effects of host age, sex and infection intensity. Significant 
p-values are highlighted in bold and significant β coefficients (for the direction and 
strength of the effect of infection intensity) are shaded gray. The dependent variable 
represents the difference between post- and pre-treatment antibody levels for each 
isotype. SWAP: Soluble worm antigen preparation, SEA: soluble egg antigen, Derp1: 





4. 3. 2. Effect of treatment and baseline infection levels  
 
Schistosome specific antibodies 
After allowing for the effects of host gender, age and baseline infection intensity, the 
increase (in anti-worm IgE and IgG4) was not significantly different between treated 
and untreated people in the high infection area but the increase in anti-worm IgE 
levels was significantly higher in treated individuals compared to their untreated 
counterparts in the low infection area (Figure 4.1 and statistics in Table 4.3). The 
change in anti- worm IgG4 levels were not significantly different between treated and 
untreated people in the low infection area (Figure 4.1 and statistics in Table 4. 3). In 
the high infection area, the increase in IgE/IgG4 ratio against schistosome adult worm 
was significantly higher in treated people than untreated while the increase in 
IgE/IgG4 ratio against schistosome egg was higher in untreated people (Table 4.3 and 
Figure 4.2). Treatment was not associated with the change in schistosome-specific 
IgE/IgG4 ratios in the low infection area (Table 4.3 and Figure 4.2).  
 
Baseline infection intensity was significantly associated with the magnitude of 
antibody change (anti-schistosome) in the high infection area. As shown in Table 4.3, 
there were significant effects of infection intensity on IgE and IgG4 against the adult 
worm and egg antigens (positive β coefficients: positive association) as well as the 
ratio IgE/IgG4 against the egg antigens (negative β coefficient: negative association).  
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Derp1 specific antibodies 
Results from the multivariate GLM analysis (Table 4.3) show that, after allowing for 
the variations due to host gender, age and baseline infection intensity, treatment only 
significantly affected the decrease in Derp1-IgE in the high infection area (i.e. the 
magnitude of change was significantly different between treated and untreated groups 
in this area, see figure 4.1). However, IgG4 antibodies increased in untreated 
individuals in the high infection area and in treated and untreated groups in the low 
infection area. This resulted in the change in IgE/IgG4 ratio not significantly different 
between treated and untreated people in both areas (Figure 4.2). Baseline infection 
intensity was not significantly associated with the change in anti-Derp1 antibody 
responses (and ratio).  
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Figure 4.1 Comparison of changes in antibody levels  
Antibody changes are shown for treated (black columns) and untreated (white 
columns) people in the high infection area (A) and the low infection area (B) with 
standard error of means. Antibody changes are calculated as the difference between 
post-treatment levels (square root transformed absorbencies) and pre-treatment levels 
(square root transformed absorbencies). Asterisks represent significant differences 
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Figure 4.2 Comparison of changes in the ratios  
Mean changes in ratios IgE/IgG4 for treated (black columns) and untreated (white 
columns) people are shown for the high infection area (A) and the low infection area 
(B) with standard error of means. Asterisks represent significant differences between 
treated and untreated people at *p<0.05 and **p<0.01 obtained from analysis of 
variance after allowing for the variation due to the potential confounding variables- 
host age, sex and pre-treatment infection intensity.  
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4. 4. Discussion and conclusions 
 
There is mounting evidence that anti-helminthic treatment not only transiently clears 
or reduces infection, but also has longer term benefits in terms of reducing morbidity 
and the development of parasite-specific immune responses associated with resistance 
to re-infection (Colley et al. 1986; WHO 1993; Mutapi et al. 2003; Black et al. 
2010a; Black et al. 2010b). On the other hand, there are several studies suggesting 
that anti-helminthic treatment increases the incidence of atopic reactivity (Lynch et 
al. 1993a; van den Biggelaar et al. 2004), although there are some studies showing 
the opposite effect (Lynch et al. 1997). Variations in parasite transmission dynamics 
may influence the effect of anti-helminthic treatment on atopic reactivity as well as 
parasite-specific responses.  
 
The current study investigated the effect of praziquantel treatment on anti-
schistosome and anti-Derp1 IgE and IgG4 antibody responses in the two villages of 
differing schistosome infection levels described in chapter 3. The results show 
changes in antibody levels as well as the ratios in the two villages 6 weeks post-
treatment. Although there were changes in untreated groups, only those which were 
significantly different between treated and untreated people were attributed to 
treatment. Changes in untreated groups may reflect the natural fluctuation of humoral 
immunity in endemic areas as has been previously reported (Reilly et al. 2008), or 
treatment contamination (‘untreated’ individuals may have received treatment from 
the local hospital within the follow up time). 
 
Treatment was associated with a significant increase in the levels of schistosome 
adult worm specific IgE responses in the low infection area and the ratio IgE/IgG4 
against adult worm in the high infection area regardless of host age, gender and 
baseline infection intensity. High levels of parasite specific IgE have been associated 
with resistance to schistosome infection while IgG4 are associated with susceptibility 
(Hagan et al. 1991; Black et al. 2010a; Pinot de Moira et al. 2010). The increase in 
the levels of IgE over IgG4 (ratio IgE/IgG4) following chemotherapy observed in this 
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study supports a role for praziquantel in enhancement of putatively protective 
acquired immunity as reported by others (Colley et al. 1986; Hagan et al. 1991; 
Karanja et al. 2002; Joseph et al. 2004; Black et al. 2010a). In the low infection area, 
although IgE responses increased, the ratio IgE/IgG4 did not change significantly 
possibly due to the low levels of infection in this area, and therefore low levels of 
IgG4 antibodies (Li et al. 1999; Naus et al. 2003).  
 
The present study showed that levels of schistosome infection prior to treatment were 
related to the increase in anti-schistosome antibodies (IgE and IgG4), consistent with 
previous reports (Mutapi et al. 2003). Praziquantel damages adult worms and mature 
eggs, releasing previously concealed antigens to the host immune attack (Harnett and 
Kusel 1986), and therefore induces quantitative and qualitative changes in host 
cellular and humoral responses (Colley et al. 1986; Grogan et al. 1996a; Joseph et al. 
2004; Mutapi et al. 2005a). It is therefore expected that the biggest boost in antibody 
responses occurs in individuals with a heavy parasite load before treatment.  
 
Variations in anti-schistosome egg antibody responses following praziquantel 
treatment have been reported (Mutapi et al. 2003) and studies on S. japonicum 
associated anti-egg IgE responses with resistance to re-infection (Zhang et al. 1997). 
In the present study, the increase in anti-egg IgE and IgG4 was significantly 
positively associated with pre-treatment infection intensity although there was no 
significant difference between treated and untreated individuals. Furthermore, the 
magnitude of increase in anti-egg IgE/IgG4 ratio was negatively associated with pre-
treatment infection intensity in the high infection area, suggesting that, in contrast to 
anti-adult worm responses, anti-egg IgG4 were more increased than IgE in 
individuals who were heavily infected prior to treatment. This is suggestive of, but 
not conclusive evidence for, the immunomodulatory role of IgG4 (Maizels and 
Yazdanbakhsh 2003) following the rapid release of parasite ‘inflammatory’ egg 
antigens after praziquantel treatment.     
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In this study, IgE against Derp1 decreased significantly following treatment while 
IgG4 did not change significantly in the high infection area, resulting in a decrease in 
the ratio IgE/IgG4. In the low infection area, none of the changes in anti-Derp1 
antibodies/ratio was associated with treatment. Unexpectedly, anti-Derp1 IgG4 
responses increased in untreated groups as well as in treated people from the low 
infection area. The reasons for this increase are unknown however these groups had 
relatively low levels of infection at baseline compared to the treatment group in the 
high infection area (for which no significant change occurred). This result is 
consistent with a recent study that reported a significant effect of anti-helminthic 
treatment (albendazole) on infants’ eczema when administered to uninfected 
compared to infected mothers during pregnancy (Mpairwe et al. 2011). Despite that 
this was not the case for praziquantel in the aforementioned study, and that anti-
Derp1-IgG4 also changed in untreated groups in the current study, further studies are 
required to determine whether anti-helminthics have a direct effect on host immune 
responses in the absence of infection.  
 
High levels of allergen-specific IgE antibodies and high IgE/IgG4 ratio are associated 
with the clinical manifestation of atopy (Johansson et al. 2004; Bullock et al. 2005) 
and as reported in chapter 3. The decline in IgE anti-Derp1 observed following 
treatment in the present study is consistent with findings in Gabon (van den Biggelaar 
et al. 2004). These authors reported a significant increase in skin sensitization, while 
allergen-specific IgE slightly decreased, over the course of a 30months of 
praziquantel - mebendazole treatment of helminth infected children. Since atopy is 
inversely associated with schistosome infection (Araujo et al. 2000; van den 
Biggelaar et al. 2000) and (chapter 3), this decline in allergen-specific IgE may 
reflect the mechanisms involved in praziquantel-associated desensitization (Satti et al. 
2004). These authors demonstrated that blood basophils from S. mansoni infected 
individuals were ‘desensitized’ (i.e no histamine release) to schistosome egg and 
worm antigens after treatment. Sensitized basophils release histamine and cytokines, 
including IL-4 capable of inducing Th2-IgE responses (Min et al. 2004; Yoshimoto et 
al. 2009). Furthermore, it has been shown that serum IgE levels are closely related to 
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FcεRI expression on basophils (Malveaux et al. 1978; Saini et al. 2000). Therefore, 
basophil ‘desensitization’ may have impacted on the levels of Derp-IgE reported in 
the current study.  
 
However, since anti-schistosome IgE increased following treatment, an alternative 
explanation is that the polyclonal stimulus of ‘cross-reactive’ IgE, characteristic of 
helminth infections (Hagel et al. 1993c; Lynch et al. 1993b; Yazdanbakhsh et al. 
2002), may have been removed with treatment (parasite killing) and an anti-
schistosome IgE response enhanced in the presence of high levels of parasite 
antigens. This is in line with findings that anti-schistosome chemotherapy induces 
qualitative changes in serological recognition of parasite antigen (Mutapi et al. 
2005a) and increases cellular reactivity to parasite antigens (Colley et al. 1986; 
Grogan et al. 1996a; Joseph et al. 2004). An increase in Ascaris (geohelminth)-
induced Th2 cytokine responses (IL-5 and IL-13) without significant changes in 
allergen-induced Th2 responses have also been reported following anthelminthic 
treatment (Cooper et al. 2008b). 
 
Together, findings from the present study show that within 6 weeks, a single dose of 
praziquantel treatment can increase antibody levels associated with resistance to 
schistosome infection/re-infection while decreasing the levels of sensitization to the 
house dust mite in schistosome endemic areas. In addition, the effect of treatment on 
atopic responses was apparent in the high infection area but not in the low infection 
area. With the current WHO recommendations to implement control programs in all 
endemic areas for schistosomiasis, this study highlights the need to investigate the 
effect of treatment at different levels of endemicity. There was no evidence from this 
study that praziquantel treatment of endemically exposed populations will exacerbate 
allergic sensitization. This does not preclude the possibility that deworming may 
impact on allergic diseases and further longer term studies are required. 
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Chapter 5 
Relating soluble CD23 and total IgE to atopy in S. 
haematobium endemic areas 
 
5. 1. Introduction 
 
Helminth infections, including schistosomiasis, and atopic disorders are characterised 
by high levels of IgE antibodies. In helminth infection, parasite-specific IgE 
responses are protective (Hagan et al. 1991; Zhang et al. 1997; Hagel et al. 2008; 
Black et al. 2010a) while in allergy high allergen-specific IgE levels are associated 
with the clinical manifestations (Bruynzeel-Koomen et al. 1988; Busse and 
Rosenwasser 2003). Nevertheless, in both cases, these responses have been associated 
with increased CD23 expression. Thus, an increase in circulating CD23+ B cells as 
well as soluble CD23 (sCD23) has been associated with resistance to schistosome re-
infection (Mwinzi et al. 2009) while CD23+ B cell numbers were higher in asthmatic 
compared to non-asthmatic children (Aberle et al. 1997). It is however unknown 
whether numbers of CD23+ B cells or levels of sCD23 influence the clinical 
presentation of atopy in schistosome endemic populations.  
 
Schistosome infection is negatively associated with skin sensitisation and asthma 
severity (Araujo et al. 2000; van den Biggelaar et al. 2000; Medeiros et al. 2003) as 
well as allergen-specific IgE responses (chapter 3). Polyclonal stimulation of IgE has 
been suggested as an explanation to the low levels of allergic reactivity in tropical 
populations (Hagel et al. 1993c). This theory suggests that the elevated levels of non-
specific IgE observed during helminth infections saturate mast-cell and basophil Fc 
receptors and interfere with allergen-specific IgE binding (Bazaral et al. 1973; 
Godfrey and Gradidge 1976). This theory has however been challenged by 
observations that basophils release histamine in the presence of high levels of 
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polyclonal IgE and high polyclonal IgE/specific IgE ratio (Mitre et al. 2005; Pritchard 
et al. 2007).  
 
The CD23 (BLAST-2 or low affinity FcεRII) is a 45-kDa transmembrane low affinity 
IgE receptor found on the surface of IgM+ IgD+ B cells (Fournier et al. 1994). It also 
appears on the cell surface of macrophages, platelets, monocytes and eosinophils 
(Gordon 1992). It is characterised by three lectin domains (heads) bound onto the 
membrane by a triple α-helical ‘tail’ (see figure 1.3, chapter 1). The binding of IgE on 
membrane-bound CD23 is thought to inhibit the Cε gene transcription and IgE class 
switch, thus regulating IgE synthesis (Conrad et al. 2007; Gould and Sutton 2008). 
However, there is also a possibility that co-ligation of membrane IgE (Fc-IgE) and 
membrane CD23 by allergen-IgE complexes leads to a negative feedback for IgE 
synthesis (Gould and Sutton 2008). Nevertheless, the tail region of the CD23 can be 
cleaved by endogenous proteases, in the presence of IL-4 and IL-13, resulting in 
release of sCD23 fragments to the serum (Letellier et al. 1989; Gould and Sutton 
2008). These CD23 fragments are involved in either negative or positive regulation of 
IgE synthesis depending on their size and oligomerisation state (Conrad et al. 2007; 
Bowles et al. 2011).  
 
Following observations that schistosome infection intensity is negatively associated 
with allergen-specific IgE while positively associated with schistosome-specific IgE 
responses (chapter 3), the aim of the current study was to determine whether sCD23, 
negative and positive regulator of IgE, is associated with the relationship between 
atopy and schistosome infection. This investigation builds on previous animal studies 
which showed that helminth-induced CD23+ ‘regulatory’ B cells were able to 
suppress experimental allergic inflammation (Wilson et al. 2010).  
 
Levels of soluble CD23 and total IgE were compared between the 2 villages with 
differing schistosome infection levels previously described (chapter 3), and related to 
current infection and markers of atopy (i.e allergen-specific IgE antibodies and skin 
prick tests results).  
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Hypotheses 
- Soluble CD23 are elevated during heavy S. haematobium infection and are 
associated with reduced atopy 
- Soluble CD23 production is associated with the polyclonal stimulation of IgE in 
schistosome endemic areas. 
 
5. 2. Materials and methods 
5. 2. 1. Study population 
 
From the cohorts recruited from Magaya (high infection area) and Chitate (low 
infection area) communities at baseline, a sub-cohort of 434 participants (211 from 
the low infection area and 223 from the high infection area) provided enough sera to 
enable immunological assays for CD23 and total IgE (the remainder were excluded 
because of the lack of enough sera after assays described previously). The 
demographic composition of this sub-cohort is detailed in Table 5. 1. All participants 
in this study were lifelong residents of the villages and had provided at least 2 stool 
and 2 urine specimens for the diagnosis of helminth infections. They were egg 
negative for geo-helminths and S. mansoni; and had not previously received anti-
helminthic treatment. None of these participants had patent infection with 
Plasmodium parasites but 33 were HIV positive. The potential confounding effects of 
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                                                    Age groups (years) 
  6-10 11-15 16+ 
 N      103 86 34 
Mean age (years)       8.2 12.5 38.8 
Sex ratio (M:F)     50:53 37:49 14:20 
   Magaya: 
   High 
infection 
    area 
Mean infection #     16.3 39.8 2.4 
 Prevalence     51.4% 61.4% 23.5% 
 HIV positive cases      4   4 6 
 Post-treatment n     56   47 20 
 n       77 51 83 
Mean age (years)       8.5 12.3 39 
Sex ratio (M:F)      38:39 24:27 11:72 
  Chitate:  
  Low infection 
  area Mean infection #        0.76 1.03 0.22 
 Prevalence         9% 11.8% 4.8% 
 HIV positive cases         4   2 13 
 Post-treatment n        43   32 22 
 
Table 5.1 Demography and infection levels of the study populations  
The sample sizes (n), mean age, sex ratio and infection levels are shown, for each 





5. 2. 2. Treatment 
 
As described in chapter 2, after collection of all samples (urine, stool, blood), all 
consenting participants were treated with the WHO recommended single dose of 
praziquantel (40 mg/kg). Six weeks following treatment, samples were again 
collected to check the efficacy of treatment and to monitor the effect of treatment on 
immune responses. A total of 224 participants (out of the 434 included in this 
chapter) provided sera at the 6-weeks follow up and of these, 4 of the treated 
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individuals did not clear infection (i.e. were egg positive at follow up). These 4 
individuals were therefore excluded from the post-treatment analysis of this study, 
leaving a total of 220 people (123 from the HIA, 97 from the LIA, see table 5.1). All 
treated participants included in this analysis were schistosome egg negative (i.e had 
cleared infection) after the 6 weeks period.  
 
 
5. 2. 3. Immunological assays 
 
As described in chapter 2, venous blood was collected from each study participant 
and serum was extracted for enzyme linked immuno-sorbent assays (ELISA) to 
quantify antibody levels. To determine the levels of soluble CD23, microtitre plates 
were coated overnight with 100 µl/well of capture antibody (anti-CD23, R&D) at 1 
µg/ml in carbonate bicarbonate buffer. Plates were washed and blocked with 2% 
BSA/tween20 for 2 hours before the addition of samples. Serum samples were diluted 
at 1:2 in 2% BSA/tween20, and secondary antibody (Biotinylated Anti-human CD23, 
aa 150-321, R&D) at 0.2 µg/ml. 100 µl/ well of streptavidin at 1:6000 were added 
after 4 washes and plates were incubated for 2 hours at 37°C. For the total IgE, plates 
were coated overnight with 5µg/ml of the capture antibody (anti-IgE, Dako), serum 
samples were diluted at 1:50, and the secondary antibody (anti-human horse-radish 
peroxide conjugated IgE, Sigma) diluted at 1:1000.  
 
For both isotypes, the substrate (ABTS, Southern Biotech) was used for the 
colorimetric reaction and the optical density read at 405nm. The antibody 
concentrations were extrapolated from a series of titrations of standards (purchased 
from R&D Systems and NIBSC respectively for CD23 and IgE) which were run on 
each plate. The top standard concentration was 0.1µg/ml for CD23 and 1: 10 dilution 
for total IgE. Antibody levels were expressed as ng/ml and International Units 
(IU/ml), respectively for CD23 and total IgE.  
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Levels of allergen- (Derp1, Indoor Biotechnologies) specific IgE responses 
(expressed as optical densities read at 405nm wavelength) obtained from the cross-
sectional study (see Chapter 3) were used in this study.   
 
 
5. 2. 4. Skin prick tests (SPT) 
 
As previously described (chapter 2&3), skin prick tests were performed using 
Dermatophagoides pteronyssinus (house dust mite or HDM), Grass mix, Alternaria 
tenius, and Aspergillus fumigatus (all from Diagenics), and positive responders (skin 
prick result equal or higher than the positive control) classified as atopic individuals.  
This chapter includes 225 people (out of the 434) skin pricked (mean age: 21 years, 
range: 6 to 86; and mean infection: 0.7eggs/10ml, range: 0 to 28) and SPT refers to 
skin sensitisation to the HDM.  
 
 
5. 2. 5. Statistical analyses 
 
All antibody data were square-root transformed and infection intensity log10(x+1) 
transformed to fulfil the assumptions of parametric tests conducted (Barnard et al. 
2007). All the statistical analyses were performed in PASW statistics 17 and values of 
p< 0.05 were considered significant. 
 
Infection intensity and prevalence were compared between the two villages using the 
univariate general linear model (GLM) and chi-square tests respectively. In the GLM, 
infection intensity was the dependent variable while sex, age, HIV status and village 
were the independent categorical variables. Three age groups reflecting 
epidemiological patterns of infection (as determined by post-hoc tests) were defined 
(6-10; 11-15 and 16+). It would have been appropriate to further split the older age 
group into two to account for the slight variation previously observed in the low 
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infection area in the cross-sectional study but the sample sizes were too small to allow 
statistical analyses. To test whether age-infection patterns (pre-peak, peak and post 
peak infection) previously shown for the cross-sectional study (chapter 3) were 
reflected in the currently selected cohort, post-hoc Bonferroni tests were performed 
between age groups of the same village (with data split by village). 
    
Antibody levels were compared between villages using an independent t-test. As this 
initial analysis showed significant differences, and since the fundamental difference 
between the two villages were schistosome infection levels, the relationship between 
current infection status/intensity and antibody levels was determined. This was done 
by multivariate GLM using antibody levels as dependent variables and age 
(categorical, 6 to 10; 11 to 15 and 16&above), sex (categorical, male/female), village 
(categorical, HIA/LIA), HIV status (categorical HIV negative/HIV positive) and 
infection status (categorical, infected/ uninfected) or infection intensity (continuous) 
as independent variables. B coefficients were used to determine the direction of the 
association and sequential sums of squares applied, entering the variable ‘infection 
status’ or ‘infection intensity’ last in the models to account for the variations due to 
all other confounding variables first before testing the effect of infection on antibody 
levels (Mutapi and Roddam 2002). 
 
To establish whether atopic and non-atopic individuals (determined by SPT) 
exhibited differences in their antibody levels (Total and sCD23), a binary logistic 
regression analysis was performed, using skin prick status as the dependent variable 
and sex, age, village, infection intensity, HIV status, sCD23 and total IgE levels as 
predictors. SPT results and specific IgE against the house dust mite were related in a 
univariate GLM with Derp-IgE as a dependent variable and host sex, age, village, 
HIV status, infection intensity and SPT status as independent variables. 
 
To determine whether sCD23 levels were related to levels of IgE (total or anti-Derp1) 
antibodies, a linear regression analysis was conducted on residuals after allowing for 
host gender, age, HIV status, village of residence, and infection intensity. 
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5. 3. Results 
5. 3. 1. Epidemiological patterns of S. haematobium infection 
 
Consistent with the larger cross-sectional cohort (Chapter 3), infection intensity and 
prevalence were significantly higher in Magaya (the high infection area, HIA) than 
Chitate (the low infection area, LIA) in the current selected populations (23.2 vs 0.6 
eggs/10ml; F1,428=63.295; p<0.001) and (49.8% vs 8.06%; χ²=90.743; p<0.001) 
respectively. Age-infection profiles showed a statistically significant infection peak at 
the age of 11-15 years in Magaya but no age group in Chitate showed a statistically 
significant peak (Figure 5.1).     
 
 
Figure 5.1 Age-infection distribution 
The mean of the log10 (x+1) transformed infection intensity (eggs/10ml urine) is 
shown for the high infection village (black columns) and the low infection village 
(grey columns) by age groups. Bars represent standard errors of mean and asterisks 
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5. 3. 2. Levels of sCD23 and total IgE differ between the 2 villages  
 
Overall, levels of soluble CD23 were significantly higher in the high than the low 
infection area, (t=10.659, p<0.001) while total IgE levels were higher in the low 



















Figure 5.2 Comparison between villages for antibody levels  
The mean of the square root transformed concentrations of total IgE (A) and soluble 
CD23 (B) are plotted for the high infection area (HIA) and the low infection area 
(LIA). Bars represent standard error of means and asterisks represent significant p-
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5. 3. 3. Infection intensity, but not infection status, is positively 
associated with levels of sCD23  
 
A multivariate analysis showed a significant positive association between 
schistosome infection status and levels of total IgE but not with sCD23 (Table 5. 2), 
while infection intensity was positively associated with both sCD23 and total IgE 




 Total IgE  
F and (p)  
sCD23  
F and (p) 
Sex 0.158 (0.691)f>m 5.555 (0.019)f>m 
Age 3.627 (0.027) 29.298(<0.001) 
HIV status 0.438 (0.508)N>P 0.072 (0.789)N>P 
Village 8.794 (0.003)L>H 78.902 (<0.001)H>L 
S. haematobium 
Infection status 
5.683 (0.018)I>U 1.908 (0.168)I>U 
 
Table 5.2 The effect of S. haematobium infection status on total IgE and sCD23 
Results from a multivariate GLM analysis allowing for the effects of host gender, 
age, HIV status, and village of residence. Sequential sums of squares were used for 
this analysis and F- and p- values are reported in the table. I: infected, U: uninfected; 
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  Total IgE  
F (p) 
    sCD23 
    F (p) 
Sex 0.158 (0.691)f>m     5.593 (0.018)f>m 
Age 3.625 (0.027)     29.498 (<0.001) 
HIV status 0.437(0.509)     0.072 (0.788) 





    3.867 (0.05) 
    (β =0.028)# 
 
Table 5.3 The effect of S. haematobium infection intensity on total IgE and 
sCD23 levels  
Results from a multivariate GLM allowing for the effects of host gender, age, HIV 
status and village of residence. Sequential sums of squares were used for the analysis 
and F- and p- values are reported in the table. #β-values shown for the direction of the 
relationship between infection intensity and antibody levels; H: high infection area, L: 
low infection area, f: female, m: male. 
 
 
When the population was split by HIV status, the positive association between sCD23 
and infection intensity was stronger in HIV negative individuals (F=5.358, p=0.021, 
B=0.035) while a non-significant negative association was observed in HIV positive 
people (F=1.932, p=0.176, B= -0.049). HIV status did not affect the relationship 
between infection intensity and total IgE. 
 
5. 3. 4. Atopy is negatively associated with levels of sCD23 
 
A binary logistic regression showed that atopic individuals (as determined by SPT), 
had significantly less sCD23 levels (β = -7.32, Wald=7.663, p=0.006; illustrated in 
figure 4) but levels of total IgE did not differ between atopics and non-atopics (β 
























Figure 5.3 Antibody levels by atopic status  
The mean of the square root transformed concentrations of total IgE (A) and soluble 
CD23 (B) are plotted for SPT (skin prick test) positive and negative individuals. Bars 
represent standard errors of the means, ** represents p<0.01, ns represents p>0.05 
obtained from GLM analysis allowing for the effects of host sex, age, HIV status, 
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The relationship between the levels of sensitisation (Derp1 specific IgE) and skin 
prick results was determined in GLM analysis. After allowing for the confounding 
effects of host age, gender, HIV status, village of residence and infection intensity, 
atopic individuals (as determined by SPT) had significantly higher levels of anti-







































Figure 5.4 Anti-Derp1 IgE antibodies in SPT positive vs. SPT negative people 
Mean levels of Derp1-IgE (square root transformed absorbencies) result from a 
contrast GLM allowing for the effects of host gender, age, HIV status, village of 
residence and infection intensity. SPT: Skin prick test, ***p<0.001. 
 
*** 
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5. 3. 5. Dissociation between total IgE and CD23 
 
To determine the relationship between CD23 and IgE responses (total as well as 
Derp1-specific), linear regression analyses were conducted, adjusting for host age, 
gender, HIV status, village of residence and infection intensity. As illustrated in 
Figure 5. 5 A&B respectively, anti-Derp1 IgE responses were significantly negatively 
associated with levels of sCD23 (p=0.001) while significantly positively associated 
with total IgE levels (p<0.001). Furthermore, there was no significant association 













































        
                                       





























                  

























Figure 5.5 Linear regression analyses of IgE and sCD23                                  
Anti-Derp1 IgE responses (square root transformed absorbencies) are plotted against 
CD23 (A) and total IgE (B), and CD23 plotted against total IgE (C). Resid: Residuals 
of the square root-transformed concentrations of sCD23 or Total IgE (allowing for 
age, sex, HIV status, village and infection intensity), Derp1: Dermatophagoides 
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5. 3. 6. Effect of treatment  
 
A repeated measures analysis between pre- and 6weeks post- treatment antibody 
levels showed no significant changes in either total IgE or sCD23 due to treatment or 
baseline infection intensity (Table 5. 4). However, as the analysis showed temporal 
changes and differences between the two villages, the data was split by village to 
capture these differences. This analysis showed variations in the levels of sCD23 in 
both villages and total IgE in the low infection area, but these changes were not 
significantly associated with treatment after allowing for the confounding effects of 
host age and gender.  
 
 
            
Variable sCD23 Total IgE 
Time 371.53(<0.001) 18.095(<0.001) 
Sex 1.783(0.183) 0.019(0.89) 
Age groups 33.425(<0.001) 5.069(0.007) 
Village 18.039(<0.001) 13.133(<0.001) 




Treatment 0.42(0.518) 0.054(0.816) 
 
Table 5.4 Effect of treatment on antibody levels 
Changes in antibody levels 6 weeks post-treatment were analysed by repeated 
measures GLM (n=220). The effect of treatment is tested after allowing for the effects 
of host sex, age, village of residence and baseline infection intensity. F- and (p) 
values are reported and significant results at p<0.05 are highlighted in bold. The 
degrees of freedom are: 1 for sex, village, infection intensity and treatment; 2 for age 
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5. 4. Discussion and conclusions 
 
Immune responses to helminth infection, including schistosomiasis, are characterised 
by Th2 polarization with high levels of IgE antibodies and yet, allergic disorders, 
which are also dependent on IgE, are generally low in helminth endemic areas (van 
den Biggelaar et al. 2000; van den Biggelaar et al. 2001; Smits and Yazdanbakhsh 
2007; Cooper 2009). On the other hand, high allergen-specific IgE antibodies, in the 
absence of infection, correlate with allergic disorders (Busse and Rosenwasser 2003; 
Bullock et al. 2005). Understanding the mechanisms involved in the regulation of IgE 
antibodies during helminth infection may therefore be relevant for the management of 
clinical allergy.  
 
The low affinity IgE receptor CD23 (or FcεRII), believed to be both a negative and a 
positive regulator of IgE synthesis (Conrad et al. 2007; Lemieux et al. 2007), and the 
total IgE have been the focus of this study. Levels of soluble CD23 (sCD23) and total 
IgE were measured and related to markers of atopy (i.e skin prick reactivity and 
levels of anti-allergen IgE antibodies) and current infection in areas of differing 
schistosome infection levels.  
 
The data presented show that levels of sCD23 are significantly higher in the high (S. 
haematobium) infection area than the low infection area. A further analysis 
demonstrated a significant positive association between levels of sCD23 and current 
schistosome infection intensity regardless of host village of residence. Since infection 
intensity was previously negatively associated with atopy in this population (see 
chapter 3), levels of sCD23 were compared between atopic and non-atopic 
individuals (atopy as tested by skin prick tests) to determine whether the CD23 is 
associated with atopy. This analysis revealed that atopic individuals exhibit 
significantly lower levels of sCD23 than their non-atopic counterparts. This result 
contrasted with earlier findings that sCD23 are significantly elevated in asthmatic 
compared to healthy controls (Sanchez-Guerrero et al. 1994). However, these authors 
also showed that sCD23 and monocytes expressing CD23 were elevated in patients 
with intrinsic (i.e non-allergic) asthma but that these, in contrast to allergic patients, 
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did not translate into elevated levels of IgE, nor positive SPT. In the current study, 
SPT positive individuals had significantly higher levels of Derp1-specific IgE than 
their SPT negative counterparts, suggesting an association between the levels of 
sensitisation and the clinical manifestation of atopy in this population. Furthermore, 
regression analyses revealed a significant negative association between allergen-
specific IgE and levels of sCD23.  
 
These contrasting results may reflect the fact that soluble CD23 may be involved in 
both the negative and positive regulation of IgE synthesis (see Figure 1.3, chapter 1). 
Thus, Gould and Sutton proposed a model in which a CD23 trimer molecule binds 
three IgE molecules and three CD21 molecules, forming a signalling platform for the 
survival and differenciation of IgE-committed B cells (Gould and Sutton 2008). More 
recently, Bowles and colleagues, working on engineered recombinant soluble human 
CD23 fragments, showed that the binding affinity of these molecules is dependent on 
their ‘tail’ length and that monomeric CD23 (16 and 25kDa) decrease while the 
trimeric CD23 (whole extracellular domain) increase IgE secretion by PBMCs 
(Bowles et al. 2011), confirming earlier findings (Sarfati et al. 1992; McCloskey et 
al. 2007). The enhancement action of the trimeric CD23 was dependent on their 
ability to bind the CD21 receptor. Interestingly, the 25kDa recombinant monomeric 
CD23 fragment used in these experiments resembles that released by ADAM10-
mediated proteolysis (Bowles et al. 2011), suggesting that inhibiting CD23 fragments 
may occur naturally in vivo. Although the ELISA assay used in the current study was 
not specific to a given CD23 fragment, the results suggest that during heavy S. 
haematobium infection, IgE-suppressive soluble CD23 are produced that may inhibit 
allergic sensitisation.  
 
The role for CD23 in suppressing atopy has been shown in murine studies. Thus, the 
airway inflammation- suppressive function of B cells has recently been associated 
with high expressions of CD23 from mice chronically infected with H. polygyrus, an 
intestinal nematode (Wilson et al. 2010). Furthermore, a strain of mice naturally over-
expressing IgE responses possess a variant CD23 present at low levels on B cells, 
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which fail to trimerise and bind IgE (Lewis et al. 2004). Nevertheless, in contrast to 
human, murine CD23 does not have the C-terminal tail that binds CD21 (see (Conrad 
et al. 2007)), and these findings may not fully reflect the physiological function of 
soluble CD23 in humans. 
 
In the current study, in contrast to CD23, levels of polyclonal IgE were significantly 
higher in the low than the high infection area, and were not significantly different 
between atopic and non-atopic groups. Furthermore, a positive association was 
observed between these antibodies and allergen-specific IgE, suggesting dissociation 
between the levels of total IgE and sCD23. This dissociation was further confirmed 
by the absence of correlation between these antibodies in regression analyses. 
Nevertheless, schistosome infection intensity was also significantly positively 
associated with the levels of polyclonal IgE antibodies, consistent with previous 
reports (Hagel et al. 1993c).  
 
These results reject the a priori hypothesis that the reduced levels of atopy in 
schistosome infected people are due to polyclonal IgE stimulation, and are in 
agreement with studies which showed that high levels of total IgE do not inhibit 
histamine release (Mitre et al. 2005; Pritchard et al. 2007).  
 
In this study, there was no significant change in the levels of soluble CD23 and total 
IgE following treatment, contrasting with findings by Black et al (Black et al. 2010a). 
It is possible that the absence of significant changes in CD23 in the current study may 
have been due to the short follow up time since these authors found significant 
changes 2 years following repeated praziquantel treatment. Consistent with this 
hypothesis is the fact that some soluble CD23 fragments have been reported to be 
stable in vitro for up to 3 weeks (Sarfati et al. 1988). 
  
Polyclonal IgE responses have been suggested to prevent binding of parasite-specific 
IgE on effector cells, rending the host susceptible to helminth infection (Hagel et al. 
1993a). The absence of significant changes in the levels of total IgE post-treatment 
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may therefore reflect the praziquantel-induced transient resistance to re-infection via 
stimulation of parasite-specific IgE (Mutapi et al. 2003; Black et al. 2010a) rather 
than the non-specific IgE induced by live parasites (Hagel et al. 1993a; Lee and Xie 
1995).  
 
In conclusion, data from this study suggest that heavy schistosome infections are 
associated with high levels of soluble CD23 with possible inhibitory effects on 
allergen-specific IgE responses and therefore suppress atopy in human populations. 
This inhibition is possible via cleavage of the CD23 molecule into small soluble 
monomer fragments with down-regulatory effects on IgE (Sarfati et al. 1992; 
McCloskey et al. 2007; Bowles et al. 2011) or inhibition of the trimerisation of these 
fragments. There is no evidence, from the results presented, for a role of the total IgE 
on the relationship between atopy and schistosome infection.  
 
Since different-sized sCD23 can result in either down-regulation or up-regulation of 
IgE antibodies (McCloskey et al. 2007; Bowles et al. 2011), and because the CD23 
tail has several sites of proteolysis (Brignone et al. 2001), and enable trimerisation, 
further studies on the identification of soluble fragments released during heavy 
schistosome infection are required to confirm the current findings. Ultimately, 
purification of schistosome proteins responsible for the CD23 cleavage and/or 
inhibition of trimerisation, would be invaluable for therapeutic interventions in 
clinical allergy. 




Effects of praziquantel treatment on antibody responses 
against schistosome and bystander antigens in pre-school 
children 
 
6. 1. Introduction 
 
Chemotherapy, with praziquantel, is the only wide scale tool for control of 
schistosomiasis. However, current control programs in endemic countries target 
school children, typically aged 6 years old and above and, consequently, younger pre-
school age children (i.e. 5 years and below) are frequently not treated. This is partly 
because they have been regarded as being at very low risk of infection and infection-
associated morbidity and partly because there has been lack of safety data on 
praziquantel in this age group (reviewed by (Stothard and Gabrielli 2007)). Yet, the 
reality is that exclusion of these children from control programs leaves them at high 
risk of developing chronic pathology as has been shown in high endemic foci (Garba 
et al. 2010b).  
 
This health inequality is now being addressed with the realization that pre-school age 
children do experience significant levels of infection (Bosompem et al. 2004; 
Odogwu et al. 2006; Sousa-Figueiredo et al. 2008; Garba et al. 2010a; Stothard et al. 
2011a). The WHO is currently advocating studies on the safety and efficacy of 
praziquantel, as well as methods of diagnosis and drug delivery in this age group 
(Sousa-Figueiredo et al. 2010; Mutapi et al. 2011b; Stothard et al. 2011a; Stothard et 
al. 2011b).  
 
In keeping with this effort, the aim of this study was to assess the consequences of 
praziquantel treatment beyond the reduction of infection, through examination of the 
effects on schistosome-specific responses and responses to bystander antigens.  
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Praziquantel treatment of older individuals has been shown to enhance antibody 
responses associated with resistance to re-infection with schistosomes in endemic 
areas (Mutapi et al. 2003; Black et al. 2010a). On the other hand, schistosome 
infection is associated with reduced atopy (Araujo et al. 2000; van den Biggelaar et 
al. 2000)(chapter 3) and asthma severity (Medeiros et al. 2003).  
 
Schistosome infection has also been reported to affect antibody responses associated 
with resistance to Plasmodium falciparum, the causative agent of malaria (Courtin et 
al. 2011). These authors showed that IgG responses to merozoite surface protein1 
(MSP-1) and glutamate rich protein (GLURP), were significantly lower in S. 
haematobium infected individuals than uninfected. However, anti-schistosome 
chemotherapy did not show any significant effects on antibodies against merozoite 
surface proteins in a meso-endemic area for malaria (Reilly et al. 2008).  
 
All these studies were conducted in schoolchildren and adults and the effects of 
praziquantel treatment on schistosome and bystander antigens in younger children 
remain to be determined. Given that PZQ treatment releases a large amount of 
parasite antigens to the immune system at a single time point (Day et al. 1992), 
accelerating host acquired immunity (Mutapi et al. 1998a; Mutapi et al. 2003), and 
that acquired immunity is dependent on the host age and infection history (Gryseels et 
al. 1994; Mutapi et al. 1997; Mutapi et al. 2005b; Mutapi et al. 2008), it is important 
to determine immunological consequences of praziquantel treatment in pre-school 
age children with a short history of infection.  
 
In this study, a cohort of 41 Zimbabwean children aged 3 to 5 years living in S. 
haematobium endemic areas were followed up 6 weeks post praziquantel treatment. 
The aim was to determine the effect of praziquantel treatment on immunological 
markers of exposure to schistosome and Plasmodium falciparum infections (i.e IgM 
directed against schistosome cercariae, egg and adult worms and against Plasmodium 
total schizont). The effects on IgE and IgG4 directed against schistosome cercariae, 
egg and adult worms, and IgG directed against P. falciparum antigens derived from 
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the merozoite surface proteins, were also determined. These antibodies have been 
associated with resistance to infection/re-infection with schistosomes (Hagan et al. 
1991; Zhang et al. 1997; Caldas et al. 2000) and Plasmodium (Courtin et al. 2009) 
respectively. To investigate whether atopic responses are affected by praziquantel 
treatment in this young age group, antibody responses (IgE and IgG4) to the house 
dust mite Dermatophagoides pteronyssinus, the most prevalent allergen in Zimbabwe 




- Praziquantel treatment enhances anti-schistosome ‘protective’ antibody responses of 
pre-school age children  
- Praziquantel treatment of pre-school age children alters allergen- and Plasmodium-
specific antibody responses  
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6. 2 Materials and methods 
 
6. 2. 1. Study area and population 
 
A cohort of pre-school children, aged 3 to 5 years, was recruited from Magaya, 
Chitate and Chipinda villages in the Mashonaland East of Zimbabwe where S. 
haematobium is endemic. Populations from the 3 villages are of the same ethnic 
group (Shona) and socio-economic status (subsistent farmers). The 3 villages are in 
close proximity, but due to the geography and seasonality of rivers crossing them, 
schistosome transmission levels are different. Based on WHO classification (WHO 
2006), the villages are of high (>50%), moderate (>10-<50%) and low (≤10%) 
transmission respectively for Magaya, Chipinda and Chitate (see chapter 2).  
 
The participants had no prior history of antihelminthic treatment (assessed by 
questionnaire answered by their parents/guardians), had been residents of the area 
since birth, were negative for intestinal helminth and S. mansoni infections and had 
provided blood specimen at both sampling times (pre- and 6-weeks post-treatment). 
Of the 41 children included in this study, 31 had received praziquantel treatment and 
were not excreting parasite eggs 6 weeks post-treatment while 10 children, whose 
parents declined treatment for religious reasons, formed the untreated control group. 
All the children were also part of a larger study investigating the safety of 
praziquantel and they reported no adverse effects 24 hours following treatment 
(Mutapi et al. 2011b). The 41 children were representative of the larger population of 
104 children in terms of age frequency distribution (number of children in each age 
group increased with age) and infection prevalence determined by egg excretion (see 
Figure 6.1). 
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Figure 6.1 Flow diagram of the study cohort.  
Numbers and schistosome infection prevalences are shown for the cross-
sectional and follow up populations. Subjects included in the present study 
are highlighted in grey boxes  
 
 
6. 2. 2. Antigens 
 
Lyophilized soluble S. haematobium adult (SWAP), cercariae (CAP) and egg (SEA) 
antigens were obtained from the Theodor Bilharz Institute (Egypt) and reconstituted 
as recommended by the manufacturer. D. pteronyssinus Derp1 allergen was obtained 
from Indoor Biotechnologies. Crude P. falciparum schizont antigens were of the 
Wellcome strain of the parasite. Recombinant antigens (from Plasmodium merozoite 
surface protein, MSP) were MSP-119 antigen, the 19kDa C-terminal domain of MSP1, 
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and MSP-2 which has 2 serotypes: CH150 that belong to serotype A (3D7-like), and 
Dd2 belongs to serotype B (FC27-like).  
    
6. 2. 3. Antibody assays 
 
A standard indirect enzyme-linked immunosorbent assay (ELISA) was optimized and 
used to quantify levels of antibodies directed against S. haematobium adult worm 
antigen (SWAP), soluble egg antigen (SEA) and cercarial antigen (CAP); P. 
falciparum antigens (crude schizont and recombinants MSP1&2) and Derp 1 allergen. 
All laboratory assays for the pre- and post-treatment time points were run at the same 
time.  
 
ELISAs for schistosome antigens: Microtitre plates were coated with 100µl/well of 
antigen at 5µg/ml (10µg/ml for SEA); serum samples were diluted at 1:20 for IgE 
(anti-SEA, SWAP and CAP); 1: 100 for IgM anti-SWAP and IgG4 anti-CAP and 
SWAP; 1:400 for IgM anti-CAP and SEA and IgG4 anti-SEA. Anti-human horse-
radish peroxide conjugated IgE (Sigma), IgM (Dako) or IgG4 0 were diluted at 
1:1000 except for IgM anti-SWAP (1:2000), IgG4 anti- CAP and SWAP (1:500) and 
IgE anti-SWAP (1:250). The colorimetric reaction was stopped after 15 min 
incubation at room temperature for IgM and IgG4 and 30 min incubation at 37°C for 
IgE. Absorbance readings of all wells were performed at 405nm. All samples were 
assayed in duplicate and 3 sera from European children (negative controls, 2 to 3 
years old) who have never been exposed to schistosome infections were included on 
each plate and were used to set up cutoff points for IgM status.  
 
ELISAs for Plasmodium antigens: Plates were coated with 50µl/well of 1µg/ml 
(schizont) or 50ng/ml (MSP 1&2) antigens, samples were diluted 1:100 for all assays 
and secondary antibodies (Sigma) diluted 1: 1000 (IgM and IgG) for crude antigens 
and 1:2000 (IgG) for recombinant antigens. The colorimetric reaction time was 15 
minutes at room temperature for all assays. Again, 3 sera from European children (2 
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to 3 years old) who have never been in malaria endemic countries were included on 
each plate to serve as negative controls and cutoff points for IgM status. 
 
ELISA for Derp 1 allergen: Plates were coated with 50µl/well of 5µg/ml and samples 
diluted 1:10. Detection antibodies (IgE from Sigma and IgG4 from The Binding Site) 
were diluted 1:1000 and the reaction time for the substrate was 30 minutes at 37°C.  
 
6. 2. 4. Statistical analysis 
 
The antibody and infection data did not fulfill the assumptions for parametric tests, 
and transformation could not overcome the skewed distributions. Therefore, non-
parametric tests were conducted for all analyses. The non-parametric Wilcoxon tests 
for paired samples were performed to compare pre- and post-treatment antibody raw 
data (absorbencies), ratios (IgE/IgG4) and infection intensities. For comparisons 
between groups of different individuals (i.e infected vs. uninfected, IgM negative vs. 
IgM positive, etc), Mann-Whitney U tests were performed. The cutoffs for IgM anti-
schistosome or anti-schizont antigens were calculated as the mean absorbance plus 2 
standard deviations of readings from European negative controls. All statistical 
analyses were conducted in PASW statistics 17 and p-values of <0.05 were 
considered significant. A sequential Bonferroni correction was used to identify results 
that were significant in the context of the multiple statistical comparisons (Rice 
1989). Significant p-values in this context are those fulfilling the inequality Pi ≤ 
α/(1+k-i), with Pi: a given p-value at rank i (p-values are ranked from the smallest to 
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6. 3 Results 
6. 3. 1. Infection and antibody levels before anti-helminthic treatment  
 
At baseline, 38 children provided urine samples for the diagnosis of schistosome 
eggs. Of these 13.2% (CI95 4.4-28) were schistosome egg positive (mean egg count of 
10 eggs/10ml). Of the 41 children included in this study, 17.5% (CI95 7.3-32.8) 
showed immunological evidence of recent exposure to egg antigens (positive anti-
SEA IgM), 39% (CI95 24.2-55.5) to cercariae antigens (positive anti-CAP IgM) and 
22% (CI95 10.6-37.6) to adult schistosome antigens (positive anti-SWAP IgM). All 
the treated children were schistosome egg negative at follow up but infection intensity 
increased for the infected untreated child. 
 
None of the children were P. falciparum positive as determined by thin and thick 
smears or by the Paracheck serological test but 21% (CI95 7.1- 42.1) showed 
immunological evidence of recent exposure to parasite antigens (positive anti-
schizont IgM). No significant difference in Plasmodium-specific antibody levels was 
observed between schistosome egg positive versus egg negative children although 
those positive for anti-SWAP IgM and anti-SEA IgM had higher titers of anti-
schizont IgM than those who were negative (Z=-1.701, p=0.0445 and Z=-2.101, 
p=0.0165 respectively for SWAP and SEA). Similarly there was no significant 
difference in levels of Derp1-specific responses (IgE, IgG4 and the ratio IgE/IgG4) 
between schistosome egg positive vs. egg negative (Z=-0.173, p=0.4315; Z=-1.152, 
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6. 3. 2. Effects of praziquantel treatment on antibody levels  
 
At baseline, there was no significant difference in mean antibody levels (all isotypes) 
between children who were subsequently treated and those who were not. 
Furthermore, infection levels were comparable between the two groups (Z=-0.146, 
p=0.884 for mean infection intensity and χ²=0.043, p=0.662 for prevalence). 
 
Six weeks post treatment, all of the treated children were free from infection, 
resulting in a significant fall in the mean egg count (Z=-1.626, p=0.034) while 
infection intensity increased for the one child who was egg positive at baseline in the 
untreated group. There were no newly infected children in the untreated group. There 
were significant changes in levels of the majority of antibodies between the two time 
points, but, these changes were not always restricted to treated children as shown in 
























Treated group (z 
and p values) 
Untreated 
group (z and 
pvalues 
 
   
CAP-IgM -4.037 (<0.000) -0.357 (0.36) 
SWAP-IgM -2.626 (0.0045) -0.533 (0.297) 
SEA-IgM -0.987 (0.162) -0.357 (0.361) 





responses SWAP-IgE -2.633 (0.004) -0.968 (0.166) 
 SEA-IgE -2.747 (0.003)  -1.599 (0.055) 
 CAP-IgG4 -0.35 (0.363) -0.106 (0.458) 
 SWAP-IgG4 -2.018 (0.022)  -0.415 (0.339) 
 SEA-IgG4 -0.718 (0.237) -2.601 (0.003) 
    
Derp-IgE -3.497 (<0.000) -0.968 (0.166) Anti-allergen 
responses Derp-IgG4 -3.746 (<0.000) -1.96 (0.025) 
    
 Schizont-IgM -2.308 (0.01) -1.992 (0.023) 
Schizont-IgG -2.222 (0.013) -0.734 (0.231) 
CH150-IgG -2.103 (0.018) -1.473 (0.705) 
Anti-
Plasmodium 
responses MSP119-IgG -2.043 (0.021) -1.897 (0.029) 
 Dd2-IgG -3.333 (0.0005) -1.992 (0.023) 
 
Table 6.1 Change in antibody levels in treated versus untreated groups 
Z and (p-values) from the non-parametric Wilcoxon tests comparing pre- and post-
treatment antibody mean levels are shown for each antibody isotype. Significant 
results (p<0.05) are highlighted in bold and those fulfilling the Bonferroni 
inequality are shaded grey. The sequential Bonferroni (Rice 1989) was done by 
ranking all the p-values from the smallest to the largest and checking the inequality 
p1 ≤ 0.05/16; p2 ≤ 0.05/(16-1) etc; with p1= smallest p-value (here 0.00 in the 
treated group, 0.003 in the untreated group), p2=second smallest p-value, k=16, 
α=0.05. CAP: cercariae antigen preparation, SWAP: soluble worm antigen 
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Schistosome-specific antibody levels 
 
Adult schistosome worm and cercariae-specific IgM titers, but not egg-specific IgM, 
rose significantly in treated children. There was no distinct pattern in these changes 
between children who were egg positive and negative at baseline (Figure 6.2A).  
 
Adult worm and egg-specific IgE titers also increased significantly following 
treatment. Anti-adult worm IgE increased in all the children who were egg positive at 
baseline but this increase occurred also in some children who were egg negative at 
baseline (Figure 6. 2 B).  
 
The mean of adult worm specific IgG4 titers was decreased following treatment 
although this decline was not significant after Bonferroni correction (Table 6.1). 
Nevertheless, the biggest decrease (Figure 6.2C) occurred in children with mild 
infection at baseline (0.3 to 10.7 mean eggs/10ml).  
 
In comparison, levels of all anti-schistosome antibodies (except egg-specific IgG4 
which declined) did not change significantly in the 6 weeks period for untreated 
controls (Figure 6.2A-C and table 6.1). No significant changes occurred in the ratio 
IgE/IgG4 against all the 3 parasite life cycle stages (Z=-1.118, p=0.453; Z=-1.139, 
p=0.128 and Z=-0.02, p=0.492 respectively for adult worm, cercariae and egg 



















SWAP_IgM 3.947 0.4065 
CAP_IgM 10.734 0.5995 
SEA_IgM 2.108 -0.4365 
SWAP_IgE 2.12 1.467 
CAP_IgE 0.3695 -0.958 
SEA_IgE 3.045 1.745 
SWAP_IgG4 -0.145 0.2255 
CAP_IgG4 0.101 0.077 
SEA_IgG4 -0.958 -0.0845 
Derp_IgE 5.93275 0.9255 
Derp_IgG4 15.368 6.716 
 
Table 6.2 Temporal changes in mean anti-schistosome antibody levels 
*The mean of the differences between post treatment and pre-treatment (post- minus 
pre-treatment values) antibody levels are shown for treated and untreated groups and 
significant changes are highlighted in bold. SWAP: solube worm antigen preparation, 




















Figure 6.2 Change in anti-schistosome antibody levels  
Serum IgM (A), IgE (B) and IgG4 (C) levels (optical densities) against adult worm 
(SWAP), cercariae (CAP) and egg (SEA) antigens are plotted as lines connecting pre- 
and post- treatment levels for treated and untreated children. Participants who were 
egg positive at baseline are highlighted in red lines. Stars represent significant 
difference of mean absorbencies from the Wilcoxon test (at **p<0.01) and after 
Bonferroni correction. Bas: baseline; 6 wks: 6 weeks post treatment. In the treated 
group, all were egg negative but in the untreated group the infected individual was 
still egg positive (with increased intensity) at the 6 weeks follow up.  
 
 
Derp1-specific antibody levels 
A significant increase in IgE and IgG4 against Derp1 was observed in treated children 
regardless of baseline schistosome infection status (Figure 6.3). However, an increase 
in IgG4 was also observed in untreated controls. No significant change was observed 
in the ratio IgE/IgG4 in both groups (Z=-0.431, p=0.333 and Z=-0.357, p=0.361 
respectively for treated and untreated groups).  
 
C. 








Figure 6.3 Change in anti-Derp 1 antibody levels 
Serum IgE and IgG4 (optical densities) against Derp 1 allergen are plotted as lines 
connecting pre- and post- treatment levels for treated and untreated children. 
Participants who were egg positive at baseline are highlighted with red lines. Stars 
represent significant difference of mean absorbencies at **p<0.01 from the Wilcoxon 





Plasmodium-specific antibody levels  
A decrease in IgM and IgG against the total schizont occurred following PZQ 
treatment Figure 6.4A). In treated children, IgG levels against all the malaria vaccine 
candidates MSP-1 (MSP119) and MSP-2 (Dd2 and CH150) were decreased six weeks 
post-treatment (Figure 6.4B). Untreated children also exhibited a decrease in IgG 
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against Dd2 and MSP119, and IgM against the total schizont over the same time frame. 
However, only the decline in IgG against Dd2 in treated children remained significant 












Figure 6.4 Change in anti- Plasmodium falciparum antibody levels (optical 
densities) 
P. falciparum schizont specific- IgM and IgG (A) and IgG anti- merozoite surface 
proteins (B) MSP-1 (MSP119) and MSP-2 (Dd2 and CH150)are plotted as lines 
connecting pre- and post- treatment levels for treated and untreated children. 
Participants who were egg positive at baseline are highlighted with red lines. Stars 
represent significant difference of mean absorbencies at **p<0.01 and significant 
after Bonferroni correction. Bas: baseline; 6 wks: 6 weeks post treatment 
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6. 4. Discussion and conclusions 
 
With increasing calls for the inclusion of pre-school children and infants in mass 
chemotherapy programmes for schistosome control (Odogwu et al. 2006; Stothard 
and Gabrielli 2007; Sousa-Figueiredo et al. 2010; Mutapi et al. 2011b; Stothard et al. 
2011a), and studies in school children and adults showing that antihelminthic 
treatment affects responses directed against schistosomes and  unrelated antigens 
(Mutapi et al. 2003; van den Biggelaar et al. 2004; Black et al. 2010a), the current 
study aimed to investigate immunological consequences of praziquantel treatment in 
young pre-school age children.  
 
The study shows significant changes in the levels of anti-schistosome adult worm 
IgM and IgE antibody titers 6 weeks following praziquantel treatment in 3-5 years old 
children living in a schistosome endemic area. Anti-schistosome egg IgE and anti-
cercaria IgM also increased significantly following treatment. There was a decline in 
anti-schistosome worm IgG4 levels following treatment, essentially driven by 
children presenting with S. haematobium eggs in urine at baseline. However, this 
decline was not statistically significant following Bonferroni correction, possibly due 
to the small number of egg positive children at baseline. Nevertheless, this 
observation is in line with the view that helminths, including schistosomes, elicit 
regulatory responses (Maizels and Yazdanbakhsh 2003) especially in young children 
where they interfere with the development of ‘protective’ immune responses (Hagan 
et al. 1991). The results suggest that this trend may be reversed by praziquantel 
treatment but further larger cohort studies are required for confirmation. 
 
The increase in anti-worm and anti-cercariae IgM responses is consistent with 
reported changes in adult worm (and cross-reactive) antigens exposed to the immune 
system following the killing of adult worms by praziquantel (Fallon et al. 1996).  
Anti-egg responses have been proposed as a diagnostic tool for schistosome 
infections in young children where egg counts are less reliable due to low levels of 
patent infection or to single sex infections (Sousa-Figueiredo et al. 2010). In this 
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study, anti-egg IgM responses did not change following treatment, suggesting that 
while anti-egg responses may be good markers of the presence of a patent 
schistosome infection before treatment, it may not be a reliable tool for use in 
evaluating the efficacy of treatment. 
 
This study showed that, consistent with findings in older individuals (Black et al. 
2010a), praziquantel treatment boosts the anti-worm IgE immune responses 
associated with protection, suggesting that this young age group may also benefit 
immunologically from anti-schistosome chemotherapy, which reduces re-infection in 
older children and adults by stimulating IgE responses (Mutapi et al. 2003; Black et 
al. 2010a). Furthermore, anti-cercariae IgE responses which are associated with an 
acute immune hyperactivity to cercarial exposure (swimmers’ itch), did not increase 
following treatment allaying fears that the increased antigen exposure following 
praziquantel treatment may result in anaphylactic shock in these children.  
 
A relatively small number of participants in this study were egg positive at baseline. 
The change in anti-schistosome antibody levels in children who were egg negative at 
baseline suggests that these children may have had pre-patent infection, single sex 
infection and/or low levels of infection undetected by the egg count technique (Alan 
Wilson et al. 2006). This is consistent with the higher proportion of children 
mounting anti-schistosome IgM responses compared to those excreting eggs in urine 
in the current study.   
 
In this study, although mostly not significant after Bonferroni correction, anti-
Plasmodium responses declined in both treated and untreated children, suggesting 
that this change was not due to praziquantel treatment. Since the decline was both in 
IgM responses directed against the schizont (marker of exposure to Plasmodium 
infection) and IgG responses directed against the vaccine candidates MSP-1 and 
MSP-2, it is likely that the decline was reflecting normal dynamics of Plasmodium 
antibodies in the absence of infection. Levels of antibodies to several Plasmodium 
antigens vary with the seasonality of parasite transmission, often being higher during 
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periods of high transmission than at the end of a low transmission season (Cavanagh 
et al. 1998). Furthermore, levels of anti-Plasmodium antibodies directed against both 
crude and recombinant antigens tend to be higher in individuals carrying parasites 
than in those without parasites (Cavanagh et al. 1998). The region of Zimbabwe 
where the present study was conducted is mesoendemic for malaria with an incidence 
of 0.2 to 10 cases/ 1000/ year (Mabaso et al. 2006). The absence of Plasmodium 
parasites on blood smears of participants in this study and the decline in the levels of 
anti-Plasmodium antibody responses may therefore reflect the end of a malaria 
transmission season in this area (at the time of sample collection). 
 
In the present study, there was no significant difference for Derp1 specific antibodies 
between schistosome infected and uninfected children at baseline. Following 
treatment, Derp1 specific IgE and IgG4 were significantly increased, resulting in the 
ratio IgE/IgG4 (which is associated with allergic reactivity (Wang et al. 2010)) being 
not significantly changed. Hagel and colleagues indicated that a certain ‘threshold’ is 
required for parasite infection to suppress allergic reactivity (Hagel et al. 2004), 
consistent with findings from animal models (Smits et al. 2007). The low levels of 
infections in the present study population would therefore explain the absence of 
significant changes in the ratio IgE/IgG4 against Derp 1 allergen. The increase in 
allergen-specific IgE responses in treated children may be due to cross reactivity 
since levels of these antibodies directed against schistosome antigens also increased 
following treatment. However, cross-reactivity cannot explain the increase in IgG4 
against Derp1 in treated and, to a lesser extent, in untreated children, since the anti-
schistosome IgG4 declined. Changes in anti-mite IgG4 antibodies following seasonal 
changes in natural exposure to house dust mites have previously been reported (Nahm 
et al. 1998). Investigations on natural temporal variations in levels of exposure to 
mite were beyond the scope of this study but this finding requires further 
investigation.   
 
Taken together, findings from this study suggest that praziquantel treatment of 
preschool children has comparable effects to those reported in studies on older 
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children and adults, boosting antibody responses associated with resistance to 
schistosome infection/reinfection six weeks following chemotherapy, but not altering 
Plasmodium-specific responses. The small sample size may have led to a weak 
statistical power, which does not allow definitive conclusions to be drawn on some 
observations; however, findings from this study highlight the need for further 
investigations. Furthermore, longer-term cohort studies will determine the effects of 
praziquantel treatment on allergic sensitization and clinical manifestation of allergic 
diseases as well as the longer term effects of earlier (praziquantel) intervention on 
morbidity and immune system homeostasis in this young age group.  




General discussion and conclusions 
 
The current project was designed to test the hypotheses arising from meta-analyses 
and animal studies on the relationship between atopy and helminth infections (Cooper 
et al. 2006a; Smits et al. 2007; Feary et al. 2011). The goal was to help resolve the 
controversy behind the hygiene hypothesis and understand the short and long term 
consequences of the currently expanding helminth control programs. Of particular 
interest in terms of the consequences of chemotherapy, the current project 
investigated the short term immunological effects of praziquantel treatment in pre-
school age children (who are normally excluded from mass drug administration).  
 
In communities naturally exposed to differing levels of S. haematobium infection, the 
study has indicated that current schistosome infection intensity, but not a cumulative 
history of infection, has a significant negative association with atopic sensitisation 
(chapter 3). However, praziquantel treatment enhanced anti-schistosome antibody 
responses while declining atopic responses, although the magnitude of these changes 
was dependent on host previous history and intensity of infection (chapter 4). It was 
shown in chapter 5 that the levels of soluble CD23, the low affinity receptor for IgE, 
are positively associated with current infection intensity and negatively with atopic 
responses. Interestingly, sCD23 levels were not associated with total IgE levels.  
 
Investigations on an early (pre-school age) chemotherapeutic intervention revealed 
that praziquantel enhances the natural development of putative protective immunity to 
schistosome infection but does not affect their anti-malarial responses (chapter 6). In 
addition, treatment of pre-school age children may enhance their serological 
recognition of schistosome worm antigens (Appendix I). 
 
These findings will be related here and discussed in relation to original questions and 
aims set out at the beginning of the study (chapter 1.5), especially in terms of what 
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they contribute to the issues of atopy and helminth interrelations and possible 
implications for schistosome control programs and the management of allergy. 
 
 
7. 1. Current schistosome infection intensity and not history of infection 
is relevant for atopy 
 
A study using S. mansoni mouse model suggested that the protective effect of 
schistosome infection on airway inflammation is dependent on the intensity and 
chronicity of the infection (Smits et al. 2007). In contrast to mouse models where 
worm count is ethically feasible, quantifying excreted eggs (in urine or feces) is a 
technique routinely used as a proxy for schistosome infection intensity (worm 
burden) in human studies. This means that single sex infections and pre-patent 
infections are not quantified. Furthermore, it is difficult in this context, to characterise 
the differential immunological effects between male and female worms (Boissier et 
al. 2003) as well as the influence of tissue trapped eggs.  
 
Nevertheless, consistent with findings in the mouse model, the current study has 
shown that in human populations endemically exposed to S. haematobium infection, 
skin sensitisation and allergen-specific IgE and IgE/IgG4 ratio are inversely 
associated with infection intensity in a community where heavy infections occur 
(chapter 3). Examination of cohorts recruited from two areas with different infection 
levels and transmission dynamics allowed comparisons between infection intensities 
while overcoming the confounding effect of host age. It would have been sensible to 
compare infected and uninfected or lightly infected individuals in the same 
population as has been done by others (van den Biggelaar et al. 2000; van den 
Biggelaar et al. 2001). However, levels of infection in an endemic area vary across 
age and the highest infection levels are usually aggregated in children compared to 
adults (Fisher 1934; Woolhouse et al. 1991a). Since host age is independently 
associated with the development of atopy (Zheng et al. 2011) and possibly with the 
relationship between atopy and helminth infection (Cooper et al. 2006a), the study 
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extended the current knowledge of the relationship between infection and atopy 
across a large age range. Moreover, this relationship was studied in areas where the 
rate of development of purported protective immunity differs (Woolhouse 1998), 
allowing to test whether the different dynamics of acquired immunity against the 
parasite affect the natural evolution of atopic responses.  
 
In the communities of Magaya, Chitate and Chipinda where the study populations 
were selected from, the prevalence/ intensity of infection follow the curved-shape 
typical of endemic areas, i.e peaking in childhood/adolescence and declining in 
adulthood (Fisher 1934; Woolhouse et al. 1991a; Mutapi et al. 1997; Woolhouse 
1998). Furthermore, the peak of infection occurred at a younger age in the high 
transmission area compared to the low transmission area.  
 
The selection of lifelong permanent residents of the villages meant that host infection 
levels and humoral immune responses reflect their history of exposure to parasites 
since the source of transmission is relatively stable (contaminated rivers and ponds 
are used for everyday activities as there is no other alternative). This does not 
preclude the possibility that some individuals may be genetically more 
resistant/susceptible than others as has been demonstrated by gene polymorphism 
studies (Gatlin et al. 2009). Furthermore, the large genetic diversity among 
schistosomes and snail intermediate hosts, leading to heterogeneous 
resistant/susceptible strains (Rollinson et al. 2001; Rollinson et al. 2009; Stothard et 
al. 2009), suggest a daily complexity of acquisition of cercariae within the same area. 
This adds to heterogeneities associated with water contact behaviour (Chandiwana 
and Woolhouse 1991) and all these factors influence the epidemiological patterns of 
infection.    
 
Nevertheless, the study presented in chapter 3 showed that, regardless of transmission 
levels, schistosome infection acquired during childhood has no effect on allergen-
specific IgE in adulthood once infection declines or is cleared, in contrast with 
findings on Trichuris infection (Rodrigues et al. 2008). These authors showed that 
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heavy infection with T. trichiura acquired around two years of age protect the host 
against atopy up to 7 years of age even after infection was cleared. The difference in 
the age of the study populations and the methodology does not allow direct 
comparison with our findings. However, these results are in line with the view that 
different helminth parasites have differing effects on atopy (Flohr et al. 2009).  
 
Previous studies have suggested that tissue-dwelling parasites (such as schistosomes 
and filarial nematodes) induce stronger immuno-regulatory responses than 
gastrointestinal parasites (Maizels and Yazdanbakhsh 2003). However, the results 
presented in chapter 3, taken together with results by others (Rodrigues et al. 2008) 
on Trichuris (gut-dwelling nematode) infection suggest that while tissue-dwelling 
parasites actively induce stronger regulatory mechanisms, some gut-dwelling 
parasites acquired at an early age may ‘shape’ or tame the host immune response 
away from the Th2-IgE development. In evolutionary terms, this may be explained by 
two complementary mechanisms: first, geohelminth parasites are more widespread 
and have simpler life cycles than schistosomes and filarial parasites (no intermediate 
hosts usually required) and may therefore have exerted a stronger selective pressure. 
Trichuris sp, in addition, have a direct cycle within the definitive host, with no 
migratory steps in the respiratory tract that are thought to potentiate allergic 
symptoms at low and moderate intensities of infection (Lynch et al. 1997). Second, 
the gut is generally colonised by microbial parasites, which are controlled by Th1 
immunity and this type of immunity is associated with the host failure to expulse 
worms from the gut (Antignano et al. 2011). Therefore, although the Th2 response is 
detrimental for both blood- and gut-dwelling worms, the latter have an added benefit 
for triggering a Th1 response (in addition to Tregs and associated regulatory 
cytokines and antibodies) not only for their survivor but also to ensure the stability of 
their niche (Bradley and Jackson 2004). This is in line with observations that the rise 
in allergic disorders coincided with a change in the composition of the children’s 
gastrointestinal microbiota (Sepp et al. 1997).  
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It has emerged that the composition of the gastrointestinal microbiota has profound 
and complex effects on innate and adaptive immune responses, maintaining immune 
homeostasis both in mice and humans (see (Ivanov and Littman 2011; Jarchum and 
Pamer 2011)). Furthermore, gastrointestinal stimulation by pathogens and comensals 
in early life may affect the development of T cell memory to allergens (Holt 1996). 
Interestingly, Trichuris spp may facilitate access of the intestinal microflora to the 
epithelium while the latter initiates their egg hatching (Bancroft et al. 2012), 
consistent with a strong evolutionary interrelationship between intestinal microbiota 
and gut-dwelling helminth.     
 
The same scenario Th1 versus Th2 may apply for the co-occurrence of 
schistosomes/filariae and malaria. However, while a Th1 response in the gut would be 
beneficial for both the worm and the host in terms of reducing microbial colonisation, 
a prolonged Th1 against blood stage Plasmodium parasites is detrimental to the host 
as it translates into cerebral malaria (Nuchnoi et al. 2008). In these conditions, a 
down-regulated Th1 response would be of interest for the host as well as the worm 
parasite (in terms of niche stability). Consistent with this hypothesis, it has recently 
been shown in a murine model that schistosome infection reduces the incidence of 
cerebral malaria in a Th2-dependent manner (Waknine-Grinberg et al. 2010).    
 
These speculations/observations do not preclude the possibility that geo-helminth 
infections may dampen Th1 and Th17 mediated inflammatory diseases via Treg 
responses (Osada and Kanazawa 2010). In addition, geo-helminths such as Ascaris 
lumbricoides may protect against severe malaria (Nacher et al. 2000), possibly by 
preventing sequestration of parasitized red blood cells with the release of nitric oxide 
(Nacher 2002). There is also evidence that helminth-induced ‘protection’ against 
atopy is not a lifelong protection, even in the case of gut-dwelling nematodes, since 
parasite removal is associated with allergic sensitisation (Lynch et al. 1993a; van den 
Biggelaar et al. 2004), although this is not always consistent (Cooper et al. 2006b; 
Cooper et al. 2008b). This inconsistency may be due to host genetic factors: for 
example, Th2-upregulating variants being associated with host resistance to helminth 
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infection (Fumagalli et al. 2010), it is possible that parasite removal (and therefore 
removal of the regulatory response) would exacerbate atopy only in those individuals 
who originally had lower levels of infection (Hopkin 2009). In addition, it has 
recently been pointed out that regulatory immune complexes induced by helminth 
parasites are highly polymorphic (Mekhaiel et al. 2011). Further birth cohort studies 
will shed more light as to when and how long these parasites may prevent atopy, 
taking a genetic predisposition into consideration.   
 
 
7. 2. Allergen- and parasite- specific IgE are differentially altered by 
praziquantel treatment 
 
In the study presented in chapter 3, it was shown that while most anti-parasite IgE and 
IgG4 responses rose with age in S. haematobium endemically exposed populations, 
anti-Derp1 IgE and IgG4 did not show any age-associated trend, suggesting that these 
responses are differentially regulated. Upon praziquantel treatment, allergen specific 
IgE declined while schistosome-specific IgE increased (chapter 4). The finding that 
anti-schistosome IgE responses increase following praziquantel treatment is 
consistent with results by others (Butterworth et al. 1985; Mutapi et al. 2003; Black et 
al. 2010a). The increase in anti-schistosome antibody titres, consistent with increased 
cellular responsiveness (Colley et al. 1986; Joseph et al. 2004) may result from the 
removal of immuno-suppression (induced by live parasites (Maizels and 
Yazdanbakhsh 2003; Osada and Kanazawa 2010)) and/or exposure to high levels of 
parasite antigens following worm death (Doenhoff et al. 1988; Fallon et al. 1992; 
Mutapi et al. 2005a). The magnitude of change in these responses will therefore 
depend on the host worm burden at the time of treatment as well as their exposure 
history (Woolhouse and Hagan 1999; Black et al. 2010b). Consistent with this 
hypothesis, the study described in chapter 4 showed that the biggest changes occurred 
in the high infection area where participants, in addition to having heavy infections, 
had a longer cumulative history of exposure compared to participants in the low 
infection area. However, even in the low infection area anti-worm IgE responses 
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increased significantly despite low levels of infection. This is in agreement with the 
hypothesis that a ‘protective’ response against schistosome is only produced once a 
certain threshold of antigen recognised is reached (Fisher 1934) and that 
chemotherapy accelerates this process (Mutapi et al. 1998a). 
 
The decline in anti-Derp1 IgE responses upon treatment in the high infection area 
(chapter 4) contrasted with the negative association between infection intensity and 
Derp1-IgE at baseline (chapter 3). Indeed, assuming that heavy schistosome infection 
‘inhibit’ atopic sensitisation as shown in chapter 3 and in studies by others (van den 
Biggelaar et al. 2000; Smits et al. 2007), removing parasites (treatment) would rather 
increase atopic responses as has been reported in Venezuelan schoolchildren (Lynch 
et al. 1993a). However, a decline in anti-allergen responses has also been observed in 
Gabonese schoolchildren following anti-helminthic treatment despite an increase in 
skin sensitisation (van den Biggelaar et al. 2004). Although the short-term (6 weeks) 
aspect, the parasite species and the age of our study population do not allow direct 
comparison with these studies, these findings together highlight a complex host-
parasite relationship. Indeed, these studies were comparable in terms of length of 
follow up (22 and 30 months respectively), parasite species (Ascaris and Trichuris) 
and age of the population (5-15 vs 5-14 years). However, socio-economic levels, 
which have been shown to influence allergic reactivity (Hagel et al. 1993b; Hagel et 
al. 1993d), were different between these populations (i.e. slum versus peri-urban).  
 
A possible explanation for the reduced atopy in helminth infected individuals is that 
regulatory responses, deployed by the parasites to ensure their survivor in the host, 
may affect atopic responses due to the similarities between atopic and anti-parasite 
responses (see chapter 1). Therefore, it is possible that low levels, intermittent or 
primary helminth infection may potentiate allergic sensitisation because of the 
increased IgE synthesis in the absence of a strong regulatory response (Hagel et al. 
1993b; Acevedo and Caraballo 2011). This is supported by recent studies showing 
cross-reacting antibodies between helminth (Ascaris and Filariae nematodes) and 
house dust mite extracts (Acevedo et al. 2011; Santiago et al. 2011). The cross-
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reacting IgE response may be the result of a polyclonal stimulation of IgE induced by 
helminth parasites (Turton 1976; Lynch et al. 1987; Hagel et al. 1993c; Lee and Xie 
1995), possibly as a mechanism of immune evasion.  
 
Although cross-reactivity between schistosomes and house dust mites has not been 
demonstrated, observations (chapter 4) that anti-mite IgE responses decline post-
treatment suggest that these responses were replaced by the parasite specific IgE 
responses. Consistent with this view, the levels of total IgE did not change 
significantly post-treatment (chapter 5) despite a significant increase in schistosome-
specific IgE responses. In addition, it is well known that S. mansoni eggs secrete 
glycoproteins capable of driving a Th2 response (Everts et al. 2009). Since a Th2 
polarisation favours IgE switch in the B-cell progeny, it is conceivable that this 
response is not specifically directed against the parasite.  
 
Interestingly, while negatively associated with atopic responses, schistosome 
infection intensity was positively associated with anti-parasite antibody responses at 
baseline in the current study (chapter 3). This suggests that the regulation of atopic 
responses in this population was independent of their anti-parasite responses. In the 
case of schistosome responses, increasing parasite burden corresponds with 
increasing IgE responses (positive correlation). However, a stronger IgG4 response 
may prevent resistance to heavy infection as shown by a negative correlation between 
anti-schistosome IgE/IgG4 response and infection intensity (chapter 3). This was 
consistent with a significant increase in this ratio following treatment (chapter 4) and 
results by others on S. haematobium and S. japonicum infections (Hagan et al. 1991; 
Jiz et al. 2009). In the case of atopic responses on the other hand, increasing parasite 
burden seem to negatively influence their serum levels. A plausible explanation 
would be that the ‘cross-reacting’ anti-parasite IgE responses undergo affinity 
maturation with increasing parasite burden so that the levels of ‘allergen-specific’ IgE 
decline in heavily infected people. This is consistent with observations that the 
intensity of parasite antigen recognition is higher in serum from heavily parasitized 
individuals compared to uninfected (Mutapi et al. 2008). It is also consistent with the 
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decline in allergen-specific IgE responses post-treatment (chapter 4) since 
praziquantel releases large amounts of parasite antigens serologically recognised 
(Mutapi et al. 2005a).  
 
 
7. 3. The CD23: a regulatory pathway? 
 
The CD23 has long been identified as a natural regulator for IgE (Henchoz-Lecoanet 
et al. 1996) with the soluble form capable of inhibiting or enhancing IgE synthesis 
(Bowles et al. 2011). Because of the differential effects of schistosome infection as 
well as praziquantel treatment on allergen versus parasite specific IgE (chapters 3&4), 
this study sought to determine the relationship between soluble CD23 (sCD23) and 
infection as well as atopy (chapter 5). It was shown that skin prick positive 
individuals had significantly lower levels of sCD23 than their skin prick negative 
counterparts, and that sCD23 levels are positively associated with schistosome 
infection intensity. Furthermore, the levels of sCD23 were negatively associated with 
allergen- specific IgE responses, suggesting a role for these molecules in the 
decreased levels of atopy in schistosome heavily infected people (chapter 3). 
Interestingly, the levels of sCD23 did not seem to be related to polyclonal stimulation 
of IgE (no correlation between sCD23 and total IgE) which was shown to be higher in 
the low infection area, where atopic sensitisation was slightly higher (chapter 3). This 
suggests that the potential regulatory mechanisms involving the low affinity receptor 
for IgE was independent of the polyclonal stimulation. On the other hand, the positive 
correlation between the total IgE and the allergen-specific IgE (chapter 5) is 
consistent with the view that polyclonal stimulation may potentiate allergic 
sensitisation (Lynch et al. 1997). 
 
The immuno-regulatory effect of CD23 has previously been reported in immune 
disorders. For example, Singh and colleagues reported lower levels of sCD23 in 
children presenting with juvenile arthritis (JA) compared to age-matched healthy 
controls (Singh et al. 2011). These authors also showed that the levels of sCD23 were 
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increased in remission compared to active disease state. In addition, variation in the 
FCER2, the gene encoding for CD23, has been associated with severe exacerbations 
and poor lung function in asthmatic children taking inhaled corticosteroids (Tantisira 
et al. 2007; Rogers et al. 2009). However, levels of sCD23 are also associated with 
the pathogenesis of autoimmune disorders, making this molecule a current target for 
therapeutic intervention (see (Acharya et al. 2010)). Furthermore, lumiliximab, an 
anti-CD23 monoclonal antibody, is in clinical trials for the management of chronic 
lymphocytic leuchemia (Byrd et al. 2010). 
 
Studies on a role for CD23 in atopy and food allergy yield conflicting results (Oymar 
et al. 2000; Li et al. 2006; Byberg et al. 2008). These results, taken together with data 
presented in chapter 5, may be due to the fact that the effect of sCD23 on the 
synthesis of IgE depends on their size and structure (Bowles et al. 2011). The 
negative association between Derp1-IgE and sCD23 found in the current study 
(chapter 5) may reflect the negative effect of the 16kDa fragment released by Derp1 
proteases on IgE synthesis shown in vitro (McCloskey et al. 2007; Bowles et al. 
2011). However, since sCD23 levels correlated with schistosome infection intensity, 
it is also possible that schistosome parasites are capable of cleaving the membrane 
CD23. Consistent with this hypothesis, it has recently been shown that schistosome 
hyper-exposed individuals show decreased percentage of CD23+ B cells compared to 
healthy controls (Onguru et al. 2011). 
 
The membrane CD23 is cleaved by metalloproteases in vivo (Weskamp et al. 2006). 
Although not on CD23, the cleavage properties of parasite proteases have been 
previously reported. For example, in vitro studies have shown that proteases derived 
from S. mansoni cercariae are able to degrade recombinant human, rat and mouse 
IgE, rending them unable to bind their receptors, especially the CD23 receptor (Pleass 
et al. 2000; Aslam et al. 2008). In addition, Culley and colleagues have shown that 
metalloproteases contained in excretory/secretory products of the hookworm Necator 
americanus are able to cleave eotaxin, a chemokine mediator of eosinophil 
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recruitment (Culley et al. 2000). Further studies are required to assess whether S. 
haematobium products possess such properties on CD23.  
 
 
7. 4. Early development of acquired immunity enhanced by praziquantel 
 
A number of studies have shown that first exposures to schistosome infections occur 
at a very young age, and that heavy infections in pre-school (<6 years old) children 
are more important than previously thought (Odogwu et al. 2006; Mutapi et al. 
2011b; Stothard et al. 2011b; Garba et al 2010). These young children are often 
exposed when accompanying their mothers or siblings at river sites or when they are 
bathed with contaminated water. It has been shown that these children mount anti-
schistosome immune responses (Imai et al, 2011) and the aim of this project was to 
assess whether these are altered by praziquantel treatment. 
 
In a cohort of children aged 3-5 years, living in S. haematobium endemic areas 
(chapter 6), it has been shown that praziquantel treatment increases anti-schistosome 
antibody responses putatively associated with resistance to re-infection. These results 
are consistent with findings from epidemiological studies of the effects of 
praziquantel on acquired immunity against S. haematobium (Mutapi et al. 1998a) as 
well as S. mansoni (Mutapi et al. 2003; Black et al. 2010a) and S. japonicum (Zhang 
et al. 1997) in older individuals. These results were also consistent with those 
reported in chapter 4 for older individuals from the same and neighbouring villages. 
Furthermore, the increase in antibody titres may be a result of increased serological 
recognition of parasite antigens (Appendix I), some of them identified as vaccine 
candidates.  
 
Interestingly, while anti-parasite IgE increased, IgG4 declined following treatment in 
egg positive children, suggesting that an early anti-helminthic intervention may divert 
the host immune response away from an otherwise ‘ineffective’ response (Dunne et 
al. 1987; Hagan et al. 1991). A recent murine study has shown that anti-parasite 
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immune responses induced by praziquantel treatment fail to confer subsequent 
protection because of a concurrent IL-10 production (Wilson et al. 2011), explaining 
the need for several rounds of treatment to induce protective responses in humans 
(Black et al. 2010b). IL-10 is involved in the production of IgG4 antibodies (Jeannin 
et al. 1998). Therefore, although the sample size was too low to draw definitive 
conclusions, the findings that IgG4 responses decline after treatment in pre-school 
age children suggest that an early chemotherapeutic intervention may prevent 
immunomodulatory responses associated with susceptibility at an early age.  
 
This study suggests that an early (pre-school age) anti-schistosome chemotherapeutic 
intervention would be beneficial in terms of acquired protective immunity to 
schistosome infection/re-infection. In addition, praziquantel treatment did not alter 
antibody responses to malaria vaccine candidates, suggesting that this intervention 
would not interfere with vaccine development efforts.  
 
Following praziquantel treatment, anti-allergen (house dust mite) antibody responses 
were increased in 3-5 years old pre-school children (chapter 6). Although IgE 
increased concurrently with IgG4, resulting in IgE/IgG4 ratio (marker of atopy) 
maintained at pre-treatment levels, these results supported findings that schistosome 
infection and atopy may be associated (chapters 3-5). Consistent with the hypothesis 
that IgE responses induced by schistosomes may be cross-reacting with the house 
dust mite, both anti-Derp1 and anti-schistosome IgE levels increased post-treatment 
in pre-school children. This was in contrast with results from older individuals where 
only anti-schistosome IgE increased while anti-Derp1 decreased (chapter 4). A 
possible explanation is that the post-treatment IgE response of these children may 
mirror the pre-treatment IgE response of older individuals with a longer experience of 
exposure as has been shown in school age children versus adults for IgG1 and IgA 
isotypes (Mutapi et al. 1998a). Alternatively, this may also point out the role for low 
levels of infection in potentiating allergic sensitisation as has been reported in Ascaris 
infection (Acevedo and Caraballo 2011).    
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7. 5. Implications for schistosome control programs and the 
management of allergy 
 
The World Health Organization currently recommends praziquantel treatment, albeit 
with different treatment regimens, in all endemic areas for schistosomiasis. In 
addition, evidence is now increasing that schistosome control policy should be 
revised to include pre-school age children as target for treatment (Stothard et al. 
2011a). The current project has shown that chemotherapeutic intervention will have 
differing consequences in communities with different infection levels and cumulative 
history of infection.  
 
Three different settings have been evaluated in the current project in terms of 
chemotherapeutic intervention: a high risk endemic area (>50% prevalence), a low 
risk endemic area (<10%) and a young population previously ignored in terms of 
control strategies (pre-school age children). The findings suggest that in high 
transmission areas praziquantel treatment will induce more changes in anti-parasite 
antibody levels than in low infection areas. In addition, although heavy infection may 
dampen atopy, treatment may reduce atopic responses, especially in high transmission 
areas. On the other hand, early chemotherapeutic intervention (i.e below the age of 5) 
presents the added benefit of declining immunomodulatory responses associated with 
susceptibility to heavy infection. Notwithstanding the fact that the development of 
aquired protective immunity to schistosomiasis is heterogeneous in nature and is 
influenced by both the host and parasite genetic factors, gender and exposure patterns 
(see chapter 1), further longer term and larger studies are required to assess how these 
praziquantel-associated changes in pre-school children affect re-infection rates in 
endemic areas.  
 
The findings that atopic responses and anti-schistosome IgE responses may be 
differentially regulated suggest that deworming in schistosome endemic areas is 
unlikely to exacerbate atopic sensitisation. Further comparative studies on the impact 
of deworming on allergic diseases are required in light of dissociation between 
Chapter 7                                                                                           General discussion 
  
 179 
sensitisation and clinical allergies in the tropics (Flohr et al. 2010). In addition, in 
view of the complexity associated with in utero sensitisation and early development 
of immune responses (see Figure 7.1), further mechanistic studies on birth cohorts 
would be invaluable for understanding the long term effects of anti-helminthic 
treatment as well as the complex interrelation between helminth infection and atopy 
















Figure 7.1 Hypothetical pathways of immune maturation from birth up to 5 
years of age 
(A) Immune phenotype of a child born from a healthy (non infected and non atopic) 
mother: predominance of a Th2 phenotype is observed at birth but is progressively 
replaced by a predominant Th1 reponse and development of Tregs, if the child is also 
uninfected and non-atopic (Tulic et al. 2012). The expression of CD23, in healthy 
individuals, increases with age from 0 to 2 years and decline thereafter  (Lin et al. 
1998) and the levels of soluble CD23 and CD21 decline steadily after the age of 5 
years (Singh et al. 2011). The regulation of IgE by the CD23 at this age is however 
not fully described. (B) The phenotype exhibited by an atopic non-infected child born 
from a non-infected mother. In this case, the switch from a Th2 skewed to a Th1/Treg 
is significantly delayed (Tulic et al. 2012) while the levels of CD23+ B cells may be 
higher (Jarvinen et al. 1998). (C) The phenotype of a child born from a helminth 
infected mother. The child is sensitized to helminth antigen in utero (Capron et al. 
1980; Carlier et al. 1980) and, at birth they exhibit an anti-parasite immune response 
comparable to that of their mother (Malhotra et al. 1997) which has been shown to 
persist up to 14 months of age in the absence of infection (Malhotra et al. 1999). It is 
also likely that these children exhibit a relatively developed regulatory response as 
has been observed in children born from farm exposed (Schaub et al. 2009) or 
malaria infected (Lisciandro and van den Biggelaar 2010) mothers. It is not known 
how anti-helminthic treatment of these young children, either before or after 
infection, would alter these phenotypes (denoted by question marks). The regulation 
of the CD23 expression (and its relationship with IgE levels) in children born from 
helminth infected or atopic mothers also remains to be determined.  
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The current study suggests that it is unlikely that deworming young children may 
interfere with anti-malaria vaccine development efforts since praziquantel treatment 
did not affect anti-P. falciparum responses. However, it should be noted that the 
current study was conducted in an area with low malaria endemicity and during a 
period where none of the participants had patent P. falciparum malaria infection. 
Therefore, similar studies in malaria highly endemic areas are warranted to expand 
these findings and assess the short and long term consequences of combined 
therapeutic interventions.   
 
 
7. 6. Future prospects 
 
This study has raised questions relevant for the management of atopy and 
schistosomiasis. For instance, it is imperative to investigate whether there is any 
cross-reactivity between schistosome parasites and house dust mites to help 
understand the implications of co-exposure. These studies would inform on the 
management and diagnosis of allergy/atopy in schistosome infected or exposed 
people: for example, if cross-reactivity exists, it will be important to assess whether 
atopic individuals are more likely to respond to cross-reactive epitopes than non-
atopics or vice versa. In addition, an important extension to findings presented in this 
thesis would be to assess whether ‘cross-reactive’ responses are associated with 
susceptibility to heavy schistosome infection and whether chemotherapy reverses this 
trend on a longer term. Identifying and characterising cross-reactive epitopes would 
also be invaluable for anti-schistosome vaccine development efforts, avoiding the 
‘sensitising’ vaccine ‘trap’ as has been the case for Hookworm vaccine (Bethony et 
al. 2011).  
 
It is of interest, for the management of atopy (and clinical allergy), to further 
elucidate the role for schistosome parasites on IgE synthesis. Indeed, since only heavy 
schistosome infection may present some protective effect on atopy (chapter 3 and 5), 
characterisation of parasite derived products, as well as the molecular events they 
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induce will be invaluable for the control of atopy while avoiding some of the most 
debilitating infections.  
 
Investigations on the consequences of praziquantel treatment of pre-school age 
children presented in this thesis were limited by the sample sizes, especially the 
number of infected individuals. However, the findings showed that it is important to 
extend these studies on larger cohorts and in a longer term approach to understand the 
effects of an early chemotherapeutic intervention on the development of ‘protective’ 
immunity and on atopy and allergic diseases. These studies would incorporate the 
genetic predisposion as well as in utero exposures in light of studies showing that the 
development of atopy in childhood is influenced by environmental exposures (Schaub 
et al. 2009) and anti-helminthic treatment (Mpairwe et al. 2011) during foetal 
development.  
 
A number of studies have highlighted the possibility of an in utero sensitization by 
helminth parasite antigens which subsequently impact on immune responses at birth 
and beyond (Capron et al. 1980; Carlier et al. 1980; Malhotra et al. 1997; Malhotra et 
al. 1999). These early studies have demonstrated that neonates from helminth 
infected mothers show high levels of circulating parasite antigen (Carlier et al. 1980), 
cytotoxic antibodies (Capron et al. 1980) as well as antigen-specific cytokines 
(Malhotra et al. 1997). Malhotra et al (1999), looking at in utero exposure to 
Wuchereria bancrofti and Schistosoma haematobium, further demonstrated that the T 
cell immunity (Th2 biased, see Figure 7.1) acquired in utero is maintained up to at 
least 10 to 14 months of age in the absence of infection. A recent study has also 
shown that maternal infection intensity with S. mansoni is associated with the levels 
of anti-schistosome IL-5 and IL-13 in cord blood (Tweyongyere et al. 2011). The 
study also reported that several uninfected infants born from infected mothers 
exhibited detectable levels of schistosome egg specific IgE, IgG1, IgG2 and IgG3 at 1 
year of age. 
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On the other hand, a recent study has demonstrated age-related changes (in the 
absence of infection) in the thymic cytokine milieu (in parallel with peripheral 
changes) from a Th2 to a Th1 skewed as children age (Tulic et al. 2012). The authors 
showed that this Th2 to Th1 switch was however delayed in atopic children, and so 
were the turnover and function of thymic Treg cells. It is currently unknown how this 
T cell maturation is affected by in utero helminth sensitisation, early exposure to 
helminth parasites or early treatment (Figure 7.1). Taken together, these studies 
highlight the need for further mechanistic studies on T and B cell maturation from 
birth in the presence or absence of infection as well as the effect of anti-helminthic 
treatment in these different settings to understand the consequences of mass drug 
administration targeting pre-school children (under 5 years of age) on atopy as well as 
the development of protective immunity to schistosomiasis. 
 
Furthermore, an investigation on early (from birth) regulation of the expression of 
CD23 in schistosome endemic areas and the effect of praziquantel treatment on this 
regulation would not only be relevant for the control of schistosomiasis but also for 
the diagnosis and perhaps the management of atopy in schistosome endemic areas. Of 
note, the impact of pediatric HIV on T and B cell maturation and regulation in the 
context of schistosome infection, atopy as well as the effect of anti-helminthic 
treatment should be explored further in view of the results presented in this thesis 
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Appendices 
Appendix I  
Preliminary results on treatment-induced serological 
recognition of parasite antigens in pre-school children 
 
Background 
The most powerful tool for schistosome control would be the development of a 
vaccine, which would not only overcome the risk for drug resistance but also would 
minimize the chances of developing severe pathology (Wilson and Coulson 2006). 
Characterisation of immunogenic antigens that trigger protective immune responses, 
for their subsequent expression as recombinant proteins, is a possible way of 
developing vaccines (Wilson et al. 2004).  
 
Proteomic analysis has enabled identification of several S haematobium immunogenic 
antigens with S mansoni and S japonicum homologues in human epidemiological 
studies (Mutapi et al. 2008; Mutapi et al. 2011a). Furthermore, praziquantel has been 
shown to enhance serological recognition of parasite antigens (Mutapi et al. 2005a). 
However, these studies were conducted on pooled samples, potentially from 
individuals with different infection histories, genetic background and immune 
responses. Therefore, to take into account this heterogeneity it is important to 
characterise immunogenic antigens at an individual level, especially since it has  been 
recognised that a cocktail of recombinant antigens is more promising than single 
antigens for anti-schistosome vaccine development (Wilson and Coulson 2009). 
Furthermore, since an anti-schistosome vaccine is likely to complement treatment 
(Bergquist et al. 2005) and target young children (Chan et al. 1997; Siddiqui et al. 
2011), this study aims to characterise praziquantel -induced antigen recognition at an 
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The provisional results presented here are from 3 individual sera collected pre- and 6 
weeks post- treatment. All the 3 children were S. haematobium egg positive at 
baseline, were born in Magaya village (high infection area) and had not been treated 
prior to the study (assessed by questionnaire). None of them had S. mansoni or geo-
helminth eggs in stool, HIV or patent malaria co- infections. One of these children 
(male, 5 years old) was among those whom parents declined treatment and was used 
as an untreated control. The other 2 (male and female, 4 and 5 years old respectively) 
received the recommended dose of praziquantel (40mg/kg) after collection of baseline 
samples and were not excreting S. haematobium eggs in their urine at follow up. 
 
Materials and methods 
Gel electrophoresis 
 
A 1-dimensional gel separation was performed and the gel (7cm) was subsequently 
divided into 2 pieces: the first to be used for Western blotting and the second for 
protein identification. 100 µg of antigen (SWAP), diluted 1:1 in lithium dodecyl 
sulphate (LDS) sample buffer (Invitrogen) was run on a 10% gel using sodium 
dodecyl sulphate (SDS) buffer (see Appendix IV for gel recipe and buffers). The 
proteins on the piece of gel used for identification were stained with silver nitrate 




Proteins were transferred onto a nitrocellulose membrane, using a wet system 
(Invitrogen), in transfer buffer made of 20% methanol, 25mM Tris and 192mM 
Glycine. The membrane was stained with Ponceau S solution to check transfer 
efficiency. The membrane was then blocked with 2% BSA in TBS/0.05% Tween20 
for 3 hours, washed 2 times (10 min each) in TBS/0.05%tween/0.2% triton x-100 and 
cut into strips. On each strip, 1.5ml of individual serum diluted 1:50 in blocking 
solution was added and all strips were incubated overnight at 4°C. After 3 washes, 
1.5ml of HRP-conjugated antibodies were added (diluted in blocking solution at 1: 
400 for IgE and 1: 1000 for IgG4) and the strips incubated for 2 hours at room 
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temperature. After 4 washes (3 in TBS/TT and 1 in TBS alone), the strips were 
incubated in ECL Plus reagent system for 5 minutes, before being exposed on 
hyperfilm. The film was developed and bands were matched to those on the silver 




Images from the Western blots were electronically scanned and bands quantified 
using ImageMaster Platinum software version 5.0 (Amersham Biosciences). 
Identified bands were quantified based on their pixel intensity. 
 
Mass spectrometry  
 
This technique involves protein identification based on peptide mass, where peptides 
are created from proteins by endoproteinase digestion. The peptide masses are then 
matched against a library of peptide masses generated from protein databases 
(Wilkins and Williams 1997). This method, via ‘cross-species matching’, allows 
identification of proteins from species poorly defined at the molecular level 
(Cordwell et al. 1995; Wasinger et al. 1995; Wilkins and Williams 1997). 
 
Bands on the silver stained piece of gel that matched those on the Western blots were 
excised and subjected to in-gel trypsin digestion before being analysed by Mascot 
software. Mascot software compares the observed spectra to a database of known 
proteins and determines the most likely matches based on protein scores (Perkins et 
al. 1999). For each protein match, Mascot calculates an overall Protein score which 
reflects the combined scores of all observed mass spectra that can be matched to 
amino acid sequences within that protein. A higher score indicates a more confident 
match and Mascot calculates a ‘threshold’ for identity or extensive homology 
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Results 
 
As shown on figure I.1, the gel electrophoresis resulted in separation of S. 




Figure I.1. Silver- stained one dimensional protein migration: 100 µg of S. 
haematobium adult worm antigen (SWAP), right column, were run under reducing 
conditions (in the presence of 2-Mercaptoethanol) on an SDS gel with 10% 
acrylamide concentration. The standard protein (left column) and molecular weights 
(in kDa) are indicated on the left.  
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Antigens recognized pre- versus post- treatment 
 
The secondary antibody used for these assays was the anti-human IgE (Sigma). Only 
1 light band (~80 kDa) was recognized by all serum samples collected pre-treatment 
(Figure I. 2). Six weeks following treatment, sera from treated children recognized 
one more band (~100 kDa) which was absent on the blot from the untreated child. 
Furthermore, the image master analysis showed that the 80kDa band was enhanced 
post-treatment. The pixel intensities of recognized bands (and their corresponding ‘no 
band’) pre- vs. post- treatment are shown on figure I. 3.   
 
 
                             
Figure I. 2. Immunoblots of serum samples. Comparison of pre- (left) and post- 
(right) treatment immuno-blots. Identified bands are shown in boxes and molecular 
weights (in kDa) are indicated at the right end. Strips were exposed on hyperfilm for 
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Figure I. 3. Pixel intensities of the bands (and the corresponding ‘no band’) pre- vs 
post- treatment are plotted for treated (T) and untreated (U) individuals. Pixel 




The potential identities of the proteins in the 2 bands recognized are shown in table I. 
1. Overall, the peptides’ mass spectra recognised post-treatment resolved to 31 
proteins, 4 of which are homologues to those documented in S. mansoni and 2 in S. 
japonicum. None of the identified proteins had been documented in S. haematobium 
except one protein, myosin heavy chain, which was recognized by pooled sera from 
older individuals (Mutapi et al. 2005a). The S. haematobium actin protein had also 
been reported in previous studies (Mutapi et al. 2005a; Mutapi et al. 2008) but in this 
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Protein name Species Protein hits Protein 
score 
MW 
SJCHGC09409  S. japonicum Q5DFW7 CHJA 260 52019 
SJCHGC00991 S. japonicum Q5BY06 SCHJA 193 50810 
Surface protein S. mansoni T30271 182 190732 
Myosin heavy 
chain 





ACTA PHYPO 138 - 
Beta-actin Camelus 
dromedarius 









S. mansoni CAA28976 125 - 
Heat shock 
protein 70 











Q9U540 TOXGO 115 - 
Actin Coccidioides 
immitis RS 
Q1E3S2 COCIM 114 - 
Type 4 actin Pleurochrysis 
carterae 
Q9SWP8 PLECA 114 - 















Q50JT9 ASCSS 83 99667 
Beta-actin, 
cytoplasmic 
Sus scrofa (Pig) Q95319 PIG 81 14080 
Actin-3-sub 2 Dictyostelium 
discoideum 
(Slime mold) 
ACT4 DICDI 78 - 
Actin Gossypium 
hirsutum 
Q7XZJ6 GOSHI 75 - 



















Q4S2N3 TETNG 63 92826 
Actin 71  potato S20095 61 41983 
Actin  Panax ginseng Q5D4WO PANGI 59 10856 
Hypothetical 
protein 





CRYL1 RABIT 48 - 
     
Trypsin Pig (tentative seq) TRPGTR 159 25078 
Surface protein S. mansoni T30271   129 190732 
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TableTable I.1 Potential identities of the proteins recognized. The 2 bands on 
silver stain that matched those identified on immunoblots were excised and subjected 
to trypsin digestion before being analysed by mass spectrometry. The list of all 
proteins that matched the peptide masses are indicated with their corresponding 
scores. MW: Molecular Weight. The highlighted protein is the one previously 
recognized by pooled sera from adults    
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Discussion  
 
In the present study, antigens recognised by sera from children aged 4 to 5 years, 
before and after a single dose of praziquantel treatment, were identified following 
Western blots. 
 
The current data were analysed before the recently published S haematobium genome 
sequence (Young et al. 2012) and relied on expressed sequence tags (EST) published 
from different parasite life cycle stages from S. mansoni and S. japonicum (Hu et al. 
2003; Verjovski-Almeida et al. 2003; Curwen et al. 2004; Liu et al. 2006) as well as 
other ‘unrelated’ species matching (Wilkins and Williams 1997). The results from 
this analysis reveal 6 proteins homologues to S. mansoni and S. japonicum and 25 
others which have not yet been identified in any of these parasite species.  
 
The proteins identified in this study with homologues in Schistosoma sp were 
essentially of the surface and the musculature, consistent with the praziquantel 
disruptive action on these (Fetterer et al. 1980; Day et al. 1992; Gnanasekar et al. 
2009). Among these was the myosin heavy chain, which has been previously 
recognized by pooled sera from older individuals with a longer history of infection 
(Mutapi et al. 2008). Interestingly, 2 distinct fragments of this protein have been 
associated with protection in mice vaccinated with radiation-attenuated cercariae 
(Soisson et al. 1992; Eberl et al. 1999).  
 
Heat shock proteins (HSP) with an S mansoni homologue (HSP70) as well as 
homologues with several other species (HSP68 and HSP70) were identified. HSPs are 
proteins that are expressed by all eukaryotic cells to maintain cell homeostasis under 
stress conditions. Furthermore, because they are suspected of being inducers of 
multiple pathways of immunity, these proteins may be explored as potential adjuvants 
in vaccine development against cancer and infections (reviewed by (Segal et al. 
2006).  
 
This study presents the limitation that all the parasite antigens described were 
recognised by IgE. Although parasite-specific IgE antibodies have been associated 
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with protection (Hagan et al. 1991; Hagel et al. 2008; Black et al. 2010a), vaccine 
candidates eliciting IgE responses in helminth endemic areas have recently been 
shown to induce urticaria (Bethony et al. 2011). Although ‘desensitization’ of the 
IgE-inducing vaccine is a possibility to overcome this problem, identification of 
antigens recognized by other isotypes (Mutapi et al. 2011a) may be more realistic. 
Nevertheless, characterising parasite antigens eliciting IgE responses gives the 
information on what to ‘avoid’ or ‘take with precaution’ in vaccine design. 
Furthermore, given the similarities between anti-helminth and anti- allergen 
responses (Santiago et al. 2011; Rujeni et al. 2012), comparative studies (schistosome 
antigens vs. allergens) would provide the spectrum of antigen recognition and inform 
on possible cross-reactivity. This would narrow the choice of antigen vaccine 
candidates and minimise the risk of sensitization. 
 
Overall, these preliminary results provide a basis for a more extensive study on 
serological recognition of schistosome antigens in young pre-school children to 
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Appendix III: Pre-school children census and treatment side effects 
questionnaire (attached overleaf) 
 
 
Appendix IV: Buffers and gel recipes 
1. ELISA buffers 
Carbonate bicarbonate buffer, pH 9.6:  
0.795g NaCO3  
1.465g NaHCO3  
500ml distilled water  
 
Blocking buffer: 
100mls of 10X PBS      
900ml distilled water          
300ul Tween20    
50g Marvel     
 
 
Or (for CD23) 
 
100mls of 10X PBS  






500mls of 10X PBS  
4500ml distilled water 





          15mg ABTS powder  
1ml distilled water  
10ul of 30% H2O2  
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10ml citrate buffer* 
 
*Citrate buffer: 50ml double glass-distilled water + 525mg citric acid, pH4.0 
 
 
2. Buffers and chemicals for Western blot 
Separating gel:  10ml 30% acrylamide 
   7.5ml 1.5M Tris-HCl, pH8.8 
 300ul 10% SDS 
    300ul 10% APS 
   11.9ml  Ultra pure water 
 30ml TEMED 
 
 
Stacking gel: 2.49ml  30% acrylamide 
1.89ml  1M Tris-HCl, pH6.7 
150ul  10% SDS 
150ul   10% APS 
9ml  Ultra pure water 
15ml  TEMED 
 
 
Transfer buffer (pH8.6):   25mM Tris 
      192mM Glycine 
      20% (v/v) Methanol 
 
 
TBS (pH7.5): 10mM  Tris-HCl (pH7.4) 
   150mM NaCl 
 
 
TBSTT:  0.05% (v/v) Tween20 + 0.5 Triton-X 100 in TBS 
 
Blocking buffer:   100mls of 10X PBS  
  900ml distilled water  
  300ul Tween20 
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